var title_f22_5_22608="Contents: General medical issues in women";
var content_f22_5_22608=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?23/51/24382\">",
"       Adult Primary Care and Internal Medicine",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       General medical issues in women",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			General medical issues in women",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Adolescents",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/35/19000\">",
"           Guidelines for adolescent preventive services",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Breast disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/15/24825\">",
"           Breast masses and other common breast problems",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/33/8728\">",
"           Breast pain",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/23/3449\">",
"           Nipple discharge",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/52/11081\">",
"           Overview of benign breast disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/49/41754\">",
"           Screening for breast cancer",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Cardiovascular disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/9/41113\">",
"           Clinical features and diagnosis of coronary heart disease in women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/35/28217\">",
"           Coronary heart disease and myocardial infarction in young men and women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/57/28570\">",
"           Determinants and management of cardiovascular risk in women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/63/11258\">",
"           Management of coronary heart disease in women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/29/33241\">",
"           Screening guidelines for dyslipidemia",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Endocrine disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/42/33449\">",
"           Clinical manifestations and diagnosis of Turner syndrome (gonadal dysgenesis)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/52/39751\">",
"           Clinical manifestations and diagnosis of premenstrual syndrome and premenstrual dysphoric disorder",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/6/16490\">",
"           Clinical manifestations of polycystic ovary syndrome in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/36/39495\">",
"           Diagnosis of polycystic ovary syndrome in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/16/28935\">",
"           Epidemiology and pathogenesis of premenstrual syndrome and premenstrual dysphoric disorder",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/2/2089\">",
"           Etiology, diagnosis, and treatment of primary amenorrhea",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/56/34697\">",
"           Etiology, diagnosis, and treatment of secondary amenorrhea",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/31/9721\">",
"           Evaluation of premenopausal women with hirsutism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/63/14329\">",
"           Management of Turner syndrome (gonadal dysgenesis)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/28/24007\">",
"           Pathogenesis and causes of hirsutism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/2/27685\">",
"           Physiology of the normal menstrual cycle",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/37/35416\">",
"           Treatment of hirsutism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/10/3241\">",
"           Treatment of premenstrual syndrome and premenstrual dysphoric disorder",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Gastrointestinal disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/59/22455\">",
"           Clinical manifestations and diagnosis of irritable bowel syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/22/13673\">",
"           Etiology and evaluation of chronic constipation in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/57/30616\">",
"           Management of chronic constipation in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/25/12697\">",
"           Pathophysiology of irritable bowel syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/14/40169\">",
"           Treatment of irritable bowel syndrome",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         General hematology/oncology",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/3/5178\">",
"           Approach to the adult patient with a bleeding diathesis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/39/26234\">",
"           Causes and diagnosis of anemia due to iron deficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/41/11930\">",
"           Evaluation of the patient with established venous thrombosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/62/25578\">",
"           Treatment of anemia due to iron deficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/53/10072\">",
"           Women and lung cancer",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Gynecologic issues",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/1/24601\">",
"           Approach to the patient with an adnexal mass",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/15/24825\">",
"           Breast masses and other common breast problems",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/15/40185\">",
"           Cervical cytology: Interpretation of results",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/57/19352\">",
"           Differential diagnosis of the adnexal mass",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/11/30905\">",
"           Management of an adnexal mass",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/29/14810\">",
"           Overview of the treatment of endometriosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/48/19210\">",
"           Pathogenesis, clinical features, and diagnosis of endometriosis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hernia",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/37/31321\">",
"           Classification, clinical features and diagnosis of inguinal and femoral hernias in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/20/29000\">",
"           Overview of treatment for inguinal and femoral hernias",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hypertension",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/29/36314\">",
"           Choice of therapy in primary (essential) hypertension: Recommendations",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/62/37859\">",
"           Effect of oral contraceptives and postmenopausal hormone therapy on blood pressure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/63/3060\">",
"           Essential hypertension in women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/4/4169\">",
"           Hypertension: Who should be treated?",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/40/33417\">",
"           What is goal blood pressure in the treatment of hypertension?",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Neurologic disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/44/21194\">",
"           Acute treatment of migraine in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/34/3624\">",
"           Headache syndromes other than migraine",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/4/26698\">",
"           Pathophysiology, clinical manifestations, and diagnosis of migraine in adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Obesity",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/9/8345\">",
"           Dietary therapy for obesity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/4/33866\">",
"           Drug therapy of obesity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/35/30266\">",
"           Health hazards associated with obesity in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/45/13016\">",
"           Overview of therapy for obesity in adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Osteoporosis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/52/39754\">",
"           Overview of the management of osteoporosis in postmenopausal women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/28/40393\">",
"           Screening for osteoporosis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Other infectious diseases",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/29/14803\">",
"           Cellulitis following pelvic lymph node dissection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/6/30825\">",
"           Clinical features and diagnosis of chronic fatigue syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/21/4440\">",
"           Treatment of chronic fatigue syndrome",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Psychiatric disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/33/26135\">",
"           Antidepressant medication in adults: Switching and discontinuing medication",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/18/5417\">",
"           Atypical antidepressants: Pharmacology, administration, and side effects",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/13/11481\">",
"           Clinical manifestations and diagnosis of depression",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/2/23593\">",
"           Eating disorders: Epidemiology, pathogenesis, clinical features, and course of illness",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/63/44023\">",
"           Eating disorders: Treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/21/7512\">",
"           Factitious disorder and Munchausen syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/0/32776\">",
"           Generalized anxiety disorder: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/8/40074\">",
"           Initial treatment of depression in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/25/7574\">",
"           Monoamine oxidase inhibitors (MAOIs) for treating depressed adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/0/5129\">",
"           Serotonin modulators: Pharmacology, administration, and side effects",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/28/5578\">",
"           Serotonin-norepinephrine reuptake inhibitors (SNRIs): Pharmacology, administration, and side effects",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/61/27609\">",
"           Treatment of resistant depression in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/20/36169\">",
"           Unipolar depression in adults and tricyclic and tetracyclic drugs: Pharmacology, administration, and side effects",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/38/37481\">",
"           Unipolar depression in adults: Epidemiology, pathogenesis, and neurobiology",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Rheumatic disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/55/8056\">",
"           Clinical manifestations and diagnosis of fibromyalgia in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/49/35608\">",
"           Differential diagnosis of fibromyalgia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/43/37562\">",
"           Epidemiology and pathogenesis of systemic lupus erythematosus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/16/16646\">",
"           Menstrual function, menopause, and hormonal contraceptives in women with systemic lupus erythematosus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/31/41464\">",
"           Overview of the clinical manifestations of systemic lupus erythematosus in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/38/41578\">",
"           Overview of the therapy and prognosis of systemic lupus erythematosus in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/19/31031\">",
"           Pathogenesis of fibromyalgia",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Screening for cancer",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/32/35337\">",
"           Cervical cancer screening tests: Techniques and test characteristics of cervical cytology and human papillomavirus testing",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/49/41754\">",
"           Screening for breast cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/10/37034\">",
"           Screening for colorectal cancer: Strategies in patients at average risk",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/14/10474\">",
"           Screening for ovarian cancer",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Sexually transmitted diseases",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/15/12538\">",
"           Approach to the patient with genital ulcers",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/0/1032\">",
"           Clinical features and diagnosis of pelvic inflammatory disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/35/26166\">",
"           Diagnosis of gonococcal infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/44/39624\">",
"           Diagnostic testing for syphilis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/56/3976\">",
"           Disseminated gonococcal infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/10/9386\">",
"           Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/61/36823\">",
"           Epidemiology, clinical manifestations, and diagnosis of tuboovarian abscess",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/20/38217\">",
"           Epidemiology, pathogenesis, and clinical manifestations of Neisseria gonorrhoeae infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/46/42728\">",
"           Genital Chlamydia trachomatis infections in women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/35/16954\">",
"           HIV and women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/25/18837\">",
"           Laboratory monitoring of patients undergoing treatment for syphilis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/34/43560\">",
"           Management and complications of tuboovarian abscess",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/44/26312\">",
"           Neurosyphilis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/45/11992\">",
"           Pathogenesis of and risk factors for pelvic inflammatory disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/9/37017\">",
"           Pathogenesis, clinical manifestations, and treatment of early syphilis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/48/776\">",
"           Pathogenesis, clinical manifestations, and treatment of late syphilis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/55/12150\">",
"           Pathophysiology, transmission, and natural history of syphilis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/15/21751\">",
"           Prevention of genital herpes virus infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/13/8408\">",
"           Screening for Chlamydia trachomatis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/32/7690\">",
"           Treatment of genital herpes simplex virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/63/35832\">",
"           Treatment of pelvic inflammatory disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/53/26455\">",
"           Virology of human papillomavirus infections and the link to cancer",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Urinary tract infection",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/15/13561\">",
"           Acute uncomplicated cystitis and pyelonephritis in women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/19/42295\">",
"           Approach to the adult with asymptomatic bacteriuria",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/24/5514\">",
"           Recurrent urinary tract infection in women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/41/24214\">",
"           Urine sampling and culture in the diagnosis of urinary tract infection in adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Venous insufficiency/thromboembolism",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/57/6042\">",
"           Diagnosis of acute pulmonary embolism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/41/11930\">",
"           Evaluation of the patient with established venous thrombosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/48/43786\">",
"           Overview of the causes of venous thrombosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/32/42503\">",
"           Treatment of acute pulmonary embolism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/4/43082\">",
"           Treatment of lower extremity deep vein thrombosis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Violence against women",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/7/20601\">",
"           Evaluation and management of adult sexual assault victims",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/15/6393\">",
"           Intimate partner violence: Diagnosis and screening",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/41/5784\">",
"           Intimate partner violence: Epidemiology and health consequences",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/54/14183\">",
"           Intimate partner violence: Intervention and patient management",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-94867760F2-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f22_5_22608=[""].join("\n");
var outline_f22_5_22608=null;
var title_f22_5_22609="Contents: Heart failure";
var content_f22_5_22609=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?5/3/5182\">",
"       Cardiovascular Medicine",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Heart failure",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Heart failure",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Angiotensin converting enzyme inhibitors",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/45/16090\">",
"           ACE inhibitors in heart failure due to systolic dysfunction: Therapeutic use",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/43/14008\">",
"           Angiotensin converting enzyme inhibitors and receptor blockers in heart failure: Mechanisms of action",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/53/10069\">",
"           Renal effects of ACE inhibitors in heart failure",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Angiotensin II receptor blockers",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/39/2680\">",
"           Angiotensin II receptor blockers in heart failure due to systolic dysfunction: Therapeutic use",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/43/14008\">",
"           Angiotensin converting enzyme inhibitors and receptor blockers in heart failure: Mechanisms of action",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Asymptomatic left ventricular dysfunction",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/59/28601\">",
"           Evaluation and management of asymptomatic left ventricular systolic dysfunction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/12/20679\">",
"           Screening for asymptomatic left ventricular dysfunction",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Beta blockers",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/27/36282\">",
"           Rationale for and clinical trials of beta blockers in heart failure due to systolic dysfunction",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Cardiomyopathy",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/53/35672\">",
"           Alcoholic cardiomyopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/30/24042\">",
"           Atrial fibrillation in patients with heart failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/46/41706\">",
"           Cardiotoxicity of anthracycline-like chemotherapy agents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/21/34137\">",
"           Cardiotoxicity of radiation therapy for malignancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/0/19465\">",
"           Causes of dilated cardiomyopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/10/23722\">",
"           Clinical manifestations and diagnosis of amyloid cardiomyopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/42/36522\">",
"           Clinical manifestations, diagnosis, and evaluation of hypertrophic cardiomyopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/3/24633\">",
"           Diagnosis and management of ischemic cardiomyopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/12/15562\">",
"           Echocardiographic recognition of cardiomyopathies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/39/39545\">",
"           Evaluation and management of the cardiovascular complications of cocaine abuse",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/41/39576\">",
"           Genetics of dilated cardiomyopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/44/29386\">",
"           Genetics of hypertrophic cardiomyopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/42/23207\">",
"           Idiopathic restrictive cardiomyopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/20/1351\">",
"           Inherited syndromes associated with cardiac disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/57/37785\">",
"           Intermediate- and long-term mechanical cardiac support",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/51/41784\">",
"           Isolated left ventricular noncompaction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/55/10105\">",
"           Medical therapy in hypertrophic cardiomyopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/4/32841\">",
"           Natural history of hypertrophic cardiomyopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/10/22696\">",
"           Overview of hypertrophic cardiomyopathy management including treatment of special problems",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/17/14615\">",
"           Pathogenesis of ventricular arrhythmias in heart failure and cardiomyopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/62/18410\">",
"           Peripartum cardiomyopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/55/19322\">",
"           Secondary and primary prevention of sudden cardiac death in heart failure and cardiomyopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/1/30745\">",
"           Stress-induced (takotsubo) cardiomyopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/29/27097\">",
"           Tachycardia-mediated cardiomyopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/25/23958\">",
"           Treatment of amyloid cardiomyopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/59/28600\">",
"           Types and pathophysiology of obstructive hypertrophic cardiomyopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/47/21241\">",
"           Ventricular arrhythmias in heart failure and cardiomyopathy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Complications",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/30/24042\">",
"           Atrial fibrillation in patients with heart failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/25/35223\">",
"           Cardiorenal syndrome: Definition, prevalence, diagnosis, and pathophysiology",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/26/44456\">",
"           Cardiorenal syndrome: Prognosis and treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/43/8888\">",
"           Cheyne-Stokes breathing and obstructive sleep apnea in heart failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/36/9799\">",
"           Functional mitral regurgitation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/42/16042\">",
"           High altitude, air travel, and heart disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/53/38742\">",
"           Hyponatremia in patients with heart failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/17/14615\">",
"           Pathogenesis of ventricular arrhythmias in heart failure and cardiomyopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/55/19322\">",
"           Secondary and primary prevention of sudden cardiac death in heart failure and cardiomyopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/22/29031\">",
"           Treatment of hypertension in patients with heart failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/40/650\">",
"           Treatment of refractory edema in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/47/21241\">",
"           Ventricular arrhythmias in heart failure and cardiomyopathy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Diastolic dysfunction",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/38/30313\">",
"           Cellular mechanisms of diastolic dysfunction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/22/43368\">",
"           Clinical manifestations and diagnosis of diastolic heart failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/28/15818\">",
"           Pathophysiology of diastolic heart failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/54/7018\">",
"           Treatment and prognosis of diastolic heart failure",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Etiology",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/61/36825\">",
"           Actions of angiotensin II on the heart",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/53/35672\">",
"           Alcoholic cardiomyopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/25/19865\">",
"           Cardiac remodeling: Basic aspects",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/32/17930\">",
"           Cardiac tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/62/3046\">",
"           Cardiovascular effects of hypothyroidism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/0/19465\">",
"           Causes of dilated cardiomyopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/33/39446\">",
"           Dyspnea during pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/8/15497\">",
"           Epidemiology and causes of heart failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/57/28569\">",
"           Heart failure in diabetes mellitus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/47/9978\">",
"           High-output heart failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/42/1705\">",
"           Impact of anemia in patients with heart failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/51/40759\">",
"           Lyme carditis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/19/39225\">",
"           Mechanical complications of acute myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/61/26584\">",
"           Myocardial dysfunction in end-stage renal disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/57/1944\">",
"           Noncardiogenic pulmonary edema",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/2/36901\">",
"           Pathophysiology and stages of chronic mitral regurgitation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/62/18410\">",
"           Peripartum cardiomyopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/29/27097\">",
"           Tachycardia-mediated cardiomyopathy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Evaluation",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/52/842\">",
"           Cardiac remodeling: Clinical assessment and therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/3/34874\">",
"           Clinical utility of cardiovascular magnetic resonance imaging",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/26/7592\">",
"           Endomyocardial biopsy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/23/7544\">",
"           Evaluation of acute decompensated heart failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/28/39369\">",
"           Evaluation of the patient with heart failure or cardiomyopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/30/19945\">",
"           Evaluation of the patient with suspected heart failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/4/7241\">",
"           Exercise capacity and VO2 in heart failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/39/33398\">",
"           Functional exercise testing: Ventilatory gas analysis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/22/19818\">",
"           Natriuretic peptide measurement in heart failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/56/29573\">",
"           Natriuretic peptide measurement in non-heart failure settings",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/21/11610\">",
"           Noninvasive methods for measurement of left ventricular systolic function",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/53/28503\">",
"           Pathophysiology of cardiogenic pulmonary edema",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/48/33546\">",
"           Predictors of survival in heart failure due to systolic dysfunction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/61/4058\">",
"           Prognosis of heart failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/54/7018\">",
"           Treatment and prognosis of diastolic heart failure",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Inotropic agents",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/37/7769\">",
"           Inotropic agents in heart failure due to systolic dysfunction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/4/18504\">",
"           Use of digoxin in heart failure due to systolic dysfunction",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Mechanical support",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/17/11545\">",
"           Cardiac resynchronization therapy in heart failure: Implantation and other considerations",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/56/18314\">",
"           Cardiac resynchronization therapy in heart failure: Indications",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/57/37785\">",
"           Intermediate- and long-term mechanical cardiac support",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/49/31510\">",
"           Overview of cardiac pacing in heart failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/36/10823\">",
"           Rationale for and mechanisms of benefit of cardiac resynchronization therapy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Myocarditis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/28/22986\">",
"           Etiology and pathogenesis of myocarditis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/39/10874\">",
"           Natural history and therapy of myocarditis in adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pathophysiology",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/38/30313\">",
"           Cellular mechanisms of diastolic dysfunction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/24/10632\">",
"           Excitation-contraction coupling in myocardium",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/36/12872\">",
"           Nitric oxide, other hormones, cytokines, and chemokines in heart failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/2/36901\">",
"           Pathophysiology and stages of chronic mitral regurgitation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/28/15818\">",
"           Pathophysiology of diastolic heart failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/34/23076\">",
"           Pathophysiology of heart failure: Left ventricular pressure-volume relationships",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/44/32455\">",
"           Pathophysiology of heart failure: Neurohumoral adaptations",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/20/11592\">",
"           Role of endothelin in heart failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/44/27337\">",
"           Role of oxidative stress in heart failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/27/17847\">",
"           Skeletal muscle dysfunction and exercise intolerance in heart failure",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pulmonary edema",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/55/35701\">",
"           Nesiritide in the treatment of acute decompensated heart failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/57/1944\">",
"           Noncardiogenic pulmonary edema",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/56/34698\">",
"           Treatment of acute decompensated heart failure: Components of therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/7/41079\">",
"           Treatment of acute decompensated heart failure: General considerations",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pulmonary hypertension",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/63/2041\">",
"           Clinical features and diagnosis of pulmonary hypertension in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/8/7304\">",
"           Pathogenesis of pulmonary hypertension",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/24/35210\">",
"           Treatment of pulmonary hypertension in adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Treatment",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/30/24042\">",
"           Atrial fibrillation in patients with heart failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/46/30438\">",
"           Calcium channel blockers in heart failure due to systolic dysfunction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/59/3000\">",
"           Cardiac rehabilitation in patients with heart failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/52/842\">",
"           Cardiac remodeling: Clinical assessment and therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/61/983\">",
"           Cardiac resynchronization therapy in atrial fibrillation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/17/11545\">",
"           Cardiac resynchronization therapy in heart failure: Implantation and other considerations",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/56/18314\">",
"           Cardiac resynchronization therapy in heart failure: Indications",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/3/42039\">",
"           Drugs that should be avoided or used with caution in patients with heart failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/37/2650\">",
"           End of life considerations for heart failure patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/59/28601\">",
"           Evaluation and management of asymptomatic left ventricular systolic dysfunction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/11/18617\">",
"           Genetic and cellular therapy in heart failure and myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/44/10953\">",
"           Guideline adherence and outcomes in coronary heart disease and heart failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/55/25465\">",
"           Heart failure self management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/24/23942\">",
"           Hydralazine plus nitrate therapy in patients with heart failure due to systolic dysfunction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/42/1705\">",
"           Impact of anemia in patients with heart failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/31/34297\">",
"           Indications and contraindications for cardiac transplantation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/56/7048\">",
"           Indications for antithrombotic therapy in heart failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/37/7769\">",
"           Inotropic agents in heart failure due to systolic dysfunction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/57/37785\">",
"           Intermediate- and long-term mechanical cardiac support",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/34/1577\">",
"           Management of heart failure in pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/40/4743\">",
"           Management of refractory heart failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/55/35701\">",
"           Nesiritide in the treatment of acute decompensated heart failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/4/24648\">",
"           Nonselective NSAIDs: Adverse cardiovascular effects",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/49/31510\">",
"           Overview of cardiac pacing in heart failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/63/38906\">",
"           Overview of the therapy of heart failure due to systolic dysfunction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/0/18440\">",
"           Perioperative heart failure in noncardiac surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/23/18809\">",
"           Possibly effective emerging therapies for heart failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/27/36282\">",
"           Rationale for and clinical trials of beta blockers in heart failure due to systolic dysfunction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/36/10823\">",
"           Rationale for and mechanisms of benefit of cardiac resynchronization therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/55/19322\">",
"           Secondary and primary prevention of sudden cardiac death in heart failure and cardiomyopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/56/24453\">",
"           Statin therapy in patients with heart failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/2/37929\">",
"           Strategies to reduce hospitalizations in patients with heart failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/20/35143\">",
"           Surgical management of heart failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/54/7018\">",
"           Treatment and prognosis of diastolic heart failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/42/33446\">",
"           Treatment of acute decompensated heart failure in acute coronary syndromes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/56/34698\">",
"           Treatment of acute decompensated heart failure: Components of therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/7/41079\">",
"           Treatment of acute decompensated heart failure: General considerations",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/22/29031\">",
"           Treatment of hypertension in patients with heart failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/40/650\">",
"           Treatment of refractory edema in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/19/39221\">",
"           Unproven therapies for chronic systolic heart failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/54/28521\">",
"           Use of aldosterone antagonists in heart failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/38/12905\">",
"           Use of beta blockers in heart failure due to systolic dysfunction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/4/18504\">",
"           Use of digoxin in heart failure due to systolic dysfunction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/55/3962\">",
"           Use of diuretics in patients with heart failure",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-D00F0C0864-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f22_5_22609=[""].join("\n");
var outline_f22_5_22609=null;
var title_f22_5_22610="Patient information: Seborrheic dermatitis (The Basics)";
var content_f22_5_22610=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/82948\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/22/21862\">",
"         Seborrheic dermatitis",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/61/34769\">",
"          Seborrheic dermatitis",
"         </a>",
"         <li>",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/1/33814\">",
"           Seborrheic dermatitis",
"          </a>",
"         </li>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?1/53/1874\">",
"         Patient information: Dermatitis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?42/49/43793\">",
"         Patient information: Diaper rash (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?15/23/15730\">",
"         Patient information: Atopic dermatitis (eczema) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?43/41/44690\">",
"         Patient information: Diaper rash in infants and children (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?6/1/6164\">",
"         Patient information: Seborrheic dermatitis (including dandruff and cradle cap) (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Seborrheic dermatitis (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/seborrheic-dermatitis-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H18133775\">",
"      <span class=\"h1\">",
"       What is seborrheic dermatitis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Seborrheic dermatitis is a skin condition that causes redness, scaly or flaky patches, and sometimes itching. It usually affects areas with many oil glands. These include the scalp, face, upper chest, and back. Dandruff is a mild type of seborrheic dermatitis.",
"     </p>",
"     <p>",
"      <br/>",
"      Seborrheic dermatitis is common in babies. It is called &ldquo;cradle cap&rdquo; (",
"      <a class=\"graphic graphic_picture graphicRef82990 \" href=\"UTD.htm?21/22/21862\">",
"       picture 1",
"      </a>",
"      ). Cradle cap can cause redness and greasy yellow scales on the head. It can also cause red patches and greasy scales on the face, diaper area, or other areas.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H18133790\">",
"      <span class=\"h1\">",
"       What are the symptoms of seborrheic dermatitis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;In adults, common symptoms include: &nbsp;",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Redness (",
"        <a class=\"graphic graphic_picture graphicRef82991 \" href=\"UTD.htm?33/61/34769\">",
"         picture 2",
"        </a>",
"        )",
"       </li>",
"       <li>",
"        Scaly patches on the skin that can look oily or greasy",
"       </li>",
"       <li>",
"        White scales or flakes on the head or hair &ndash; This is the most common symptom of dandruff (",
"        <a class=\"graphic graphic_picture graphicRef82992 \" href=\"UTD.htm?33/1/33814\">",
"         picture 3",
"        </a>",
"        ).",
"       </li>",
"       <li>",
"        Mild itching",
"       </li>",
"       <li>",
"        Crusty, yellow material on the eyelashes and eyelid redness",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Stress can make seborrheic dermatitis worse. It often gets worse in winter, when the weather is cold and dry. It can get better in summer.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H18133805\">",
"      <span class=\"h1\">",
"       Is there a test for seborrheic dermatitis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;No. There is no 1 test for seborrheic dermatitis. A doctor or nurse can usually tell if someone has it by doing an exam and asking questions.",
"     </p>",
"     <p>",
"      If your doctor is not sure you have seborrheic dermatitis, he or she might do a skin biopsy. In this test, the doctor takes a small sample of skin from an affected area. Another doctor looks at the sample under a microscope to see if it is seborrheic dermatitis.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H18133820\">",
"      <span class=\"h1\">",
"       How is seborrheic dermatitis treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatments include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Skin creams and ointments &ndash; These can help stop itching and redness. They might contain medicines that kill fungus (called &ldquo;antifungal medicines&rdquo;), steroid medicine, or other medicines. The steroid medicines are different from the steroids athletes take to build muscle.",
"       </li>",
"       <li>",
"        Shampoos with antifungal or steroid medicine",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Cradle cap usually goes away on its own. This can take a few weeks or months. If you have questions, ask your baby&rsquo;s doctor or nurse.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H18133835\">",
"      <span class=\"h1\">",
"       Is there anything I can do on my own to feel better?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Depending on the type of seborrheic dermatitis, there are different treatments you can try. They include: &nbsp;",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Using an over-the-counter anti-dandruff shampoo (sample brand names: Selsun&reg;,&nbsp;Head and Shoulders&reg;). Use it every day until you see less dandruff. After that, use it every other day or twice a week. Leave it on your hair for 5 or 10 minutes. Then rinse your hair, making sure you get all the shampoo out. If your dandruff does not get better after 4 to 6 weeks, try a different anti-dandruff shampoo. If your symptoms get worse, see your doctor or nurse.",
"       </li>",
"       <li>",
"        Using an over-the-counter",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?38/9/39056?source=see_link\">",
"         hydrocortisone",
"        </a>",
"        cream (sample brand names: Ala-Cort; Cortaid&reg;) to help stop redness and itching on the face or body. Use it 1 or 2 times a day until the symptoms get better. If they do not get better after 2 weeks, see a doctor or nurse.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If your baby has cradle cap, you can try:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Washing the area with baby shampoo and using a soft toothbrush or fine-tooth comb to remove scaly skin.",
"       </li>",
"       <li>",
"        Putting a small amount of oil (such as petroleum jelly, vegetable oil,",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?32/46/33508?source=see_link\">",
"         mineral oil",
"        </a>",
"        , or baby oil) on your baby&rsquo;s head to loosen scaly skin. You can leave this on overnight, if needed. Next, brush the baby&rsquo;s scalp gently with a soft brush to remove scales. Then wash the area with regular baby shampoo (not baby shampoo with medicine in it). &nbsp;",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If your baby still has cradle cap after you try these things, talk to your baby&rsquo;s doctor or nurse.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H18133850\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?42/49/43793?source=see_link\">",
"       Patient information: Diaper rash (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?1/53/1874?source=see_link\">",
"       Patient information: Dermatitis (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?6/1/6164?source=see_link\">",
"       Patient information: Seborrheic dermatitis (including dandruff and cradle cap) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?15/23/15730?source=see_link\">",
"       Patient information: Atopic dermatitis (eczema) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?43/41/44690?source=see_link\">",
"       Patient information: Diaper rash in infants and children (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?22/5/22610?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 82948 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.247-05EE575892-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_5_22610=[""].join("\n");
var outline_f22_5_22610=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18133775\">",
"      What is seborrheic dermatitis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18133790\">",
"      What are the symptoms of seborrheic dermatitis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18133805\">",
"      Is there a test for seborrheic dermatitis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18133820\">",
"      How is seborrheic dermatitis treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18133835\">",
"      Is there anything I can do on my own to feel better?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18133850\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/82948\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/22/21862\">",
"      Seborrheic dermatitis",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/61/34769\">",
"       Seborrheic dermatitis",
"      </a>",
"      <li>",
"       <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/1/33814\">",
"        Seborrheic dermatitis",
"       </a>",
"      </li>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?15/23/15730?source=related_link\">",
"      Patient information: Atopic dermatitis (eczema) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/53/1874?source=related_link\">",
"      Patient information: Dermatitis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/49/43793?source=related_link\">",
"      Patient information: Diaper rash (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/41/44690?source=related_link\">",
"      Patient information: Diaper rash in infants and children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?6/1/6164?source=related_link\">",
"      Patient information: Seborrheic dermatitis (including dandruff and cradle cap) (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_5_22611="Cosmetic units of the face";
var content_f22_5_22611=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F69743&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F69743&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 497px\">",
"   <div class=\"ttl\">",
"    Cosmetic units of the face",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 477px; height: 559px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_5_22611=[""].join("\n");
var outline_f22_5_22611=null;
var title_f22_5_22612="Nodular sarcoidosis - rhinophymatous";
var content_f22_5_22612=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F50697&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F50697&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nodular sarcoidosis - rhinophymatous",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFEAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwClCpAJJH0Pap42IVhIDk9+5qvFu5BAyx6/4VNKpU4QneRhsnp9K4Io9m5etmJ3PkBehA61EAWuJU3FlODyMEDtk9qqqzhVCKwB5ORz9ahl8zzMnLsw4PX9O9UkTc0LVxJcOBJviUYyTx9KhkuSC0UKj5uN7LwBUEEQjG6TCY6qTzk+lRSO6mX7QGMZxkDr+NVoTdksXkwxkMvmbv4s1HcXKRkvKXdQMKynCn2FR3aDyc7jtI+VE449TVaKKRkZpgCqYKox4/KkJjJb6W6t2dV8i3Tg4HOPQVE/nkRqyhYWOVgxjd/tN7VZsopJXEpjLkHKR54THc1UuLuS7upIbVmY4/ezgdPYVd7Gdm9xyzyid/s7CVgMPIoARBUoEdtbG4l4jPIOOp/z0plsqxJiND5XXHdj6k+lWIrc3BSS4XECnMUR5yfXHrU3GkU7aN7l1nmOyWTkAfwJ/jWhcOkRja2OGZNigfqSahnZdpCR5+bnvn2zUloJYJHZlRriQYVGGQi49KLlpMas5t0Xcu9M9F53GqU3nm48wqNgycH+H0/GtZVBlhWONDKoGMNjn3NV7hrozeWUHJ+bYB8xz2Pesm2y+UjjMcUKoYi75GT/ADH40+fyPK3lijBuI15GO340OGGVb7wPLf3R6CqtwhQR7gUQn5RncSvqTUtlWK0uZZ/vfj70x4QZMjoB69afKpWIyBWVAcZpse7Ix93/AGu9Np7kX6CtACwyMY7ZpwhBeMhFXafoD7mpWVg6InO45LE4x7VMkW0v1Kn8cVJolqIIs7d2FDjPX0q0sQjIYgZIB4/l9aiRAHJHI6ManRgMr5Bdyc7lGcL3pFrQAp3xFdsZHyhwCO360TTKoaAhfKU7iV6E+ue4ourjLGA/eGQHV+/b2qKKNnzFKR6lQevqKLDuSwPH50bRgs3Xgck+1KJyWYqrHjLDpgfT+dReWIt32NSiJyDu5AqJZmWQgyOzYy2w4BFNolStuXEFws0XlssWB1J2qQe4PrU9yl4qyfb5pJccqQ4Zv/1Uz7JJJbRzTkR2yZddzBgx9MDvTjGoty2BGqjcu5cFgR6ntSvZGiV2TaS98sUkK+WUBCEOcYPqT3NWXQyR7nCYVuX5w2OpIrNiykiiPAkzgOW+Vj6fhVtnMkrM0e5jkP8AvMc1N7miVhZ1ijt2XfKhH3WwQc+v0x2qtBEVlXLhUYZV1BJYHtn19qsvNeRkyqoWNFwyk5zntj1NQFVmh3Qs25eTCWJA9eKaRLZFcSMHNscYBKkueSPr61X3FYAHmd8HbkjO0VK8pXyhMxmCryQOFBPT/wCvUAd3ygBdlJ245JUdAR6CqsZNleIDcVUhCMKc8Aj1qa4hH2SPGHUE4IGQvqKilt43Ecihlb753cgL6/8A1qkHmLESrYGfmDcBh60PYzirMzp4wzkRjA7E9MVWliAJGMcZPOQfer5AEeUyz9uPl+tRTRqQMAt2IYY59qkq1zOwzMI5QEOc7m4xUGw7ypIznAB71oXYK7VYZHckZqLyjLtK8KOCO5qkZNEEaxoSksZMZPUdR6gUpsGUqwIaJ2wvzc59/SrNvbectwA4Gznax5I74qWON02yMA6uuVOP0+tURylMQyw3DRr/AK4HHXjPtW3ZTCWGSF+Z+wPTI9KhlQGEsnzoCGXP3h7UyC3WdpJIQEdRuYbsflRexXLY0d6zW2+IeWudpXPK4qWTdDNbrMcMUxk8/SoNLZQjxTJkSnKkDuKn1KOR1tpJFIMbgNgdumc1oncTRTdTbLEG48ufDfRhTbqFFNuAVKNI0fToccE1ZulPmSpJiRmTCbTzkUksZurNztG9owy46hhTbJ5dDN1CxDxTIoBdcEDrk+tZqaeZw86xZDgh1Hf1x710AD3C290DyB5bj3oMBQySIQqhsSovp/fFFxOnc4u005rO5uGQ53coxPUY+6fenm1WW4ZSD9nIBkAHQ44H510l5bmLIjACNyQO2e9Vo7V0wSDIM43jrVqZi6R2NxIsMMe0koc7TVSGYpLvZS5B61NcBfMEsyjnnGcVWL5jZ+P9lPWs0djLUjbd8khLHj5d2AR9asQyLCIpIG3TMMKF/hHfPpWTawySkO8ojX7oLDIFaWngpLKikCIj52/v+1XZE3ZK5KSg24SSQDGXPCZ9Kiu0aSLyy48zd87+nvirEcOI/LhkG7nA25OKrpKYWRHiLSbsog/ib1+gpbjZSWJIJerSN95Sw9e5/wAKY8L5eUuWIHLZ+77Aepq26FZXluTkfeY9snrxURSK4lyhdcAAAdW9yKNhWKEc3m74oiUgc/vW6E+v0FMTYsmyFD5TE7doxv8AQ1fu4YpItkDtFD913P8AG390Ugsbgh4+RKuI9vQIvp9aCXEz7pJ4ZfKDKduN5U/LnrirG6aZx5alGXAOerj1rUeC1jW3jh2yzAEBDwM/3j7D361WVo3l2q5klL4VhwG+p9Kmd0XBCXfmvD5sYjiiLbVjXqT6/QVBb2c7ZWRsBsZmIzwT29a0LjyrWWJnQ3EpBDBvutj09qb8kkaPHEgdjsGJMhfUn2FTfoXa2pT8uGEuBMTGoIV8YDn6VMZEi08JDEnmsQXm53D0UU9009lZWyZhgeZkhSx7gVXuQkNwJJ920j5Il5wfc+velZoq5DuiL7hGzsvCqem73quxZ5Nz72Y/KB6VM07TxJAwiiKHcFUEtIx9TTZGkwFChduQSO9SJsq3czTRCORj5EZ+WPPQ/wCNVreNjLyMN94DrgVZMaiQbxxjg9hUyIZm3YIzxt70XZHKEAJyGbljkY6g1bVT5m+VssePmHXFU4wIXZ1V/L6Zap3fzOSMnoMcUGiZIxO8PGzDHI9qmLFUZ1EW5iAe2MiqRIBIXdjPCj196UqGjDyY8zPUc7vw7UrD5gmYPkZBJ5GPWrEbKECqoCjP1qlFGHbCsNz8jc3WpY5isucAheAD1ouFxpDbNygAEYJHQmrNhAjxltkRVOqOxBbPQgd6rySvPJufbuzuA/8ArVZjYtGA/wA2R68qM9jUlIkRFWeMb2ChclRyVPvVyW/GwLOQbjHl7nfcpXso9KzsvExYybVfjaecg9z9KVGz1DnByHOAG7f0oLLrYCAgIUbgp0Pvz7VWaSOWVt4G8gr14x0AA9fenQBJQDExM3QFjynripkhjVdzghh8rnGRnscnp9KkvoV3lMcqtCzy+W2Mg9fw9qfI0UhkaGJSwyWCSH8xUNrcCcyNG01vKrEKhXAPbP0pZz+6VQy+Wh+RccjJ7mqRm2RXXnLG/lMwEibWUDJQe/tTUDhlZdoOPLO48fnU0lwo5kUkj7zK+CPpVGST94xiG5GIO0HP+TVGLZZ85mYIoj3MMYA4+tJDI25XZwFTKmNhwPbNJExumHCBQN2V/QY/pT5AWUhjkKPvE8cdP/1UwXcRkCRhQiBH5BAIwcVXuQpACLJsAGM4z71ZVyCPnVQVPGOOnamuoYARk4GMBfX8e9S1YtO5nTkkrHJwpGd2elVHJidsZb0cd61CCWcEHcxwRt/zzVW4ixEY2xsXjHShMiSK6gFiQPn9Ccg1I84xECZBk8jPQ4qvhd6soI6YHUUPIsd1G4Q4/iUmqRm9DUitPKUTP91sZ55b1xVprAq8ph/ex5ByCMkfSkhKfZgr5KY5z1Poc1Nb7VhidGlEobCnHy+9LqbJJozJAQ3ysy4O4Y9a0kuDPCzMJRIv3wp+X602fzYeCVJYhg0S9T3x6UyIxwXLGQSEP2YcFcU1KxMoFp45FZf3Z3DDIc9R3NLaMlu8qzE7FO4ELyyn0p8VwI7eMMMvG+Ad3BQ1JdxJGq4Q8tghOymtE7kONjOVDbXtxDnEUn7yIg8H2pwmPmLwwTb5cq46jsabe2+6IbWBkhIKn+LFPW4jLwSlGCbdkm3+6e596FoMlt7dFuXtZcbfvRv2ZfT6imLAYrnJZSp4x/eHr9aQtIypAc/uvmjf2q1bSxumZWIlQ5I6kH1oBJBMrLF5j8u/3Qe1VoIWkfDcKOXbPb2pb66+1TjOQ7cBUHAA9KsfZ/LgD525AKj+tMnce6QzSRqAy9io7VYI3y5GNsfOxeB9PrTre3jPlgPtLdZWPCnqc1YKKFe4QYRvkQE4D+9O40iIfvWV03JGfvD0FRSs7rIISJZgcK5/hFOtozko7KyDOXA4X1x60/z1jVNsHlqv3cjgAdz6k0XKsUoLfMqoSWViS0knG/H9KdqcUNtNH9i34PBnAwpPtWqsEmqRMwCQ20QJaRx09vxqtDDMbWXLRxQQkMvmck/ge1ILFB4Lg4cMkabfkZh0z6CrdvbhLcxXW7znGVOcbvUsafLMbmzLQMSxYAKoxz7elNk0yW3V/NZ2uGXc2GyR9alvsUoieREJEt4l3GRh5wH3iB3Pp7Cq17HbPcSJEVabpGgbAQD+8asacFBjjZX3TMDuLEs/1IrVu7GC2txezxwrK0vlxQJhmI69O9N+9oJLlOfSGWdclSpDAM6k4YdgPapdSsri3uFbUQsbmPKQRrgAf3m9BWrcWpZwYY5Z9q79kfG3HO4/SsW8JaK4ubyeVGncYhk+YsPc0krBLyFjltNqR21sGyckxHOAOpye9UHlcXbsGViCQqvz5eaLmS4dlMKLBEw2gIuBj+7/ALVLAs0htjbwpG4zgFc+Ye7H6Urpi1RG9vLHIAmdx4Rx3Prmmy+ZGDHI+dvyuR/nrVuNp38qJQX8stsKDHXqSaqSypHHtY85yWPO6lYTA7dhQEYX72armdPMOzdycYz1FVbm8ZklCfKe+aqpMSobnPenYzdQ1ANx3ysR7mrEaJ5bH+907cetYj3aqcuwA9GNJHqtsuP3jZ78UcoKojZaQR84LZGBjp+NR+YHY78Ed1HGDWQ+rQu+UYHPTPGKWGdSGcyK2evzUco1UTehrT3qPEAVG4fx45A9B7VEJQ4Bx8vsc4rFmn3llR1B+vFWbZ2XbvPy45FJxHz62NuFkY7xHsPfv+IqdZd2QwAJHU9hVG3lEjqkThSBn3NXV4ULsOM5JXpis2mbQkrDndWIUE7QpGT1NQxyRmNQ5LEHle3t9KbOrGTCncx64PFVZspIFPC9CR1o5Wi3KxoeYscoVGJbtk4xUy3OImMkjCMdMHo3rjvWcsiMCME9ifX8aZNMMDkMRxjoR9KVg5zSMpkSRd0aksMk9cim3u1YxJGThuDkZ2+5/pWejFQWDA8/nUUsshABwvU/KeM1SRm5l1yjsgaPaQMHB27veqaM4uFCMy4+62en/wCuq5naTg8nPAHf1pDdSTiGJkQMgIWQnblferSMHM07chpsqy7zzgDHT3qxcc26sQ27O4jvjsc1gpMm49M54x0NatownRYy22VB1ByD7UjRS6E8cigbipYsP79TGFfLdS7cnLZ4I9KhRiInKpkDqBwfc1LFc/IY3CyJgnk8D/E0nqaRdiNoZEjLhtzDnIGQagu4TNCFVgTnOOuKtvetFasF+YEYBPJIqOOf58MRtdRtAGMVKG7NGZty5WQAso4xUckImiIKkEdweT7VoXcQR1ZpFJxkbe9QW8fnh32YXuQcYNWZOIWomMC+YWcJkZz930FbVvIIRskzEy4lwTwxx1HvWTZRmV5AzmNSOqnr71at4iR8yiSJOvU8fWkzSPY6N2imhYwAMHIJBAwo789qqXUavEVV3kQcAgZ2k/zqtboQSX+YgfIIxkP7GrztHIgkjEsZAyYhlSRS1ZpoYuHlLkSg4XaVK4z7UltcTbNkoZl7fNyD2rXlikCkqBOTgFEbkH1NVDbQzGYSW8kG0EbgN3NNN3JlFEYVpYVkVV6c7Tz+NQwlfm8xPlfJyDwT3H9ajjk+x/LgzRnBLRjhT7ipHV1CywPGed6pj7hrVO5g9CWPcu5IwDJGcrnneh7VLBCHjW5RsMThg38JqvDOGJcLlozuQ549x+NWC8b3BkRgiydVPQHFJ6DjqOihFuGCAmVly3cqKuWasb2FGG4D7zt9P0pkUDqm+3/eFmxkn7x/wrUg2QwNGTumflxjvUlqJXiijuLiWGEEwIcs2cZz2FS36qPKhDbWwEPHCirMAj2yF1AdecLwB7GjUV+z2kUrRq8rPtjU9CfWmhtFa7txHMEiI8mIYY4yQfTFNmtDDcxvOWnuJAFSIchT2P0qeJZUmigjCm4PMjMcKc81LqFuNOH2mOZnvnzHhTyfb2HvTTHy3K2oXsjwG2t/mWNhvC/xNUETTXEv+lQF4wcKqjhfXJ7mkggmiu9kgjxgMxiOCM8nntWtb3AgsjdzyARN8iIOWfnjHrT3EjPhK2zNNxH5Z+SJuufepEuY55JnkcPCh8yeTGC49FHpUjRC8Kfaoh5CEMYx94seisfpya1rt7e00ZLWysluboy7o5NuY19j9KS0HuZcepy3rSSWto0AddkUaqM47c023tfNeAtIJbp87mQHK46gntirU9pqDpJBp6qJo0CTzA/NknkL7fSo7iKaDybG2VhMyFp3HG0e/wBfTrTS6MTZn6vdafY291OZJJbg/L5SsVUc9D7Vzsk25ob68KkSDbGrNhQo7/TNSaxrGl6F9pigiW9u2QYMo3LGc5JPvXn2qazNqkxmvZGlbZhUGFVR6AdhVqDZzVK6jsddc+MtLsGZ3lmubnDIBCmFTPcZ4rAufHN3cPCljBFbiGPy0PJJHck+tc3CrSowiUoFGM4HFQlLmNFkUb4+5xyfamopGEq05G3da5qsqLsuTGoBO1VwOfpUDavfp807+YAMYI/liqH2hwvyp8rcnBPymq8hMjMUk+TGDjpmnZEXfc34tWgmZUO5SeDu9ame6kQlVGCRyOpx7Vk6TaOQJ7pOWz5fGf8AgRrWjtxuVgxPHXPDGk0Urma5OTvVyPbkmgx8KQMDrljzWtNBFuURBycfNt5Ge9UJo2cjBBIHGRzxSKKIJDBHztz6VahCndsIAHbvRDbS7nOA4JyWY4/DFTCN42Jjdc9MDihhFCNGcZyBkZNOR5kJ2sxx3HTFWhCVQbo/xzxUMiyOoKgADrmpsX5k0d+xZfMiB9WHBNbFvqCIqqsnA+7k8j2rnVT5d5OAexNMl8wKCH698cUWuUm1sdbLfuV3Fw2fvEYAzUEt9HuHmkNt6HriuTSUk7W3L2J561NFuK7SMleeRzS5UDk2br30DNnL57GkubyCZMN8uccg81lZBB657UBWA5yB7U0rCu2X576PP7s5A9ary3gBXAznrg1B5ZKkBTnGME1C0bICzqABjvgmnoS2ydrllbdHIcducGoZb4kDfziomY7dir945yRz9M01QVILxg5zn0Ap2T1I16lpb9FxvDYH+eK1LDVY1dpEZEGQQGFYXlbwWUcDoKiP7pskfMB/EOtTyopSsdvBcJIV2OMPx1GD+ParCOrnYy9eAfQ1wURMbgxF4yeQa19M1dlkCTMUc8bh0b2NQ42NY1e50bERShCcDdhj6VIzkbJEIBQ8EDIyapLc7lPlspcHkEdanglj3MpXGcEc9MVNjXmC4xKCztuyeg6fWmwkxEiH5SDtHufWluY9sUZ2bxJypPb2qTegghjmgbf3YccetLYL66E0aL5MVxESJVYh0xgD6Vat7mMP8+6GQjZIFyN47EVWMV1YlJJAs1rcr8p3ZwPWrEVy4/eNETIhAkXH3l7EA1TKiyyHeGECIxyBnxvJ2kYq1DNPcWi20cmwq2QGblCfT/ZpLX7FMGEO116bSSvPt64os5VhneGSDzAP9WUHJ9c+tTaxruWka5WZJFQK/cqMK3qM1TeS4W6mOZY1Yn92e/tWlNNIIlBgNvCeV8s5D/X0rLvLa8gnFzHcb7dxgr94Fe55oS6DlpsiDMbo+SFkbgZ4Cj+tZ5DtIM5GBjcgzuxXQiGF7RHuA7BudoPH4etZ5tmSHDt5cL8rg/Mp7E0J2JlC+pUt44IW86NiXcnzIj0+oqWy2PK0LD903zIdv6VKbW42ALEu5jy/X6H2qSW3cqCXVJ0PzL05FVuZ8tjSt5EgjlW3yXX5Qeo681ajcbmn2guw+VM54HeqtsiQqFRMqTkgdSad5PmRGZ/lwC2FHekbFuEtcbv3gV1DSvxgbvQev0qtHOZIJTcRmWbBEY7g/wBKLDzNtx9ndRISQM9zjk0iSLb25kyTjCkgclvWq6EF6zNrFpcs1zKyT4xgjjP/ANan2ttHNFLK7MDJGfLbIJ49c9M96zbaP+0romaULHD1L8BfqO5rQBRooo4Eby1Bwx5y2ev09qroBXhi3yLFcI+0AGRxxv8AbP5Vp3VzawXzRtErOhykI6Lx0x2xVf7UJdNtbMxKQrs7FQeTnr9eKNscF1cXssO6Nk2RqeTuI4BoAsJfLFFI86wIVLOXJ5cEYIwOlV3mM1qqWEU4y2UUcBAepJ7/AEqhp+lS28JXULcsLzBiUn7pHqe1SaxrVhoWkRt5rT3lwriKEHCx9tzev1q7X2IlNRV2dFr3iC20uaxitJMRrETJOy7VJbqSO/0FeY+KfGU8k7W2lzGGEsR9obiSXPc+lczqur3eqXJmvpDJJwiDHHAwMDsKoGGQnzZQoI4BxnFaJM4aldy0RKYd5Cli3d2JyD71k3Nq/wBoL7WZW4HFbelwPc3ABfchPBPA+tb6aOETdIxd2O5Rj5v/ANVD0IjG5y8MYcRRBI7ePHD7evqKWwt0lv2ihKYUYdWYAY9QT0rX1PQruKxadY33RvuHzYrA1G1Nxbl2hKtt+ZqTvfUq1tCPWNPit5njEiOxw25GB6+9YsVo/wBqjWIMGkbkA8YqxOBGE2EbMYq/4dRZb1nHOxenrS6itc14odqokj8BcYz19qjnDKyQRswjNXZkZrhVXCiRTk/3KWTT2Zd0hKoq/hQWtrGWrFGj8p2OAQwHfnvUpdZmyMlujEccUy5RI4w8B3Lj5uO/tQk9ulqNg3S5IZs4wPpTtchuxYAVsFCGYnle4FQyEpGdxIbPfvRFKgIbO5AdpYjFOmgE0WY5hLtOQxHU+gqLGqZWlu5UhDOxbAG1QPerP2s3Cny0ITA5Y5yfWoxAyfMwHI554qeCE+Yi7Plzg57ik2UojEttzBSBn37/AEp5smEqxspGFyQSDmrt/aSWgTCBpMjGDwM0yLzDKD93HBPc/SkWkVGtERVXdubtj+tRvH5Z3FDswfrmtVwzllIUHOcrx1qvdlmygQ7j27CkPlM2fc4OAM4+vNRCeYRYlUFv9k9PetJIDkE/Kpz261PLZIsG9yVxx0polxMe2l23A81vlXHIOOPWpbqWKTLomUHTJp7Wq7wu0HnJHTApBFnOzGP7vrTJsynNMzJlEXdnOO5pr3cLL8yFHGAB1GaluIQJAzHaqnkgYOajlgDQxuGDFhu4PT2pohjGBkZTGSrDn0x74pJpGmz5pBbrleM0n2d0dGRsAHKk9zUqfvWLPlHxl2UZz/8AWo2FbUS1j3lWycNx8xxg1JPZ+Wvcgn6GiWPONpBA53egrR00iZkimILZxkentQtQuVdOuyg8pz93jdV77XmNV3DH96q9zai3MnAVl9qzhe26oFaUHrxnoaJRFzWOlkuM+X5ZwFKsBjgVq7fMlLRckfvAmck+ozXHQ34LBIpNx6EKea6DSZFS4BUgSQDPJ+8T2zUNGsZ6m+sbQQSQAGawZsBgPmRvb2qWygkmuY5I8SSY2bS2CxHGRV2ODztPWS1kUSxsJTG3Rse9TTQxGW1ubFfLn83Y8YP3mIz8tQ4s6YyTM8zyxyTI0AWWNxviAxkDuPepVKXDO1tGI2ILBmb068/0rRvFl1ELdwhZLlD86SLjnoRTEuYreZ1vNOA3RcMnCk/SpaNEQWcUw3PJM4RRuZI3+ZT2OO6+tW7uwmtHSSXzpbeUY35BAOOcY7UrcGNrGYtG2VJLZCZ7fSpkg+zQyxzbWVjzMh5x7ZpGiM5wYywjaQr/AMs2IG38uxp90QttF9ps5I0J5IH8qsoHRnLRCXjG11OSPWpPtxCRJLKRATjL8qvtmlsNplA3BUEo5WFk2MucHb6kVQ1Bc7jGJGgUgmYDJx71cu5IiheNBHITgMDuVwP5cUWiubdmhK+UeJMEgKT0JFK4rXLkAVZwG+ZznABxT2cZOD8i+nP1qtDgnzSdpyUAP8X0qy0HkjaEJdlwFB6D3rUi4y1BlLPMhjZgSh6fL6/lUN0/muTECIBg8fxe9XHiZ5VCLuRgBhuhHrTbqNIZMBXwV3bVP3/XHtTsIfHHFJBFIVYb3+bJ+8PX3qDVLgRagLe0jeJB8o38hSerVetFhS3lmnBJfiDb0B7g0izieeP7VBl1GHfP3eODT12B6DoZWgs4rIRO9xJl1lzggf3j6DFWLcPFBALUh0jJkl3jOHPGPeq2mXkgvWaNW2OpRA3fPce9LNKrJc2/mgSMgAm7KfpWiSM7lbUtQni0e4uJg7yJJ5ZI+7GuM9fWvL7x5L67e8ldmk27Ru6Kvauq8ZuLHToLZZH/AH7F5FDZzjv+JrnbG0eS1EW4xSjnpng1pFWVzjrScnylGSMhYYgpEpbllHIFWLmFhN5EyhWGC3pj3rWkhEMLRxht68b+pJ9arxWbzYbkkfM7k9MetPmuZ8hL4ds4kju7i4DSxL8kGD/rZPStzSNUS8Eggj2RoWDF/XuPoO1UdOCpYXti672uAG3KfukHOR6VpeHtJ8uSGEIfLJ3uSaJStojWEWUZLe4ublmU+YnOBIcD6AVU1C1t7bMpjIi4WSL/AGz0x613lytvbRyDyxINp+8eOnJrzLxFqUtsrxLFHLCHDKzDLD0xUu0S5I5rW4Wido9uEwcAjlT6U7whCqmVNvzDBOKie7F0kkl0SJyeEA/nWjoEISF3A2l24PtSM3Y2oYGEyEhQFJOW6D2xWjei5vI7OJjtVdy7iNq47HA9qXw5p0jK84LmJHzucBs+nX1rU1+6gismxGDclWVxnAznggVSRaWhxGpqS5jbbgMAdvGR6iqiW0DoPKJYnpxT72KSdI1ReuQTnrmr9lp1xLJFBZlmMn7sBVz9fypW7GSSMmdFiLh5gY+ATjgH/Gr+mWrz25YhWjXkZOA3/wBetrUfB8ttAwn+ZosbQnOSefm98GqFhZP5zxojBSQfr9BTceXRlxjqVLyGTy8KmUQ9O4qAtO7xxAL5yrzyRn0rqxYLKixHH3xG6lSAB/e/xqKDS5Y5ZUmUlN5XcB1A75rNppGyg2ZUBkIBnb5s/gD9K6jT9IgltjM5UADK44Hvj0qlJpioqs7ZyCGG7J/KqMt68d2Y1nMEWMnj7+O3tSirPUrZGnqGmy2khMqMpYZUkcFT0rPlt8DkbXbpzmtqPU5dY02DzW3S2ylASvDCohaFJcswAJ+8RwPf6U5LsWtjHaBljG5eMHJxWXFdTzTy25QKkZ+8Ccj0Ga67Uru2lsBDbE+YhxIFXqfX6Vj2emPLuS2Us7EY45Jz37UW7Gc4voZDqHygG2Rc8ngn3BpJICihXkJAUH5R1+taur6ZcWbBmGAp2sAud1VobVzbEzKwkJIEYHU/4UrE2dzEu7UzoZPNfeG4Knp7VTFlJAWLuVjbqW5DfWty6s2ZVKRiHHBPXJPWsyEvCxjmibaDuUseDVrYxkrMqTB4m2DJ5yQe49j6U5GDIPKwgAxkN19Tmt+2FtPYSsWEVwjfdIyMe1ZbQKyv9mVDtIDP2zRYXmVpGZCM5KlcDLcH6Vat22lXVlQnlR3zVKWMhUaX5t57cge1RwfIqZXcxJ5A5WkkS5F7xHqILSgHhkBJxyfeuXs40OAVGetN8R6gwvDCPvHFRWLzyLuVMbTjavJatOXqZNm3BbD/AJZDa3UVchvZbVyMBs8Ek1ko9w4z5gR84Kr97FII7mTaW6P0A4wPepaRSb6HoekeJNMghInluMhdpj2dffP1rp7TxNpOrxbIrqGK7zkJJ8hJAwCD0zXivlvFAyBwZAeM96EkDbQdwGOgGRS5TRVXE+gYkuwLK8uE8uGZPLYxtlgCeG546imXUN9bwvvHneU+6N0I/eJnnNePaL4t1vRk22127RcD7PKd8bKO3tmu98LeP9P1a8eO+DWMTjIiblQw7A9h3qJQZ00sRF6M6awsUvLNXk8tC2SIgNnA6En61N9lt5Iw7o8aIo8wKc4PsTSyLC0TXOnzSu0SbhGBvV/UZ9Kfb3dsunTFzN5cjbxH93txg+maxcTsjK6G3Gny3F0uyd5LULgvn7np9fwqNdGdWcSnzbZj/AcZ9ODT7e4hugLNgyS5wDnlT2b6VqXGkzMzGa/aIMAQ235W29CPeptctXMhLOxRJdk2DEd21hg1XvLad/3trGphK7WaI8MfcetbF3p/m3MbahMpaTG54Ouc45/wqafR7rR7+WWynQQBWPz9x3HtSsDMSWZIlj3xn0QY/WiBRIJZrxygYbs9sDoKjiVriUAjBTgE/d9zVookqsszKkQxkH+L6Vra5gMt4nmP3iCxAQH+7649qsXkqSNLcOrZjCxqoGCR6VEolt5mRpSGk6Dq2zsBVwTqhIgjRxHjdvGMuew/xppDKh8wRiYxFP3J8pFPO71NULJmt45Zbt3EzdHYcfh61csmuNw+0sufNLdPuL/9epLk+dKvIeFMEMep9qaXUljrySOG2SRLjaHQYDcDPYLUM4isrfZNJskQbyPvZHp+tLKkV7JG9yq4i+ZFI4J+lUL+5tDOLe2gM9xIv7x+SMjtVX6kM5PxBcSX948yoDGoGCw/SodMk8uUgYVgQxJJP+cVYuMyu7MQCWJ9BUZRPJjihz5xcOzE8bfQVotjiesrl0KXmKkbsnIxVkW8ksclqm0eaAjfLzjPFPsYS5DBTnux/StjSQIruYRorXOwmMsfumiK1NktClbaSLVogoI2gjd6461v2nMMEbcqr9+rH0+lV9ZWa0t9LkkbMsnyyrjgNg8g+lX7SKKytLaW6kaKdmBQtwCM9frVJajVloVfIk12K5j2iKMHYjSHHTrmuO8QaU1uJBFiXywF5Xj/ACPWu81GNYpp7qK7PlynMiIvPXp/jWJ4qkkdpneGONv4RH91RjkY9xVSgrAzx+eEvcBAuSTgr6V0NrbkxxRN8yowwRwAKpvta+85OCoJKkdDnitaxXzH24Zm3DAHr6VktDK2p1GhabDsN5JcGOCDnYGwGx3A74Ncdrs6XuoNKrk4k4LHlj6mtnV5bgWUlogdN5LNludv07Csyws2FvkqCSdqr1LD1+lU+xUm9kaGh6VJq06W6SBVCNJIxOPlAzx71qaTqqWeoRwW3mKF2x+Vjblc8kMOhrS0OKLS7OWRIt8rx+Wu9cMM98VH4Z8OTy6mt7O0bQRESZdscZwMge9Wk1sVyM6oCCOeW1ZIoYp5d3lupJAbgYb8etVdR0e0tlEzQMhX90Zlzln3DDYqPX/DN5LqrajPdCG2hUDJYhWA/hA9f5UyWV7i2WFHcSMf3URPf1JrVvuUlraxi3arbG5ubqfJLbQyjO7ryB6VZvH22NpdRqES6UqdvIwOM1QvNNutTULEjAic7484/L9amuVkNoISFRYjtXBOPfI7VhrsWg1m6s0ZbGyDFo48CYDgnqc1xl7GZpQ8jGUEnnJOfWurXTNu4XYTzGBO48qay7i0kGxBGDC2f3in7vtjtWUi7FFdRmtIh9jlAz8p2ryB0rSjnubrYZXxKVAIzjj6VWs7YorBoWYL0cr15qzFHKUKLGc8DeOSg9DUq7Haw0WO2RsyBGd+Dg9f8Kv2OsRaTrNoJF2FyASORkd8Vbso5pxNCcyINuz5cEGuf1m3KXW51cFW5B6j2q1eJJ1F/JHcXhY5dASd0hAGM8N+NVEjguJ7iN0JlHysF/h9/wAqxbli+1Y1AfaVIcYZR/Wqmk6tdaVqQV2DxyyASA/eHoc+lPmu9SXLl3NmeK3hgnihC+Yw5kfkde1ZF1ofm26SQyRyErll9/6V0t7aQDVWUSpI0vLOnI9hzVp1W2tCixD7QCVLp2BNXa4mrnn3/CPXHnll3xui+Zh8hcelUfsMieY7QyASHcNrYUZ6E/jXoGoX8Y1Oe0+ZVbHlhucisrxNZhSZml2owB+Rhx9VoaMJRVtDlXgQW75c8gH5RjDe/vVeGIi4WLbkNkjjAq5pFwlvdHzoxIueQD196l8XxWcepY0+dzEVD7pF2liRRayMdDz7xRBF/aQdTjK8n3zWppaLHCucgdAFXG6qWukieJjEXYg4BFW9OM0dlE0/MvXnqFob0JtqaDalZReYbq3YOFIUcHPvTLK4jmjXchjXB3DOCR7U57cSKJUPAOCBwSO9Iqq6kuWURn5Fbnj61MnpYpKxVnWKSTgOyqAVVu4+tWbK2kuLpbeOMMW4CqeoqR1REjkETbnGCyds9jUd1Fsh3QtJHcRjIIOM/jQnqDWhPJpk1pcm1ulClsFcdQOx96zbixkWVo2ISVcr0wT7Gp7TUbhbqCW+Dy4xwxySB2FamozpfgXClGaQhindcetVcm1zb+HXi6e0SPSrr/Uh/wB2TwyEnkD1Br1ltMsL5o543mgEbZNtIQFYD0NfP18pSSKdEIyRlh1XFeu+D9WW50I3l3cebLG2xhzlW7N+VZTj1R2Yaq/hZ1moT212sJjthFdSrsikQDchU9/bvUUltvQw313HFgBWaNiVb6+lZepQ3rWz3NnGQYz5ZjfA2q3O4H1rUNpHqGgxtcrELxey5Bx25NZONzuUhuoCSF4o7Eq88agOE5L8dwe/0qW2vp7XzIL2J2O3DrnOQfb+tWre0L6ck0UbxT2/3Sq4DHoSfeoGmuF0x2kghWaP5gQwOVz3qbWKucvFljHG+EV1BwO9Xpp4orVI51G4EkHu1ZSyRI0aLMpYk/8A1qtygGBGeIlIwMAHkmqXkYFqHzCFv5OVVNiqecA9TmqsFzLexXbqjJHGD5Z559c+tJFF9ntZYprhhbE+cWbtx9386mbUo4ra3lxtt5vlKYwoz1JqwvqKpkfTIj5u2SZ98jLztA6Ae3alklkVfLglXH8ZyCQO/HrSNHOssLmVI7ZF2ogXAIPY+1O1G3gsvLuItiSy/L7qfpVJEsz7l/nuX3OEZAscZUgn3FM0qZ4pN8KNGsUbK0rDoTTLhkt2kuJJme4lP7sY4VfX/wCtVKC7dopZHkb7Kp2pgcn3A96SepL0RmwQGaOV9yKVDN8x64PpVmytommjYenQ9R61CoBErKuwbs8npzVvSJBHdCNlYq5xjvj1BrVI5lYk07UUe8YRBUVcdTywzjIHer8QQ+J0nty4SVfmGOjCseLTEsr6V87wTkdsc9K3JYTDBDPC2SCZFOOoprQqNzY1xkkjhiJVZEf7p7VjeM1vLi9g+xuzQRKqx9+T2B9qqaWJZC0lzJ99eSTnn1rWSTz5VJDbI/vGPnjsfamrXGyGwv4p7x7SRyZoV3Mg5ycVmeKLk20AWOUo0gw6k5zUtpb28fiMvaITczyAZY/dwP51h+NJ5DdvaeThgcBcfMx+lNuyJu+phfKoaRgdu7oO9dP4SW2gmS51Ar9nTqgP3vy5zWAoMYij4y4ChepJ9a0Gtltl2TBmI5YAYKn0+tZrQUdxlxfNqGq3QaLER4Q8ggehzXRaNamLEBhwqoEDL1YHnrWVpemFpomUH94xwDwc+/tXpQS0sNGjuG2tcKCjADhQR0P881UbvVmkYmXdfZYuJrlFBjwsmOd2OlWWSGyitRYOyyFFdg38R6/SuP1C3fVWkAnMUSkYkJ+SIdifarPha6lM6Q3EhePyymcZx71SmXfWxZ1m91C/1FFuLh5eCUBG1cnrmmaXqagzQuTJIjY64CnPX8q27jT4UDK92FmAyrbsgH/6/rWNBpsFpeFGfcjqQGBzlye5704p3uOV+hsWzXNrrS3kjW7xCNmVwML04H61m2Ks7Xc8uwLbrwW6sT7d6bIHdJRMWWNTsXaewPJ9zWa0jtG1urkMSzFy38PZSPWlJq4LTU6SzKGARTRqQoGCRnIA7n0rLvLJSxkMR2SEMSp/IfSq6XCwI8jMAQoXg8Y7k+1W2mneEyiVhHKFOeyj2qGXFpkBindo0VHe3XqDwf8AJp6Wy2CGVpBACCzRls7ge31p2m3Rjx5i7gW/1hJbH0rT1n7Ld6Utv5YE5IcseoH0qUrlM5q41tLWS0a0j3QsQJdx5PParV4ouHZ0QxTByy7OAAelZk2nQx3SxyDDphlB/wAPxrQnthDG81qzyREbgg+7gcn3HNNNszs1uZ1/BJJaoLh3E+drbVxj3rOk0Y3dud8p8xeVP94fWun1N47uSO6trf8A0a4wGhz9w4/PFVb63kWeN7eF2gAAKA/dHfFTbUGrq5BZG7Dfar0yTSxoojaRfvJjqT3Iqkuq3d9qUVuzgQc52LkjPeuhj/eW7R3SukcoIiYDpgVy32S7tL1bq3bYchlc/wAQBqrtGctNjevLKGaVBIAJVwvzHD47nH8qg1rTJRp8dzJEYtp2IjoMlM9SaS61J7qTN3EJbiWQyNNuIYHsPoK27vz59MCOPPtpFACvnjAxwf1qlZg0eXXtiXcMsbo4/i7EeoPap5ytyFR9zODuYt1wB610On/Z1+3W95HksDsDvgAjpWHdIPkUuh28lux9qlaGEkcd4gj8yaLczOFY4LcFR71qWcQQRQxkEFf9Z1J+vpVHxDtuNQtVKkoDyAc969F1PSp7PS7NkaNUVP3OxQd4PUN700rkJGPpSWk6JJczTrcQAqSsYKH0GfrUqadI8xJWLy3B2hl4qzp4TTJgvlzCXhiBz839a29GjjkS4MgWRm4ht8Hez57elG+xrGKW5zkWhYJUS8Ku5QpyBmqcOmIYzHJIpO5vlzzgd67+90n7AysxeGZ0w8agdT2x3+tcdMrwzsGTDKeX70pKwNJGJq1qxYeWoBU8Y9ar21ttkOc5bAIA710V1GzoZWUjdzn+lZzqRLEYxnJxwelJJ7MzkupFcoqQAg8q2Af5ir/h/Um0LUfMQ+dCwxIpGQM/xD3FV7tkabyGKq8kZK+mRyAazBcRmR4TksAMseOvatLaGSlZ3PXdEv2vYrm2uY288hZYpc53J1/z6VuaHcGQMl7H5MeQBI4yAB2rzPwZqoAFpdsy3NuT5E27+Dup9a9Fhu7lcwTNHJDIgxz1GOmKwasz0adTmVzWtxL9meOATSxSS8Mp+VPcH2qSaKJgLRFk8tGO4ZG9Wx3PoaoaLJBPZRRxzPGlufKmQKWHXPGO/PerEttGLt5reaVWwF2NgbiOhNS4m8Zu+pwrKHcSjAl+6wHarkAkZw8hOyMZYe/vVB5WMzStEBJF8u8dGParFndt5W596iQ7JB/OlYzTLd4BMCrhHL4YIehHpUlhKguzHLBiAL0YcZ9QKoMY3lEYc/u+A/cD0qS4YvHHCg85kbJYMflHvTsFzSuLuGF0trly0r8AKuSFqlNFGlwJ7hy0SDC26HPPuae17ArIfKQXhxtkZu3tVASXFzLI3l7LVM7ivBZqdxXK1xcreTSsq5CfMV7KB2rNnv5pkERVFCnp0H4Vq3O1IvKMaRbvm2qQWY/7R9Kw5+GdlCscYyOQKl3uTJluwzLAybRw3IzRLGSgdVAnj4PuKbpbAE7MFtuT7095jvEi8qOGXHIrdM51G6J5r5Ug8x2AIHzZFOtbmTarK7PASARn5cVRv1ilXK7XVhyuOlZ6XbW4CRoAvbHFO4O6ZuST+XvC52sf4e1S2mpSR2TBHI25JOcFj71jfbVYLldq53ECqsl0ElaNTlHPFCJczutEgWHSZrxpkV3Pljf95u5xXAyXEj6zJMG2tCxYSLz+NOudYkeAQBwIlyQC2CD7VmWF1/pUiKpdnxkemKbd7JCcro1LbzDco0YbLSAeYeq/StzVS1jdmzkdWdCHXA5Of4j7ms+1cGbejAlegx+YqRo5b7VXlAiC4BCr2oVrFRT6HUeHdHlnkjnVik6kn94+N34V1QtjqUDG4mijb5tscecu+CAT2x6YqlbWNra+HbDUNUZ49u4qUbLNj1H1qa21rTdTuEe0upVvY4/3abAFMmeB7fWtFFJWZ03see3lpfjVvIAeKEKI5I8nA+o9etdZo+nWlrHJJNJtEcZCjHU+p9fpWjqIu31RZdShUvGCS7DG4/1rD8QXZmgMatIkYGWUDLE+xqWrDjFLUr3N7vct8qoWztHQD1FXtOuIdQnZVAcquRnlhjuBWHBaTTahJZRsJJ1RSQTwAe2a2tG0eex1MXjsVzCepB3nPHToMVPvML6jbwK7SBCcxMAAc8D1xWTLcxB3Eih0A2/KO/1qbWpWtluJFjYxhyCV65NR3dtI1vbx20bsjKHfjO0dyandjuiex0yXVVFtaiF1Y8xu2M/j6V0E+iTab4ejtfOt3mjGCYn3uMdR7CsrRw9tLcyEYhQfIf05rX8j7XbNLGY5FjXczD+LH8600tqTGOtzG8L5dvLl3+XDvlZc4JIBINVdC1JdV8ULHqfmwW0tuRE0C5Jxnkj60+3na2uLoGIl2+XbnoD3FUtBA0LXPtqYM2DsD+4Pr9ahFSvfQ2vEvlrdRSLbgRKmN2OGx3zVfQ9UtYtVlW9QG0kt2VQq/ck7H1xUTX4vLhJbligzl8LwOeaILGKVvNdgGZioPOVX3pN63QWuW9O06eW9DQRlyvzMC3AGece1T3WsFtTuoY7dVWRdhY5yCOmB9OKn1No9EuIVJkiuGUxtE45K9cgdwam+x2msXyXtsQkz8SKzYIx0zjimU3fYpXItp42by5EMR4iHQMO4/rWPcNMXj8pA6TAsVI5GTxj0reu4ywM26BySQSowFI7n1rIsI3uYQ9zbs5ViQ0eVOB2I7+1PyM2i7aWMUkSXLkpKuAFJ5Iz2qNrh5YFiYgRqpAJ68GnteItqLdkcQgEoQOc9cE/1rlPEk8j6gnkO8aBeWC7ufcUN8om7I0blLX7L5sgTzAxH+8tYV/DBtLj5EXoMdT71jtPObh0XzHKAE46j/wCtTr6+Kwt5wPTPzdBikmc85GPDDFfeKrVJJcR713ewzXu/i9447OKK3gsY/kG5YzlzgcE+hNeHeE4lm1drxvuAhsnriu+v9bmT9xNCspcA7l6hey/SqTsmEO7LEFkZMGXMe7gFeSB65rc8Og6K1w8UXmzZMcM3fcejCseKcP5RzgAfdU5xnvWxrErabpsMturuhy4dj904pU0aytuMkuhdXbmeePoVHz52N6EnvXH6/aut1JNvVsfIR6j1xVHQLXULnU2uZZGkjZyQAMgY5ziuk8RxLcy20mwoxzu7ZHaqlZ6ma96Jj6PP9q0j7PqWwtk7GU8gVSkREbjHGeB6etPuFa1QuNsaL83vinW8E8kD3cxEaOv7sZ6qTU3vuZvsVba1gm/eFN7qNqHOSM9ay77TZUmlkEKiUfdLDk+laFvdzaddQRWcW987nJXOM9K6bxARNZpeGIRLgKflwWPrTb00JUUzkdLuXivYJJo/nBBK9Qa9B1oG8NpeadMwUJ82Dww68/SvNb6ZoJFKg/M2QD1xXZeFNSayhinmjEgB2sjDOM9xWclZXZrRlryneCKXUdMVtI1CGwIiG5FlxznOWwOTRKLmG1t3NwLi4ZQs8isWEg+vbFQfb/7HmXzRauJVGNsAAYH0Pt0qWHMl3c+XljKqlBGNqqMe3GazerOyOhgywkBo0XLKoZeePwqgEbkybiykNtBxg96SLUGmzGxPkgbeOMUPcYdApcMvy79vGKm9xMtlt6jCALL8zSelR2wEEJFrIpdicSHJJHpUSyxM7fvdzqMFemfWklmMQjUSC3RhkEY/X0pxRNx81tE5e5kPmzqMb8ZX6Cq8czqBAjMCMvluEX3pJZ4/OA5kGeGTkE+9MFxuYrMvRss56v7CjqJsjnmBdnADkHb8/GaqTh5pFhUqo9MYGKJpWaQyxKqKrHlz0Pt61ZtZFSFvMG+aTJQ/xfXFXGNzKUuhUVTbu5zzFyMenoafd3SxtGz8RueeOv1qvf28m9JYyd56qOSw9ak028jdsuqyKnVZF/StGjOMrMnmiVoWeF9pxnA71lSbSQWTLDt/Wtx5ISWMSLEC2dnUL7A1DJKo/hDH2qNmatJowZXV02gkEcZrLu55EO3fxnIPeuinCbCNq72Jxzn86zbm1ikTJySew7U0zBxsVIWFzEWUAyHgj3rRsrFI1Tk7jndjjtVKzdLa4RmACE4/HtmtzBEY8xSQG5P+FWQiWxDJKsWwCNkyvOec96tW2IJRLIxBz83HJHtUcOwlRnkdSO49BVzULEPYG8ScIiHocbuegFTZ9Dphsdh4mtX1aHS0sYGkaaNNg3Y56D6Zri5dGv8AStfgyHEwfEpJ+XIPBX6etdB4L1dWt/7OvBKVbBRh1Vq61obL+0v+JldnCRMYWZuXftn2IrWyl7xpbmRYYJL4VkvblZmlYEl35RsHnk1wF40sl2mcqH+cIBnaO1dP4hvVvJVSNFWEINsG9sR8eh4z71yk10Vl3sFGG+Ur2HesqjTZrE6bTLK1tfMuYZlkmkTDtt+Uue2T+VR+Xdxq1wzI8avkkkZJA5XHbrWVbalC9u8TuVQEN05J9at6XdwPdlFZRvHJZv4vWrUroLWNGzs7OeT9+Xf5clV4G7sM9zzVe9v0sJvs0SGFeInVR1Hq3ritQoYblIghKKMhs/yFVpNTspZS0tnGzopVMjjjqR709EgtctaibR9Pt7aZwnl/LhBjeOME981m6gLa08yPTJZDAMl9/BGexxXP32rzPdSmTKgkE5HOPakS7M8G9MlSedw61DncaRBeFmu1kMh8wHKyDr9Kj1GB3t5bh3M8CKDI4+UIaikuEaXLzbW3c8dPYCrKGOSxuoZdxSRflQcZI71muw2jOVWVgXw2RjCkjd71qW0o3RqJH2K/zgtx7VTuwuxQkIZAu0ktg/Wnw+VAI8Llj8uVP86dyUjpr63t9bSB7q/dLoYjDSD5do6At1FLYBQHWDcJI8qyZ6g9Dn/CsBXkt7p3Vly2MCQ5/StXR7mS7spDcHcIV2bgcfKTxj6GrTuw0vdG9eXcU6LDHHFG8KZXyhyeP4qygCryh/MZHO9ccEfT05pNOtW0+SO6iuI59/yt2ZecfMKTXXnaJjZhyQxI2jHHfBoTE9io1v5cU4jLMxOQzdR+VYGrwH5ZjjGdrbe5/pXQTxuumBLssskQ2vHx8w+ormtXuHR/3JXaQpAXoT2/GlLzM5GReQyQ3SyeYVmQYG3sD2rl/E12U8uHoWOFH9a7W5jkis42nVUlf5jtIP0rj73WlsdSuElsLe4E0LIjy9Y2P8QoirHNIXRXkSECBfmJrpLQSOhkkfylI4YZ4rk9MmSEBncLt5J71uWmoRzuoErFOg2dqVhpq50NpN9nEZttzsrcODjJ96uJdtcLJayXI2A5VFyw3E8g1iWUTC4Q5k8tzkntXTwvmNkghVSG3BY15OOOaqnNx0NOXmsdDp1giw3NwqxJsUITH69f5Vk67PG2x0wVJJUsOQKmjlvba28yVGiWQ7i7KPyFYM0zandeVECWHIA9KqT7FNpaGfNarfzmJSSh5P8Ate1bF3bs9qisq8Kike3XPt6UkMUVrJIZUVhGpXAPBY9/oK09GzLb3G11Z5OPm9MdqSRna5zMGhTm6e53+VDuCs3r6Vraxej7BHYwuZZYzguRlcEfpXT2ltDDb480Ms42ssg9OmK5HVI47CUqjqfOzkjnFVy2QmrHEXtm7yvuZmeJufbPpXQaKI3kjSV8cfLzxn0/Gsq58yV5FOVHQGtPTXSN02xqQF2jPTNRLYiHx6HZ/vLuG2t1ico4bYAudzDqAe1XftrSXr20cQtJ4cb2diQ5wOSPf2qvp90r2UpWO6LLbm2cgfuwpPLqf72DjFL5Uf8AaAgMEwjjiSGKRx82FHRvesjsi7nIxMgyqF0U/e9KtxyOm1WClCeQTziq+B5Ow4JPQ04xEykmMkovB3damxCZNdKyEtDHE7k/Lg9KYfLuHK3uXIzyvXd9acnlRrtlBRH4AQ5OfrUc0SFNkW7zFJ6dfxqrA2WYZhGFYsqheiAdaz7kx+a5cMV7emaS6kDFdjszAbQAMYPuaiZSjYLnco3AdqaRm5E3LKpjVS68LuHPvUu4xlpGfG0cL0A+pqraDax81T8w4IarMgEkaRv05P0HvVpWM73I7cyFzM+0luBzgAUySCCd9xQp6Mgxj61OZ1wqIgIPr29xVqZFjTjGewbpSbKUbmF9nkjBRZN46kEYqJmmtnC9FUZOCDurXcli24DA4GDnJqndQmVFUx7QBnI+tTcHEzJtSC5IUjPoOazrrVMh9pPpirt1powQGQnJDMD932NY8unuhIAyo7gVWxDuY+oXU0o3RbgoIPNd9Y3H2iwjdsFmRW4PTNchLYF1DKpK9M4q9ou+3SSDJ2sNy+x/wqk+hNranVSSsEUI48084NTWly88PlvINinJBHBNZ0Dx3CIGG1h1GafFP5MxRVG5h90dxQ9DWMuprWsz2rMYiQ/HJrUTVEnvftOpfMyL8qIcAEdCaw3mZVG1uXGMYzSQIUjHzGVn6A9ajma0OmNjoXvJL+bK5ByMlhkYpl7FH9oCwN5nGA7DBJ+lY9rdXNvI2M+URg9wPrUxuAzp5YeRs446kVLdy07LUs6Fp1y2qyreBEjA3xlzwVHfir02gzBheRuAEZhhQTu79Kszv5lpFcxJtCKFPzZGM10sup2GnafHchJGvmxtVANij1POTWyiiFtYnur23h0OBbxgLyJNjDBLA9sEcbfeuInuS05ErqocghgvTPWpde12XUZ2MgX73ylVwFHoMe9Y01xKtwjSxshIyM9CKic7s1i7G1GY4vPDqJIpYzHluoH94ehp0Fsi26C1+YyMT5Y4CD2z2rLS5SQGN+Vbrjv7VMly0UKonyBDjj+VQnYehS1EJb3SyNGAOhbqc1paNbveyqhl3P8Awpwv61m3482Ml8eo5/pTdHlntLhJ4S0TIfvlun4U1q7ibtoTFJZprhI7c7sseedwHU1WMrorGZTFnhfQ1oxy+bcq53+epznHDjuD9agv3ivJNi7Vtg4bywTwM8gUaPVCuy3fxpBcRK6AZUYcHPUCr+iXI02GR5QJIFcfL2YdxntWLqH2ea9m+yys9tnKZJyfYVpWd0k+nSWEyEB3DvJjuP8A9Qq1pIV9DQ0tl1C6VbU482QRqg547f8A666u+t7PSJoodSuHWSaMsIJY9oB6Afn375rhdDEkN9GEfywxyi9M49+1eg63Y6Jq8tvfPcXU94qqSA25Sc9CewXFaUldNkTfY5rxBYSWsKSiaORZYyQvbGOje9efX6rIY0YMu5Ac9APpXo3jSWH7NGYJQ2//AFi5yR715drF7tYuRuKLtT6UqsbMznIZe3G2ELgYTpz2rhfE4Ec1qxBVsENnmuw8mOSwW4EjidiRsPIxXE+LJHNzEGX7jYPoOKSRyyY2ONJ2QPtbnd7V1Xh60jjVS0ZGScjoD7VyunjIBYcZ6jriu309ijKuUJYfNk/0pN3KiktTeeSKd1jVfKhQbXXOST61o209uijYXYomSxPU54+lYUM0SuQhLH72emalkkhVv32SrD6Y+tZpu51Xsjb1SW81C0gtyBvUlgEYkqPc1esrW10XTvkQpduckuclge/09qytM1AQ27+WvDjB2nkge9R6lqcl5exrl5JWACL6D0/D1rVSuZu25R1CG91O6isrMHacvIw4G0dq3LK5OmRQxvH8yrjIf/0KjSo/IWWV8neCnHSql4rlwigDngEZJoV0TtqTz6pI6uFkdFGdo7H0rntRmkklDuwO7jdnOa0TpFz5SPdjEhYlZFbOR6EVn30a5KZMuCQCRjB9hQ3qS22tSlLHuk8tFJXfy3p61OFEcwUKCiDLY4xk0to/lIXkIGOAKzZrkzTyMnykHPPcCoqPQUNHc9D0+6szbG0u9Qt0jNsYUVztXeWzvU9wRwe/FGp3skGuxwwyO9usaKZW/jwMFjVHT7y/n0Swi0uOKdUTDHy0Lo+48MDztx0Nbd/eCcM8jwHyzHGojVcrLj94qn+JcevSoeqN4yszlpSo4ABGMgjrmkZ2jG/Y4A6465qGKRDGACxYjAbvmkc4AG9i/f3oJciwZxEpUPvVznBFPikWbewBiUckg43VW+ZHwSoQ/MM84NKI1ZeWVmzyd2MU0F7krSYAONgxycc1UyDJsyQp5z0Jpbj5YTuZnbOBVdAZWjJIUL1OKtGcmTRfJLK5H7sDkUQs7bp8fJj7vTioZnaVikOTGp/OrTsYoDESGXjHHehsSVwibGMBhnGMj9KsvKTHyC3qelRud9uBtwxPIzwKc0gdkQ7hsXqq96zbZrG2wxGYOzFTs6Yx29qWVd8Cu7KADt54qaUlYgGOMjGCeSKhnlDRRps4wcrtz+NLXcohuIkKP5QEcYIOSevrWcxcthY0G7n147VqTxLIhQhtoGTx3qK3tXWV3VQyqMnJ6VSldamcoFa4iluWXMLQblCrhcBgOpoltUWXCJhAMEj2rXu7u4MUTSTIQseACeQKzWHl24eVpXk3AqB0FDHZIo3Fs2cwqy9zjnNSLJ9ot23EZGOe4I6VZK7Jd7zSCQndsBAFQXVuRctJGXWR+flXhvwqk+5m4knmblBJwhPX3pyymNwZCFxxn2qhNNdQsfNiO3PXbwKT7YkzBI0zJ7DOfpQ4lRqWNqHbMxKNuA561bsWgQF51YuOgU8fjWLZSiIkqCM/wsatqwYB2JBHYf1qbWNlNNGrd3u9ti8R4yF7VDJdF41HmMChGI+v5VVgeMJh+SDnB47VHcGPIeN1B7knp7UalKSJXu2ZjGAWI527f506SVZbdI5t28nIK9vao1RJIlPO4DO4f0qJopXBKkIEXcM9SfQUlcbl1LEKRCd8nG0goWPf0FWI2EgLAsvOOR/Sss7mUBuCp5Wp42bJcOd+OnagcGtyxeuvkYVWJJwDmoorhcASvjkg7vSmsZHdUIUL1JJyao33lrufzG/eDjBzj2osNytqXXn3KDHKQnBXk/MM9qXzCeQyliSMH0PpWfkpAoIYqFGB2B96l3xx7WTPXtz+lAua7JpbhYyQmYix4J9qvWU5JBkZfLA+bd6nuKoXTwNbrLBGZHdtrJ1A9wfWs9pnhnDSPIiKMDvzVfCyFLudtqOoQLptrPbxBJlyJGJ4f3A7VhaXrs0JkeFpIn6nZx+dU/Ma4C/anPlkdAOSfSjVHtY7hTDGWBUBVU/xd8+tXzNq6ZEpO5fvdZlmUtJncc7mHNYLIZTvJADDgNSTXuGkChcEYJ/nj2pjidZVMgwcB1HYr2INGr3MpSu7DgyRxsoBGM84wK858VX3m6y4ib93FheO57112v6l9mgfyiTOw+VT0GepxXnUsMoYlgSepPrVwSOepLodDpU/nRBkxgHDbq6ezk2ncB8+MHBrgdGuDb3TISQJRt59e1drprKZlTLhSOmeQe9KURwnc6S0dGA24xjneen0q2l1bRAGVUdlYbXbJ28c4FZDQyRsxX5k9QetNh3Sbh8mMYOT0qOWzNuc3hONiMhBRMkFe1SWsyuqqil5GOd+Pm//AFVlmOG3iR5JCFJ+4OhrVtpyqIloAjAdScfnSSHzXLxn+ytyzcLzzUS3DPIrEOikfKD/ADqKRolAMk5mkbkjbwKhuI712eR5YIIAAUx8xkHv6VdhcxYuZpOFSR9vQ5PWs28xACAWZuueuasvKGQhX3kAAZ4qjM26QAkkD7xAzikEmQ7GuQWZsBMEKPeqjxKJpj/EfusDg/Stqa3JVl+UBsYKHPHpVMQCXeCwWSPlc/xUpq4onSaXa2r6dBGNOiupJbVriOaUtlpVblBj0Hana3GY763nhs0jVoUk8teGj47j1z3qvpy29lbWbCG9nkdTL5kcxVEbOMAAcEYGTVrfBczSNJFMsjLzHO5cn15/lWe+htEwLcSxow3Hr1FOHysMh2wOBUqYDgsdq56UoBEu0nJHQmmZkCShSSinLnGPepH5CjjzO+en0pHlWJSCpBJwTSkAKHJyCcEYqkK405Zhvzx1A6VDcyZRVhUqWP5VZVRj5wF28kZ6CqkQWW4ZyWKfwk9qZLJkxCuDnI6HrzVuFd0e6QEu5zk1XLbnyhAUdj3pJptuTjlOMA8VLRSdiRWJXCnGTyPWpZ3xKqkbsAVSt5fMx83zDqDV6OUs5EfJVskkdalo0jLQli27w2eQecjtSicS3Q+UuCMcDGKVGU7i0pGcDp0pRIqRvGGPAznbjPakimxDLuVUUbhuyQBnp6VESpVwMA5xjvU4RX84oQJNnysBwB3/ABp8CxqqNKgyMNz3+tO1hXuU7iJs/MeCvHfaKfEMQHD7ySMZXhc96gljkIcNJg7t3Xnb2FSW7tNGskShMHLYPDU7E82thZ0TZOYokUkYUZyenc1U8idLWNlYru5JI/l6VZuZG86PEROeDnp+FJKbrlFctnohPG71zVRREnqVWt/mXJdCcfKmSD7E1WNvHBcqQu08lZASCD/Wpy5gkaNpWVpHx97qwrUt7cvGxmlVWcc8DIx0watKxG5z0XnxtmIFxnlT1qeWSUIrMm1ScHHatkwSPGsiRgbePu/f5qhqqsySJG4ildSwC9vce4paMNYlJb8Mm1zgk8elRSeUx2O4KE8Ecc1QlRZI1RGxKiZJ3csPXHaqEzOg3CX5R1Hv7+lPlD2rR1UdyqoWR8Y6gDikTVFCkJKGJ9x+Vca8Ukq70u5N5weDjFV5bCYgMQdpy7AHj60ciF7Z9ju2mMrgvICSNxIHX2pBLiPAc7QcDjgiuJsdSvdOuYLi0lJljYkRyJuU8dweKt2+uyZUXEQdiTvOcEc9h6UcpSrHXRzRyfKTyOQelSQFYLtJGw5AK4AHT8axNO1K0vTiK5jQgn7+QPYfjVmR5FA5OcZHPSlytF+0TRf2IigICTk5JPBHpUQCb2kACkDjBrO+07YiSSpzyBzTTe5GXPPT5R2qXEaqJFxpGgUSRbQmT0/nVeWZmaNixIByvzVX+0sS5RG8tBlhnNRGYOQfKPoPQ01EUqho/b22AEfOTjDHFRTsHQ7wN4544/GqwWScny1OB3HYfWpraCSc7kfEQ74yTRypakOd2IjiMbiF3ds8gCmXV7ghMEbsY4zimX0cccRaU7ETkuCST7YqH+z5XiAaaQxuuQFHWqbI9DEukuYb4T3Vmlyem1sgN+IrMnDZMnlh89h29q6dLKKBBFI0ip3bltpqGbTpMBo3XyJDwGGBn60cwuW5ybWyTPuGF6Z9jW7aT5wm4GReSV6UlxbHcAsONo575qCKIxks0ZxjGBxg9qd09xWtsdbY3jNAi7ckdRjrWl5gkVS8a8+hrk7OfygplY5PUitiG43bQXUgr27VDNEzQdR1Bc46hRmqkt3cwy7Ej3MffO361aiuUiAG5Semc0SMrvvYsD3K9/rTTBkkUiW0DGaQmQjJ9aljmSa2wmSp4CsetV7VkgjniUqySkFt3J46DNWN29x5Cgn1TrQ/IFcrN5kj7UcgYzj1FbVrZRrav5zYkZMnj9KqW9vtOZyElx8qkdKuwv5sTMx+UckE8Gk3cpJ7spWkrqZVcr5g55H8qS6Chw8gAyASR39qr6rkKZIAUeMggnuKs6bfB1SXZFKF5KSLlSfQj0oWoWNu2llbTrI22sR2QiiPmQDcMjJ+Y4HX1pl5I73eftwulZFJkGTn6Z54qOPWpjl1stN+TjHkD5ae0v2q6EwCQnYAEhTAQ+oFRJGkCk2JMlhjj5cdjURBVlGQWbuKXaoHJJIHSkUJhmXl+oU9qAkNZFO47xkHpnqaA7s33CFGBgf1qOQh/nYYz0xUyyqsDFFG4ddxq0jJsp3boHWIEI2eSaQEbNoP4r2+tVYx9pnd3IG4+tXLSPbkFcg++M0E3FjMZaUfMwT7z9vpUV1OzqhiCq38BP8AOpX2S7xGzAjqpGAcVXkV5UDAY+bG1hg1W4ieGQBB5sbNJnggirsl0Y/unBfjIHb1qg1k0s4blVVQSR0AFPDy5YbUG/5VPZR6n1JocRqTRp3TKFQGRfM2gsB1B9KWTEm8K3KLwR7+tUIHRoGD5yn3QFyXOen0q7DsYPJlOev+H1qHEtTuSB3K5dQYkXbx1JHrSIVMO4YDnr14qC4M20In7sKwJ3dWFMmuAlm88hGyTkgHknoMU+UXNYhkjVLxpUmkyANxXkn2q/FA6lFBCRBiSMfNg9jWQJVt7xIY0bDASS8k47DJ9/StuMTy3sYhQokjbI8ng+5p2sJNDLy5WOGISIxjD7AEXdjPcmq890sahQ4XurDg7aZfXUhuJBbf8e6v5anr5h749u9Y+vTf2fod00awvIwC5ducn+R9qaQSlY0C1q5adXyxYo7k8bv9n3phnndY3WTy4BxkLnJHrWDp9jIYIZpLiVobZAsYQBQf7zfn3rd02D/iRXrqXdVcbctuIBNHUi+lzXi1OQJ99TuOXIwMYFLfJFGonufLiVhmIH7zg+gPb3rn9Wnj0eMz/umvkQO1vK2QV/hL46HPRe/esmDW1vZop5Y3v73u7HCKfr0AHoKpxa1YvaX0NvUFs7WdTKsayPjYyjr6AVnXvlpEDiMl+QuMbj2GexqLVrvM8Ju5EgAlASILvdmAPQdl7VXiSa7vGcSSO7R5fA3bQOeB0GPWjla3Jck3oWhYpcW4SSKSFiMnaeh9KSLS02S+RIwMb52MSNx+nerGkoZ5mElxdRx7s7pIwxI/PpXRraRSS+Wm2Rcj5n+U/XBqXoNK5xdzZ7yPKT99jkMuQPyqpdaa8cok8pSMZK5yQP512F20iyXDr5Yt1XIYjn03H2qqtoBuuVRJXk+QOGOGPpRqVY5S0tVA/dDhuuR0Pv7VettNEbGM3OH+9gsavtGgdVuI2hlILbVORxV2z8pjEwALtzh1xx2+tK47GfFHOVwqxlM/fGTkUtwrQoDHGHIxw54H41qJp5llaUy4PQRj5cfSmzWm6AGa8jt4i+CWBJJ9lHJoV2LYoxrBHKYyFebbuZA+QKuRQM0WZTtbH7vsKz782dlHNPBBPLIoyZHIVmUdcAVLo0zPp1vJPPmZlz8/BGe+KJKwRdye2ZfmRQE2jc+f4vqau2rR5EanjHyxBsEZ71jGIz3UIhLS+Y4gdTwOehJ7c9/etTUJbbTP3iOk0sQCOyDIDd1A9B696XS479BLuQyS3IuYFgjGPKmkcEHPpTJ7AoqSRTkbuCenTrVnyYbt4vOj/dPGrvu6HPp709ri1gnWOaUJ5hMZbqc9RTCyRQtrZJySY8xEcM3BB+tTS6cDA7xhRJGclW53VoAKpdY0klJX7oGB9QagtYpYlf8AekDGU3DlPxqWr6lXtoYs1mTECFMTFuQOlRtp2+PzFm3bugBycV0saG5kbewMKYXOen+NJ9lUCTySryQrzgcH6VN2VY5JNOdmKRDcT0/xpU0x1PmBQpB25BrozAhEM0oZZcnIB4I9qbG1vJJK0I3yI22RfWq3RNkjKgt2ScJJGFToznvWpa2y4ddqu2QQM9VrQaKK1YRSXSywhQ+CudpPbFNhhCRljgqWIVuxWk2ylFCJBBDLtktwoGWAYc+1TRwhX6omeQFOPcCnhVlAMTb5BgKCaaq5UoRnnJLDnFTc25UiOdlafLfdbuecflSJGTJtL4IznbTnVIJowigRg5HXmhOW6E5PSmSxskYuFMR+ZlHOf51j28qadfBXRHiDZAfO1vY4rdcA7Citkgqcjn8aydSt45YGGG3A8ntVIzkjrbGJrmzjuoNM0iKNk3gyTMrbM4yRnpnvUepwpb6iyMba3/drlIiWVTj19ayNFv8ANlYvdWcpR0ksXYEBZV7bc9CCfpV7VmV70I0UkIgRIVSXG8hRjLf/AFqdhRZnZBC7WA9KSRsbii545FJBtZAxC7SemOlOfPzZ+VegqC3sRZ2bQEJQnJ4/SmX0ixxu5TAGdoAq1uKqdmCO+fWsvW2ItAd2HJxjtWqVjNsoxeaqJmHhhkndVq1RWuVJbLDnaG6fhSRBSgXOcDvT90Vv5QjjBnbIAU4JpszXcnlj3rkEoQQcMcZFO3GZo3Rw+eDjHPpVYqJ5jJeKxAAJAPFT6VqKW9wZRbxgKhA3HhW7HHtTt0E5EwE1rN5ZdszZDZH3RREjTTeWJWTygUVwMj/69Nt7k3sEszZ8tjlWY8j3NPthtZwjEoVyd3rQ0UmmKyeSi+SMiMAKxPDUzzh80cZTC/eA4GTVi6WMiMpuyvCqoyDnqTVTyVnDGVTGFYfKT09SalK43dEOo6goigjuJC1ycgRx5bvjJ9qn0iwuJp/MndRLtKjeflC+w6Cm/ZIbRo/IZLmaUb2KjiMdOc9/ao5BcyadPmYJggA4/h7nHqaojXdmqt1Z28L/AGcK8knAuZRhmUf3R2H15NTaYbg3T3GQxWJtkjHAj3L1PvzWZZWexUcFnHBIxycdBn0q3q1ss+mKrF2RpWaRFOOO2T3yaFuWr2MvUZI0NtYaczTPKMyyr0jTsAf7xqDVdOgbT7qzSPbdrbmVo3+8Oev1610OtMttqC2tvCI51giYsq4CjaDx7k1z+mjOqXF3c72eTClmO4k/4CnsyHqrE+kXq+VaNCPKhjVVG9doKn0z1raljjtbSa90ibZDnY+Uy+eyqOnJrJvYrSaEpagbFOEyfu/T/GtiTUIo9Ft7eyiWVIow9x5mB5rMPmz9OADTiraikm9Dkrix0W6uJY75JIZEIkK27bo2Y/3geSfXBxWfcWESbbOzv7aIs5MXz+WcdcDPTmt46fbajptzZ+XtVj59vO7cxsfvJu7g9qqy+E9NhltJLrVrJWPWGItK49RgDk+hq1q9TN3Ssitp+h6lb6W1xcQx+adsUAVgzzuxJJDfln2q6zWFhprW890k2oK2Jvs7BYlA/hDnqB3x1NZ/iLWI457eLRIbi1tIC4JY5kIIwef4R9OeTWLaWS3JLz20iM2AhcExr9FH8zTly7kxTWh1+mpFqbNJbQk28WCbqUlYw3sT1rVgH9oXEafat9qvMjqQC/8Asg1kNq115CafPcTSRxRhIbaNAkYHcHH9cmmi2hkjRCYrYx/ehhY7j6ZNYSS6G8G+pueKktYdCWeOZCLrf84PG0DG36ZrmZ76bVDbQWxVLa1RQskbcscc4H1rT1XUSLKCx020jaCKPbI4G9yCeQueF579ae0Vha2xvr7dBbwLiKCIASSt0CqB0GcZNO3QObW5i6qx+2WWnW4cvtLybjkKvuauXCPBEYZVM5QBty5DAeo+npTbKy8y53O5a/lRpLmUtny/7qe4H9K1tKmA1KP7QoS4SExxlyAjv/eGevTpSS10Hfuc/e3twsabVFww+VLiJsHaeoYdPoafputwXtmLe5tkSQjy9zgrlvqDSz201tLKfOUWkob5OjRsfT2Pr61mm4jlsI44zDFdxyhZop/uyxt/GfQg/wA6pRuRJ2Zc/trS5IZrXUtNkWZF270uWAc9COn41qWNzpVnPPDFpvmeSFSPzrhnyCAQT04wcVyM2nXFvcR/aFZUnlUcnIX0ZW/zxXRw6ciS34v9RsoWLKGbzCrKAO68n8q05G0Z81mbd1em7ga1u/It7OZGRUijCqjDkH17DrVG+0pLeL7YVLkR58tOJGBH8YPb3rQu77S7Oye4son1CSSASRvMoWNXVcZRPvN7k8Vy+mfaL2e0ub+d7m4vHTeIyQUQsD078dqThpqWpdDc1TUXitGg8g/abfaAtrllRdoyDn3rnbq4u9QtGa0gkTKGTDsAc56+tegTpFqNjqE6PDFNfTEW8SjHmIhySQemTj24rAsrCW6eeTb9mgtx+9nc4XPovqT6VDWuhSempBZanJfrHAodfl6A4YMcAjNTadvhhWO4nb905Vsn/WAHg47/AP1qZawpp8sWpWkokmkVkZQciJiPlYnoW9u1LrbQrprfa48XKoVLK2CZP4cD+dS49yky/wDvI7l2McZTZk8Y3H1Pviplm8wIUiYNKcY9B6f/AFqrXGoyR6ZEzICGiXcrjJB6E/SqWh3U6mSG4DuY5T17gjKn8qhps0UknY1LqGWRrltw8pCCCy5+uf8AGnqkClPMj8v5dwfPDD0zVKS98m+kE0gW1eIggn+L0PqCKn8kyxZkcqBzGF/hA5xRYadxmGnMjFA6KMfNzj/IrSsLdJUQiT5cbSG4H0pJlaRQE2gkfMgHPT1qraMLWWKBYsK/IDEnB+tLfcpaEtraO3mPEUCxtgHOCuPShZQbjD7k46jkA+tWCq24KxsJYnYnfnofWoGuBMQQE3J+7bnHOO9Tyl81tyNwSW3su5mwgB6e9RyGQckSRyowJ75FVblt/wC7lLR5YAMP8atAvG5idmZwD1+8aqxnzXZIzs/zOyqD0YelRzQiSJDCjO7HAKAtn8KitWMKlX2mMcHPbPWnI32UAwuyBGJRkPTPpSQ3qSRQpcJa+b/aFv5cXlZjtjLHKoYnI9Dyc1Pfzl76PbBOkcUaRqkww5UD7x9zUF88NhYWMk97qyO6eb5VvKAqJkjPP8q1bixtngkniuLuZkiil3TkMWR/un1H0NXchbmQpIV/kxnjnvUiyMwCttA78cinjCxAenH0qNMmUxk4GPzFZo0IyQhaQqcdMk1i6vMWKIBlN2BWzIpYbt3yL1B71jTwAAKs6KC2MOpOPxraOpjJ2K0lyY3MZRgpP+sAyOO1Kt1C0irGkkp6kkYIz71bj025uJ2itrmzEeAzMJPmC+gB706bTktFdfMgjc5PDbuPw7mtmmt0c61ILa4muWeWeMx2y8LzlvTOKr6haMtuscJYRyn5gB8zD611eg6cunWP9o65uSHAZIT96QnpkdlrJ8Q6u99qHCCPPIRAAEH+Jp26i6FaBmt7RbeGR0cjL+YdxP0pYnlgvI4ndmV8/P3zSWzhGV41AA6secVYOJd0y8En5QVwR71my0jQjc4GNsY3ZJb1qORI4VaOEmVnOXZz0J61Xt+VcyMW3nBQ9uetaIiA5XjbwcjrUN2NlqN3wpExUEyrj7o6j6VDIiPIchmG4Db3PsasRxu0o8piq4GM+v8AhV4QucyFCGA25XpU81i1C5A87rM/y7VYY2AdPpRC0ioBM3HQKwx+P4Vo/ZnW2ikADGT7o6sB3JpuyRUJVByCnzdTnvUuVzSNMoXUk8p3BlmmA2+Y/QDoPyqCPS408vyn3zfxuwwo9cVsWVkq2gR1baHOWXqx9K0L6JXEUUSmLja5bkmkpMfsUzjJdPjuWdgjyNygwNq1beyaFEhiiiZCoBCtz0rqI4okWVmVWDqFXHAU+opv2ZC7lGwSDt2+npV8zD2KObhtmdsYlUsD8o+5gVCdOE8TGG3HmhsrIow2e1djHaxxGF5AZc43YPSrl1ZOVFwvy7ANojOM5PGB61Epy6FxorqeXXGmbQI7qANL0LOMAj0x61PZae0ELSAKTySM/KfbFdz/AGHLcSSLcwl5mG5fnGVX1IrOudCcxp5YdSD93d1Ht71m5y6j+rrocdLapLN8xWAL8wfacj6f/XqwNPjjlRyfNZWzuT7jN2LE+tb1xZup2EABTnc/X6GqMX2pCWgZNoyDEy5BB9qPaEuhYpT2t7MfLgt4lGcui8ECsS4uJxcRwvC88qEbYyflVh0OfYc1tzK3nsWRwx/hQkY/H0pgidE/duuVxnbwwGf1qlU0M3RZlG6FpPLPHIwllwPK25O0Dlia0DaSy6bam4BeSWPzowwDMMnuO2RUktmLtijGV84UhyFBA6YIqaXSZUnJnUuOABvwRj3701VSJ9i3oPm1i4t9Na4t7Kwns41Ec1tdLvktXbjCt12HqOvpXCS29wtzFd2kKlzjcgJ2EZ+6c9q7/wCzmVNs0cpxwGUjGPQjuapXNjG7s0cUrMzZZiMHH0rT6yT9VZxlz9vWN2hllijQ8qDwv+yexFTLqc91PL9pgtpbgoJDcPHhjtHHTrwK6q1s9yyRCMJKRxuXOfrWdeaA9xdsIl2MvBI+XaauOI01MpYZrYveG4bj+0Ik1SOIXFxZyzEqnzxxbCVBHQE8HHpWh4X09PDemF/EMc0t40PnW1silXktwRkE9Uz0z6Cn+G7y88P6xF/aVsL9FjZVLnDlWHTPYZ61Q1ia/vdVm1K+kkdpHLOxzyp4wPQAYAHtVurEn2UjWF8NevZNe1NorW2CrFa2kIAVFX7saDqAB1J9+9dDc6XErHUkhgNxIhGn2UacRDHzyMP4iDwM9c1xlvEfslzbRQTEtG00flgNsZeST3wR1r1W1hj07+z9Z1BAz2dgkFs+7BZ2j3uR6tzwegpQ94p2XQ4O4i/sDTrcSWv23Vvld7VetuSD8zj+97dqzxpQglF/rzFbl8iOyHD4PViDyox3PJ7UzxBeXlhqUo0pWtpJcTPIjb3nUjcG3nk5zzWFg/a5Z3mmS6lwzNISzv6En+KiVtiVctaq95NdSSW3lEgEMjfKu0DgCmeHbhcys/mDUG2iVZB9z5eCPbFSWwaV0eaB4lI3ZJ++ue1Q3VrPbarPO1wsb3D7yn8IXGFBqbDvqXJT5+oQw3OXCo7MpHQYwPzqzHeRQWIEuQYmCxluhHQDNQbZRPJ5u0pOcqcHIIHTPcfWufvEkvAVtJ2JjYI8EgyRg/5waXKPmsduJii7gxYsvzAHkH/CoU1BXu44vLZJRhsE5OM8c0aZFbagmFeaxvGASOVzmNm7DPb8a0L1pow8WsaTapeRZ3Sx5jY4+nBNCj3LcmQXU3l3BtpsBA2SQOSfT6VmzCSNJ3gCHbzIvTeO3PrSa5eRyW6RSR3AcjLeYwYgf3lI/wAiseJpbaZGQs+9d0gY5V/9oe9OxMp6nQtcW97p+yPzI5iA6pkFQR0JPakMj3EK4ZftQGS2eNw9azLSJZZVltpNn2g7MAcMPU1fgtoBM7kqk0HLFW6+3vSaHFsduEqvIqKSOH56nHpUcUyljAU2tIAwB9uwp0siJdgmF/sz9JFHf3FR3EahMsPMeOTKnsCKi1i73N+Jlg0OEajcReWwLQxtaicxrnrkkYGR0rOF3fwSSwS3EdykzJOZFXHmrj5D7AD+HtUg1SB4Vt7uyjufKGFKyGNlXrg46is6+eX+2CbgwqJIo3jSMHbHGV4X8BQHU0QRjIB+lMMZbDBifYdaVS2c/jTgyuTt3MQOMcVBtoQuvnJyFz6HrWVqRjVk+TB3c4PWt0xqYi207hyzGuevFLyAluB82B6elax8zCpoO0+wuNR1OG2tEDzXH7tFBAGevJ7fWr0l9pGj6dAkdkJtYBYP5nzJvU4yPUCsWzvCt06FgiQgl3BxuB7VkRzedeOLlQqRnK7f7vYV0I5Gzptb1GR7OKa4mWWWT99IwPRs8L+Ark5tQV3kZZNsjv8AdJ5A9/emXd410/2aJljJLOxboqjoPxrCEhVyZAN7HcD/AI1fmQ22dxpjoLTL8RYGF7//AK62oyGYDP3gMH0rkNCkCyBZJPnIztAyK7C1EbgngYA5HrWEzopalu3QglZCqtjKnbWnax+byxyF+bOO9VUKqRgg55yatRzKU6dOpFYSVzqglcmhhR2Kjo3GMdauRKFjds8L0ArOS9ZZPlYAAZAI7VHJcbJZJMnYOoFKxrzJGg8oKnyshlbgt79aki/eD5QCFyMN6/1rK89GUhfvORg5rTjbKcDY4G4E9/8A9dUooakaNncMGO9VYD5zgdv6VBLM7OzHau/kccA+hqFplbCgsrFMN2B9frTJJMKJXXasmeSeBxwR+VOyKciRTuBL8BzznpgdRiplIywYkAPgc4z/APqql5ypHs3Zbkt0x1/lSzKA7FB6bDnoatJCuakc0P2ln3AygHdzkNnjOTV6J4woQZKF1DDJGBjpWBEZCHzGArKNykZGfr2qxlBIqSOUYsMLjKjjqcUmkOMmbEU52l/MDuW2gKeSOnNTqIU8uOEKJCwKvn7vtWBHO0bIyMrMTkErjOM1JAXLedv/AHqybicZAI9vSolC5op2NieykuL0wytHuP3nT+KsvUfDkkBIROQSSiYLfU1Gt4sX+kTSS/eJSQZHX/69EN+IpJPLmlHmHGW6475JrN0rle0Rj2+izzSSSSFtu04C/eJ9xUU1pmMhgEfIX0Jrpo52iWFVnQkkAkoOefWm3F3bTwXUc0Ku8ZLNKR7+1ZunY0Vnqc/a2a7CPs7lGPyOTzn0q5/ZcrwB2VgEY7znOTTFvgI7aJBlC5IUt2z0qVdR8uKRvKYCSTleopezuLmSI00qR1YRJllPUjhvpUyeHbuGUs+Il2biH54q02sAPE/ALZGAPu1LHrEjEkleecnnANUqJLqRIY9CmjEcpO1mXBOByMVDd6aqktEEjnjUZYjIb61pS6g8qSh3K4Awc5544qlPIZWYE4zgdMfh+taqnYiUkyvqlqk4SQI4fCjcRzVTUrQMpCRhsKQe2T+PvWtKAqbUHRSXIPfpkVJPDvDZG7bGDuB60OJNkyv4cEWn6/pOqTxqGB23OOhjYbX/AENaHiK3klhmuZJzJpy2SWtlMoxjPykgf7o+tJZSxvksqqSCNpA4qS5hWfSBDG7A2zGRYieMMeSPXBppuKsS6Sepwr2zSWdnbzRFZ7aMxebn70ecj/D8ao20RfzCuJo9+ImP3l9R+Brr9QsmLrKj9fl4HOPXFUf7PVbbrsmB3uv8Le/1zUubM/YozpZU2r5kao8UYiEY6IB3H1zVMWoLvmJN2D5e4Zz9c1qC3E+BcBdsmUMj9j2B/wAarm1eJ40cMCjY3bskcenpT5yHSM4QTiLMq7flGEXorDoR/hVRYlluhMiAO8ZGRxg+hroC+1CpUmWM5VvX3rOaMJcHeqGRiMsnA29atSMpQsSXFtLPaLsZYXwCAejfWrF5Pd30Ba5LeYqjB67SBx/hUNzI3mK0UjNzyewFJDdOkyJh1UjHm43Z9jTTaFZFVooGhjlu45WVSGRUPzxnuB/eHtVSe0traZZlkee1kBZcLteFs9Mdx7V0z3LR6dt+yRPC5w8jc7T2wOoP0rk2OLgQxv8AaY3LMMZyj+hFWtrmU9GTadI1td3FpI4MUR8yMnqPUU51lDm4tlV96ksh/wCWmOh/Cqtk/kX3mMo3lPKkBGeOzD8avRxvHhHhWZQ2EkXgp6g+1Ehxuxj5aFFWKZrZhkrnlD3Aq/bTW5EOInljhXMsYbBPpg9qbI6/aEaJibcj5gTkg+lSWunXdxqESRlI1lO1GPTHqR3AqGaItSyaMSJn0u/RsbWzchcZ/DmsXWLqK616OWFHhj8lIQrNuI2jAOa2JX0WR3V72/kdRtd1hXafcKTnFYmo2jWOsRIZUmR4hJFIARvQ9DjsfapKNkvhsng/zqZgJEjEY2kchh1qoS7YHU44zR84ZQjfN39qg0Q66a4igMaShlPJBFc7PISGPl5dmwpB4HvXVS4ZDHt+XGWOeT9Kw9RVVUsMYTgcdK2g7GNSNzlVVlu5LWVVw7GVnB+Zx12/SqeoO0VxbTEgIxLMB2HYVqazHILiGWBRJjIcY/hPWsO+dJmEMOyNArKzAZLjrxXTF3OJq2hmtejzA5bAJJKjknmlhhmmukmmAJI4UfpVWCDzYHkXJKH5ver8DCMtKH3R7Q3XlfpTbuO1jYivVtWDgDCjaSR0rVtdXiZwRIoz78VzlrZyapcCCJtztwzSHaoz0yfWr0Hhy2tbu5h1DfPJEdo8hsITjrmpcG1qOLsdjbXxdACRkd6nSc8gFscZFcLaPc6aXWMmREbozZCj0BrorHUo7lPkbDDqp4NYtHRGfc22nZiHbtUluxcEsMe3rVKKXI68dMVNBNhsbcse57VLNUy/AgX/AFjYUjIwM81eiJCE5OxyFKd/1rPZnRcbvlxnOOgPYU8uEVW8tt3q9SjROxqRFiiokakR8sfM5Az0z2qeNTJ0RsITna46elUo0LXAJwiEbmWPjIq5bpCTKEgVn3cqz4wvr9aEmaKRPbgzGUgRgthipGPw/CpvLZ3lPlbiOqNzyPSqRjSK7hbDRAg8B/umpzIRb8JKVkfG4vwRQUiSQsuzeuBIrZO/GO/I7VG5naVCi7n25ZyQcAVKEb7SwNlGX2njzR+vNVireWrCNIWGQP3nD+xFAwieJI42E583+EKc7fwPvUUs7eU2ZAXBI2ryW/KmSLLCoIjhGG4cHAJ96r8/MpgiVi25X6jnrRcTLJuWtyuImHy9TGWOfXjtSmabyY8TEBjlh5Zwfz61EFdE/cy7guMgPgk98c0kl0Y5FFxLLA4x91t5K/57UdBXJo74LdHZcMq5AOY8YxVWK6Mkt0vnEhlPLcEmn7gLuR2uDtYnBkj6/hVe2jKzBgYGBztLriody1J9AgIlliJ+XCnnPOetPXzjHiJ1Zg2drcHNVoonadV+zocnpuxmpoYQWaN4plbHPlnIOKSEyWWQrMrsuORxjBXPWpg7RxsWIYBh8yjp2phMn7ltzSoOCHUdOwpbVEiQlUKMzcIx4IzzV3JsSpKd06q6jevOfQDrVjzVYYIbJMYBxkMD1OaZnG/Yn7tgAqnBxnsD3qeMI8VuVUo3IwOwH/1+afMUkOk4LLISpjIXKcceoqVZZXkdVZWYKcArgOB1I/Cm5Ajty5Mqvu+cAkY6E+oNIu9TGZR5giOA39xfX3FO4WJIWKxksQ4Y7DxwpzwasxzOsVu8YDkFsAHJUDrnvUEHH2dZGJhb5y/Udxn9aTCs0KK8aRlWCyDPQnkH3FFhiJtQu5yucsOeMYqCSVgrN5bFZBj2pX2mCbaG2xuq5Y4xj296qvcSEPGzKDnaFbkDnsaTimJysTPLG0LxsBjaSyqM9uMVVWO2MoCtJuVOTno2eBVVbwowG4Eg9Md6Ibh447gFhgt8vy8n3rNwYuddSxew5uR5chzt3K344Kms54n+0YILMMjkdRVsXAk3FiMqMDHvUtww+V1wT396WxMkmZDqDhYjtAYMwYcEdxUUEeDtX5echgf0NXbiIZUvheNoA61BKisMEEyBsLg8Y9au5i1Yo6g0oeOMMWlVgeBjdVO8T7JdNeQHyL6Fg+COpHTI7itG55eNgAzAEDJ5+tZt48ZiImVs4xuJwcelaxZhNEd9cqdWF3FGVSaMmWJQPkJ54/Gp9OuJnOZWVo2O7H98dqxpma2uC0eGZEyQ38a+lLpt6Gg3hWcRkuqk8464rRq+pipNM6ye1m0W+sjcFJLK52zqw/hRup/nmrQmkjv99lJJKwIaAxcnOeCB9KrvOLn4f6NqP3zb3U1rtY9EYBgPwOap23kxNA0MzktxH5ecl88Lis5JI3jJs6KdLuV1uD4eglkbLBzasMn6A4/CuX1dryXXI5dQiZZwvMbJtwuOBjsMdK6C6sdXuLqSeRFt7hlXei3QUsRxuK54Y1z9zFcJqrpc71mxtPmHLZ96zaLRpGIBGIYkj0p8RUt8ueOD60KdoJ5yo/KogCD5nTPUVLNEWpCFIIYZ6HmsjUn/AHbkADHXd3q7MyxASY3L/WqNzaS3KK5ZUKnKp1GPeqgTMxI3+0eWz5Q7SMDjPNc5d2yLfN5IKuueD1yf6V0jpIp2nKhW+oP0qpqVsSXmMWZE2kc43LXTCRxzic7bQI9sqKWWUhgWHQEGqtpbzCZ4gyKSQVBHBNakAzd7YyiRyuScjlD6VpXVqiRxwhTtK5QjqD6/jVkXDQ7CSCOOeWUCUPuVV5U8YPFb0VgDeGUlssu3J7//AF6o6PI+x4yFWQcbfT3retUTacuScdDWUpvY1hEydd0zYiyqqKrdgeK5xrfy5Qy5Vh0Neg3UQmt8HkY7iuWvocybVjJxx7CsjblFsb5lVFkBOeCa2raVSTtYEnvXO20Xl3MYlOFPG0VtJATgAfMvcdzRcdmzagcyRqqoflz1NK3muxGAAFA9qoQrcrkxPg9GzVkyXQTJjVsdQDSujTlkaENy7JsEhOMfhSLtE58wOyMOSDyTWF/arQud9u6juFIqSPX4flDAq2cjdTvfqCudGJd6sjB2CDAXPH/16WO42qw8z5enlyckVl2+pQTKXRsMRz60CUOxKPu3cbaaTHz2NGG9jW3kMvmszkDAbjj1p4NtcFiFeNFxsy2frWTLazLu64bnBFTRmREHBUDnA6VMkVGoaLtAIiFi3SE7V3HI6fzphdHDLMxQEY2xAdv5VXEjPGAFz16/zqWNSrBg6Dgn2NQaJ3JbaCzmnA3mNCOMLjNOe1tYZDOWRjFwD5udx9h7VLA6G4U3UXnpjG0MF4q0k6hgY9LXyz0DDJ47cUJlqNyjCZbidpDcogVSVLtmq6eW93me5zg5LIvSrbybkbdaou9uDio0jRpsrAoKjkKMZpNjUSmgH2kFZGznjAqxIY4mPlSziUZwzDt6fWovJG8Eg9RuwefwqUkNMPLkcLu6OoOKVw5BI3y2TtfHBLj+oqZkIURsY14IGcgfhUTsDuJQCQt90LgH6U9nja6czQSSRAfKMkEH+tBLJyWhDlo4wFwch+OnarcFwyvCyRom05Q7uu7vWSu1lkQedEnOA/epiyR+XFNh0B4I64x+lUtwuasUk4XOFMaZ3EHJQ+uPSmiZd6MWHmZYcEoOelYXmW4uE8oyIGIDFj0xV172WOUFZEkXZkjPv0/GmNyRdeQy/fEgVEKfLgj9KdA6rwssaMEIw6ZLe1Uo7oLKmEWMODkgHJB7VZku/N2vNbBtq7Qc8e3I5qlqTcju55QU3qVd+pwGz3H5VmLILhXIPzBuEYYxU8jzqJXjUFs4xkHNV5MpAzNGoJyuP4hQTIrSTMA4cbOcfJzu96rGZt25tqsePl/zzSzMMgKOUGMt1J96jkkUsoChOAMZ4z3P0pmDJo5wE+V1wSAB3xTzcuh3ZI7j2xWdJJ87KFX5vyAFQTTnIwTkUrXFzWRsPebmR3bgdh7+lPeRSD5ZAB4ya5yS6wD2P1qKTVVRApkJxztFHIL2iNmcqwfkkZ49RVHU9symMY5Xk1nHV42+VW69aie+hyQ+cdMDvVRizOU0Zeq3j7/JzwBtVsc0/TLlYIPs83IJASYenoaq6hua4DlVaLoAT0qqJDHEqt8yxSgtg44JroWmhzPU7IayLPw7Bp8KR3QaWS4kiByFzhQPY8ZrpNB/sqSSwvYbz7DeQur/AGe45jk7HDj7p54zXnAhdJbqWzGHLBvL67gR/Or/AIf1Syt9TtDqLnbFKHEoUnaf7rL3wcGnJDg7npfinw9YaRfJBqN5cRu4Ei5g3l0bnO7OD9a53VJkutfh2CZI47dIo1l+8yqOGPua6a/vHFh/YniG4+3i2RXa9VtxgaQZG32HGV96wtXCyeJI2gljn8qzhj3o2VbC9q55xsdMJXJFJxkggn+VKpRiRgkdOtIWGwM2SMc1HEQrMwzg9ayaNk9Sx0KoMbTxjsKrzoY1ynOeTUp+YY5KY7imlNilcbsjAz2oiNmXqCD7OpC/NjdxWffxPc2xeFyJMfeJ4x6VuNDvJeXG0DkCs+2hWCUjcoVs4JGce1ao55K5zzWhtXRpkURs2C47GrUWeZoEPlH5Qz8nA74rWuNPS5jQSHKKdwUnqanii80IIlx1IyOmPStOfQjk1M9LJWKzF283qJPX2xV/TGm8zdcIpU9CPSnzWgh+4xaU/MCOh+tRi4ORFJ+7PBGTwT7Vm9S0rG1HHvRcZDcnA9Kx9QtBENy8MxPB7VdhkCyACQFu4PerM8HmAbuw5xUs1Sucr9nJj6bcHr3rV08+YoZmIGOcetPkiWJssDsPJFRW8Rt7jcpBik6HtUMpGvb2wKoEYEuM8HmnsgLhFwx7npmnweXGP3ZCswxj0NPjdBKFVSSevtWbOuCVjOvrWN1OB8/tWabVZbpEePgDrXTMjHcIwCpHOetUoLRo7gscbegUnrTTsJwTZSk0aNoQYY8SYyMdRWWdLuvPZA8qN/CQ1d5YqlwwtpSsY9ZDtBPpntV6xsdNfIvXkDqx2sDjj8OtUm2XKj2PNUu9ZsG2O/nHoPNGfyNXodaumYCax6ddhr0QaBYXDyyvcokScoJG+ZjTF8K+cN9vGCD93Hf/AOtQ5SCOHTONGtWSRMtxDcQsejAZx+VVxrdhtJSdlI4+ZCK69fDAuLkwb4w/QA96gufBgQYkQBu2RS5n1RTwzWzOdtNUtZXA+0xsWGfQ1t2kzZykjHtkN2rNvvB4UMwVSPrWXD4emSbMEkqOvA2sanmQexnE6WaXymUhXJHfOcGpLZnEm5WwMdRWPAmq2w2rcFwO0ihqkTU7tMieAY9Yxj9KL3E4yjrY1Gyp4xu+naooo1LE4G4t0A5qoupxKC03nKw/2M5psfiTS45Wz9oGOpZMflT5dQc11Lk0OJWVThh/D3+tG1hjeX4GODzUNj4i0qfzGPmiQnaQq547H2om1yMoTaW8khxj5xgD3p28yGywu4qeCx7ZNJK80h2rkKD2HAqC3m1adRcC1QRgdj/Opprq4YcWyAex71SsRyyfQqysvmghwwH3jn+KmK0Ycksdx7gUkqvKx8y0LcHhT+tVUgvAHaO2uXjA5wOn41aUe5m4z7F4SSAvkl+wI7Co1DMD8x575xn61EljrH2M3a2c4t+u5h1qu97eRjJt0BI454oZFn1RpHCrhOQOQM1FeSBwVQYBHUnvVCOS9ZlV4lww78A1dkspV2BGQ7x827jbTUb7A20Ug6yEljyBjI9ahlICAY6nmpLpJlkYAR4Q4JHerItrXyN73kZlwDtB/Sjk7kXMqQlgFXJYmo5raZEBmUqCce9bcKRGwmMaxieE7g5bmTPYfSs3VLiaWYMz5XG8mjRC5TA1cRRqiknJHrXMvbqZSyhjn3610VyGuJ3bb8vYGktrVTuBQAA4BpqTIcTKjsncMsbH96Ocnnj+tUraCX7TLC06llUkZPJ9q623tp03K23OQdx9un41VuNOinknkZFEj8/IMNn1BrWMu5hKJXtbdztWUtlgMj+6emKqraIEcBfMbfuBHGCOgrSFq6L5i3Ts+cgN8wxj86hktbxZC0bxDcQSMHj3B7GnzaktOw7T43RZPKUlgBIC/GSPv4rS8L6ZHfeJbjUJ7cPa2iCUKB/rHJxGn4t+grK2TWRnWTf8gbbubO4Guu8G+SNIv5J3dEgeF5NnLbCrAn8C2apPW4dLFzT7YJb6mdRvJZZtQZSJY4S0QZCSxB6kDOCwGOKzbaF7S9mjlGHjbA29CPUEdQcg1orNM2qWF7GL7ZaxCKKCJQ0O0DGRLnaFPU55HNVxKkl3CkMokEcaxl1+65HXHtzgewrGqzaiWRzIVPIxTuigD2NFFYM3RJGMSIOo3d6NR4Z8cUUVKKexlI7G5Kk5BFV7s52ggEBhxRRXRHoYS6joTlCe6txV/aBtYZB3YHtxRRQVHYnlwv3VAyTVNbeMrPIVBYEdaKKkOpLZxJHOFVBye/1rUZQHcDpuA/Ciiky4mXqpKkkcc4qoXZZreMH5OpHrRRSGat1iN12gfMm78an0oBnUsNxz1NFFZdTpiX7T5pzn1xWikMbvKWUHaOM0UU+hvElsrKC9ciZT1C5B5I61Dd2cVjfm2gz5eAfm5IzRRQ9kaw3Zesbg2czsiRuyjKmRd2OK0bS/nnlhYsI2nz5jRjaT+XSiihG8TH1CV/I83cd4fFdL8PryWfVYY59sscvyurjIIoopR+MKnwM0/HGm2lveP5EKxjBOF6cVy9lBGUDlBuyaKKJfGVB3pq52cHh7TrmRleHA+zCb5T/FtzXMailtLpjE2NqkinHmImGP15ooq2lY57+8c1PaQmMkoOgrDvNPtmk2tECOaKKze4pJXJdI0y2QXCBSVXkZNaVvbxS3MSNGoVRjgdaKK0glYzOnvdJtbazbyVYAEcbuOa6Xw5a2snhqYtZ25YICWKZJ570UVcfiGtjrLzTbLToLBLK0ghW6hzLtQZOMVgXOo3NvrqWMTILWWYo0ZRcEAD2ooroRzQd1qcF4uvriXxEbHzCkEbkAJwT9a57VdOghtRMpcszk4J4HNFFclR6miVzDngUwEkse+N3Ss4g7hh3GevzUUVkmZy3IygVDJliwPc0+xiSaT5x/Dnj1ooq4mT3LSOREH4yQe3f1rEumM926yEkA4ooqyGAjX7uON1XbSJCSSo6gYooqkZssS28ZhYAEBQeh6896ybscbl+VlBwRRRVxM5DEG+WTPaNTx706LPlStnLAgDNFFC3F0KGsjKy5J5jrV8Ns0N3Z28bFY7lRFKP7ykciiito9DLqc3LELRtsDyKjOVZdx2sCxHI6VvaNJIwERc7UwBgDOKKKmZVPc//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Rhinophymatous nodular sarcoidosis. Diffuse enlargement of the nose with granulomatous infiltration resembling rhinophyma is present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_5_22612=[""].join("\n");
var outline_f22_5_22612=null;
var title_f22_5_22613="Mechlorethamine: Patient drug information";
var content_f22_5_22613=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Mechlorethamine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/57/40853?source=see_link\">",
"     see \"Mechlorethamine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/16/9477?source=see_link\">",
"     see \"Mechlorethamine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F191690\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Mustargen&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10031433\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700794",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause tissue damage if the drug leaks from the vein. Tell your nurse if you have any redness, burning, pain, swelling, or leaking of fluid where the drug is going into your body.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700267",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take if you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10031435\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691947",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat lymphoma.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691672",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat cancer.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10031434\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702449",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to mechlorethamine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703161",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an infection.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10031439\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697613",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before getting any vaccines. Use with this drug may either raise the chance of an infection or make the vaccine not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697795",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may bleed more easily. Be careful and avoid injury. Use a soft toothbrush and an electric razor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697022",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a man and have sex, protect your partner from pregnancy. Use birth control that you can trust.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10031440\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may have more chance of getting an infection. Wash hands often. Stay away from people with infections, colds, or flu.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697876",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Anemia, low white blood cell count, and low platelet count.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698114",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hair loss. Hair most often grows back when this drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698393",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weight loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698231",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Period (menstrual) changes. These include lots of bleeding, spotting, or bleeding between cycles.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10031442\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698991",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Pain where the shot was given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699064",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698988",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Numbness or tingling in your hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10031437\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695991",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695958",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be given right into an open space within the chest or belly.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695962",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be made into a solution and used on the skin.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10031444\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11390 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-58.240.98.179-5450C57513-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_5_22613=[""].join("\n");
var outline_f22_5_22613=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191690\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031433\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031435\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031434\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031439\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031440\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031442\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031437\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031444\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?39/57/40853?source=related_link\">",
"      Mechlorethamine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/16/9477?source=related_link\">",
"      Mechlorethamine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_5_22614="RNS pre and post exercise normal subject";
var content_f22_5_22614=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F80939&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F80939&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 476px\">",
"   <div class=\"ttl\">",
"    Repetitive nerve stimulation pre and post exercise in a normal subject",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 456px; height: 681px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Repetitive nerve stimulation (3 Hz) before and after exercise in a normal subject.",
"    <br>",
"     (A) Baseline before exercise.",
"     <br>",
"      (B) 30 seconds after 1 minute of isometric exercise.",
"      <br>",
"       (C) Two minutes after exercise.",
"       <br>",
"        (D) Three minutes after exercise.",
"        <br>",
"         (E) Four minutes after exercise.",
"         <div class=\"footnotes\">",
"         </div>",
"         <div class=\"reference\">",
"          Courtesy of David Weinberg, MD.",
"         </div>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_5_22614=[""].join("\n");
var outline_f22_5_22614=null;
var title_f22_5_22615="Familial hyperaldosteronism";
var content_f22_5_22615=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Familial hyperaldosteronism",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/5/22615/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/5/22615/contributors\">",
"     William F Young, Jr, MD, MSc",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/5/22615/contributors\">",
"     Norman M Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/5/22615/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/5/22615/contributors\">",
"     Richard H Sterns, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/5/22615/contributors\">",
"     Andre Lacroix, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/5/22615/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/5/22615/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/5/22615/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Familial hyperaldosteronism (FH) is an uncommon subset of primary aldosteronism. There are three forms of familial hyperaldosteronism:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      FH type I or glucocorticoid-remediable aldosteronism (GRA) due to a",
"      <span class=\"nowrap\">",
"       CYP11B1/CYP11B2",
"      </span>",
"      chimeric gene",
"     </li>",
"     <li>",
"      FH type II, which has been localized to chromosome 7p22, but exact location of mutation(s) is unknown to date",
"     </li>",
"     <li>",
"      FH type III caused by germline mutations in the potassium channel subunit KCNJ5",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The three forms of familial hyperaldosteronism will be reviewed here. Primary aldosteronism is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/13/5338?source=see_link\">",
"     \"Approach to the patient with hypertension and hypokalemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37911?source=see_link\">",
"     \"Clinical features of primary aldosteronism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/16/40199?source=see_link\">",
"     \"Treatment of primary aldosteronism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H563247\">",
"    <span class=\"h1\">",
"     FAMILIAL HYPERALDOSTERONISM TYPE I OR GLUCOCORTICOID-REMEDIABLE ALDOSTERONISM (GRA)",
"    </span>",
"    &nbsp;&mdash;&nbsp;GRA was first described in a single family in 1966 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22615/abstract/1\">",
"     1",
"    </a>",
"    ]. Twenty-six years later the causative",
"    <span class=\"nowrap\">",
"     CYP11B1/CYP11B2",
"    </span>",
"    chimeric gene was discovered [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22615/abstract/2\">",
"     2",
"    </a>",
"    ]. GRA is a form of hyperaldosteronism in which the hypersecretion of aldosterone can be reversed with physiologic doses of glucocorticoid [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22615/abstract/3-5\">",
"     3-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is rare, as illustrated by a study of 300 consecutive patients with primary aldosteronism; only two patients were diagnosed with GRA (prevalence = 0.66 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22615/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Pathophysiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normal subjects synthesize aldosterone in the zona glomerulosa (which lacks the 17-hydroxylase enzyme required for cortisol synthesis), but not in the ACTH-sensitive zona fasciculata (which lacks the enzymes required to add the necessary aldehyde to corticosterone at the 18-carbon position). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/46/28391?source=see_link\">",
"     \"Adrenal steroid biosynthesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with GRA, on the other hand, have ACTH-sensitive aldosterone production occurring in the zona fasciculata. Two isozymes of 11-beta-hydroxylase encoded by two genes on chromosome 8 are responsible for the biosynthesis of aldosterone and cortisol (",
"    <a class=\"graphic graphic_figure graphicRef70372 \" href=\"UTD.htm?0/7/123\">",
"     figure 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The isozyme in the zona glomerulosa (CYP11B2, aldosterone synthase, P450as) catalyzes the conversion of deoxycorticosterone to corticosterone and of 18-hydroxycorticosterone to aldosterone.",
"     </li>",
"     <li>",
"      The isozyme in the zona fasciculata (CYP11B1, P450c11) catalyzes the conversion of 11-deoxycortisol to cortisol and does not contribute to aldosterone synthesis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The mutation in patients with GRA is fusion of the promoter region of the gene for CYP11B1 and the coding sequences of CYP11B2, resulting in ACTH-dependent activation of the aldosterone synthase effect on cortisol, corticosterone, and cortisol precursors [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22615/abstract/2,7\">",
"     2,7",
"    </a>",
"    ]. As a result, these patients are biochemically unique in having markedly increased levels of 18-oxocortisol and 18-hydroxycortisol [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22615/abstract/2,3,7\">",
"     2,3,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The zona fasciculata location of aldosterone synthesis is probably responsible for another interesting physiologic feature of GRA: aldosterone release appears to be insensitive to the normally potent stimulus of potassium loading [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22615/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/20/2376?source=see_link\">",
"     \"Chapter 6C: Aldosterone\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Clinical characteristics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoid-remediable aldosteronism is inherited as an autosomal dominant trait, as a single copy of the abnormal gene is sufficient to cause the disease. The presence of this rare disorder as the cause of primary aldosteronism should be suspected from the positive family history and the typical onset of hypertension before age 21 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22615/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The plasma potassium concentration is normal in more than one-half of cases of GRA in contrast to the hypokalemia frequently seen in primary aldosteronism due to an adrenal adenoma [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22615/abstract/3,8\">",
"     3,8",
"    </a>",
"    ]. One possible explanation for this difference is that aldosterone release in GRA is primarily under the influence of ACTH; with the normal circadian rhythm of ACTH release, aldosterone secretion should be above normal for only part of the day. The lack of aldosterone response to dietary potassium mentioned above would also diminish net aldosterone release [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22615/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37911?source=see_link\">",
"     \"Clinical features of primary aldosteronism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The main clinical clues suggesting GRA in the normokalemic hypertensive patient are the family history of hypertension onset at a young age and the frequent development of marked hypokalemia after the administration of a thiazide diuretic (which increases sodium delivery to the aldosterone-sensitive potassium secretory site in the cortical collecting tubule). The diagnostic approach to patients with the different forms of mineralocorticoid excess is reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37911?source=see_link\">",
"     \"Clinical features of primary aldosteronism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/13/5338?source=see_link\">",
"     \"Approach to the patient with hypertension and hypokalemia\"",
"    </a>",
"    .)",
"    <br/>",
"   </p>",
"   <p>",
"    Intrafamily variability appears to occur with GRA, suggesting the presence of variations in the regulation of the altered gene",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    significant effects of modifier genes. This was shown in an affected family in which only one of three individuals with the chimeric gene had classic features of GRA, with the other two being normotensive, normokalemic, and having normal plasma renin activity and aldosterone levels [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22615/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Initial anecdotal observations of early cerebrovascular complications in patients with GRA have been confirmed in a review from the international registry for GRA [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22615/abstract/10\">",
"     10",
"    </a>",
"    ]. Among patients with GRA, 18 percent had a cerebrovascular complication, 70 percent of which were hemorrhagic strokes due primarily to ruptured intracranial aneurysms. The case fatality rate was 61 percent and the mean age at the initial event was 32 years. In comparison, there were no strokes in GRA-negative family members.",
"   </p>",
"   <p>",
"    The factors responsible for the increase in hemorrhagic stroke are uncertain but it is likely that congenital hypertension during the early stages of cerebrovascular development plays a role. The possible presence of early cerebral hemorrhage in Liddle's syndrome, another form of congenital hypertension, is consistent with this hypothesis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22615/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/51/25399?source=see_link\">",
"     \"Genetic disorders of the collecting tubule sodium channel: Liddle's syndrome and pseudohypoaldosteronism type 1\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The frequency of aneurysm rupture in GRA is somewhat higher than that reported in autosomal dominant polycystic kidney disease, another disorder in which hemorrhagic stroke can occur at a young age. It has been suggested that all patients with genetically proven GRA should undergo screening MR angiography at puberty and every five years thereafter [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22615/abstract/10\">",
"     10",
"    </a>",
"    ]. However, the benefit of such an approach has not been proven and must be weighed against the risk of prophylactic surgery for small aneurysms that might not rupture. This issue is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/33/30233?source=see_link\">",
"     \"Extrarenal manifestations of autosomal dominant polycystic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of glucocorticoid-remediable hyperaldosteronism is suspected on the basis of the clinical features described above. The plasma aldosterone is elevated and plasma renin activity is suppressed, but the aldosterone-renin ratio is typically not as high as with primary aldosteronism caused by an aldosterone-producing adenoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/13/5338?source=see_link\">",
"     \"Approach to the patient with hypertension and hypokalemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis has in the past been established by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    suppression testing and demonstration of hypersecretion of 18-carbon oxidation products of cortisol: 18-hydroxycortisol and 18-oxocortisol [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22615/abstract/3\">",
"     3",
"    </a>",
"    ]. However, we suggest that dexamethasone suppression testing be replaced by genetic testing, as described below.",
"   </p>",
"   <p>",
"    Genetic testing using molecular biologic techniques to detect the chimeric gene is now preferred over",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    suppression testing for making the diagnosis of GRA [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22615/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. The value of this approach was illustrated in a study of 117 patients with primary aldosteronism, none of whom had the chimeric gene but six of whom (one with an adenoma and five with idiopathic hyperaldosteronism) had false-positive dexamethasone suppression tests [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22615/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The genetic test can be obtained by contacting the international GRA registry:",
"    <a class=\"external\" href=\"file://www.brighamandwomens.org/departments_and_services/medicine/services/endocrine/services/gra/default.aspx\">",
"     International Registry for Glucocorticoid-Remediable Aldosteronism",
"    </a>",
"   </p>",
"   <p>",
"    The website has instructions for collecting and mailing blood samples, which should be mailed to Yale University.",
"   </p>",
"   <p>",
"    GRA is a rare subtype of primary aldosteronism and the genetic screen should be performed on selected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22615/abstract/15\">",
"     15",
"    </a>",
"    ]. Indications include primary aldosteronism patients with onset at a young age (eg, &lt;20 years), or a family history of primary aldosteronism or of strokes at a young age (eg, &lt;40 years) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22615/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In 2008, The Endocrine Society published evidence-based guidelines for the diagnosis and treatment of primary aldosteronism [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22615/abstract/17\">",
"     17",
"    </a>",
"    ]. Our diagnostic and treatment approach to GRA outlined here is consistent with the guidelines.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest the exogenous administration of physiologic doses of a glucocorticoid (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    ) as the first-line therapy. It will correct the overproduction of aldosterone by diminishing ACTH release and will usually lower the blood pressure toward or to normal and correct hypokalemia (if present) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22615/abstract/4,18\">",
"     4,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The smallest effective dose of an intermediate-acting glucocorticoid (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ) should be administered at bedtime to suppress the early morning surge in ACTH. Target blood pressure in children should be guided by age-specific blood pressure percentiles. Children should be monitored by pediatricians with expertise in glucocorticoid therapy, with careful attention paid to preventing retardation of linear growth by overtreatment.",
"   </p>",
"   <p>",
"    An alternative approach is treatment with mineralocorticoid receptor antagonists which may be just as effective and avoids the potential disruption of the hypothalamic-pituitary-adrenal axis and risk of iatrogenic side effects. In addition, glucocorticoid therapy or mineralocorticoid receptor blockade may even have a role in normotensive GRA patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H563315\">",
"    <span class=\"h1\">",
"     FAMILIAL HYPERALDOSTERONISM TYPE II (FH TYPE II)",
"    </span>",
"    &nbsp;&mdash;&nbsp;FH type II may be the most common form of familial hyperaldosteronism. Like FH type I, FH type II is associated with hyperaldosteronism and probable autosomal dominant inheritance. Unlike FH-I, hyperaldosteronism in FH-II is not",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    suppressible, and is not associated with the hybrid gene mutation. FH type II is the familial occurrence of aldosterone-producing adenoma or bilateral idiopathic hyperplasia, or both, in the same kindred. Biochemically and morphologically, FH type II is indistinguishable from apparently non-familial primary aldosteronism.",
"   </p>",
"   <p>",
"    In a study of 300 consecutive patients with primary aldosteronism, two patients were diagnosed with FH type I (prevalence = 0.66 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22615/abstract/6\">",
"     6",
"    </a>",
"    ]. In the remaining 199 families who consented to be further investigated, 12 were diagnosed with FH type II (6 percent). The clinical and biochemical phenotypes of FH-II families were not different from sporadic PA patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22615/abstract/6\">",
"     6",
"    </a>",
"    ]. Similar results were seen in a second series [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22615/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H563323\">",
"    <span class=\"h2\">",
"     Possible mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mutations that cause FH type II are unknown, but linkage analysis has mapped them to chromosome 7p22 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22615/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. FH type II is clinically indistinguishable from sporadic primary aldosteronism [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22615/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H563331\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;FH type II appears to be inherited as an autosomal dominant trait. The presence of FH type II should be suspected from the positive family history of hypertension. Intra-family variability is common with some kindred members having primary aldosteronism due to aldosterone-producing adenomas and others due to bilateral idiopathic hyperplasia. Except for familial occurrence there are no unique features or risks related to FH type II beyond those known for primary aldosteronism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/13/5338?source=see_link\">",
"     \"Approach to the patient with hypertension and hypokalemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37911?source=see_link\">",
"     \"Clinical features of primary aldosteronism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/16/40199?source=see_link\">",
"     \"Treatment of primary aldosteronism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H563339\">",
"    <span class=\"h2\">",
"     Approach to diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no genetic test for FH type II. As highlighted in the 2008 Endocrine Society guidelines for the diagnosis and treatment of primary aldosteronism [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22615/abstract/17\">",
"     17",
"    </a>",
"    ], all first-degree hypertensive relatives of patients with primary aldosteronism should undergo case detection testing for primary aldosteronism with measurement of plasma aldosterone concentration and plasma renin activity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/13/5338?source=see_link\">",
"     \"Approach to the patient with hypertension and hypokalemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37911?source=see_link\">",
"     \"Clinical features of primary aldosteronism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The subtype evaluation of patients with FH type II should be identical to patients with apparent sporadic primary aldosteronism (",
"    <a class=\"graphic graphic_algorithm graphicRef76673 \" href=\"UTD.htm?35/23/36222\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22615/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/13/5338?source=see_link&amp;anchor=H17#H17\">",
"     \"Approach to the patient with hypertension and hypokalemia\", section on 'Subtype classification'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H563347\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of patients with FH type II should be identical to patients with apparent sporadic primary aldosteronism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/16/40199?source=see_link\">",
"     \"Treatment of primary aldosteronism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H563355\">",
"    <span class=\"h1\">",
"     FAMILIAL HYPERALDOSTERONISM TYPE III (FH TYPE III)",
"    </span>",
"    &nbsp;&mdash;&nbsp;FH type III was first described in a single family in 2008 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22615/abstract/23\">",
"     23",
"    </a>",
"    ]. This initial report included a father and two daughters who all presented with refractory hypertension before age seven years and all three were treated with bilateral adrenalectomy. The adrenal glands showed massive hyperplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22615/abstract/23\">",
"     23",
"    </a>",
"    ]. Three years later the causative germline mutation in this family was discovered: a point mutation in and near the selectivity filter of the potassium channel KCNJ5 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22615/abstract/24\">",
"     24",
"    </a>",
"    ]. This KCNJ5 mutation produces increased sodium conductance and cell depolarization, triggering calcium entry into glomerulosa cells, the signal for aldosterone production and cell proliferation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H563363\">",
"    <span class=\"h2\">",
"     Mutations in KCNJ5 gene",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since this initial report [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22615/abstract/24\">",
"     24",
"    </a>",
"    ], other families with early onset hyperaldosteronism have also been identified to have germline point mutations in the KCNJ5 gene [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22615/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. In families in Europe with FH (GRA excluded), a new germline G151E mutation",
"    <em>",
"    </em>",
"    was found in two PA subjects from Italy and they presented a remarkably milder clinical and biochemical phenotype [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22615/abstract/27\">",
"     27",
"    </a>",
"    ].",
"    <strong>",
"    </strong>",
"    In four families with early onset PA, germline G151R mutations were found in two with severe hyperplasia requiring surgery; two kindreds had G151E mutations and mild PA [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22615/abstract/28\">",
"     28",
"    </a>",
"    ]. Surprisingly, G151E produced much larger Na",
"    <sup>",
"     +",
"    </sup>",
"    conductance than G151R, resulting in rapid Na",
"    <sup>",
"     +",
"    </sup>",
"    -dependent cell lethality; this may reduce PA and hyperplasia in vivo.",
"   </p>",
"   <p>",
"    In addition, somatic mutations in KCNJ5 have been identified in aldosterone producing adenomas [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22615/abstract/29-34\">",
"     29-34",
"    </a>",
"    ]. In a multicenter study of 351 aldosterone producing lesions from patients with primary aldosteronism and 130 other adrenocortical lesions, two somatic mutations in KCNJ5 (G151R or L168R) were identified in 47 percent of aldosterone producing adenomas [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22615/abstract/29\">",
"     29",
"    </a>",
"    ]. Somatic KCNJ5 mutations were absent in patients with primary aldosteronism due to unilateral hyperplasia and in 130 non-aldosterone secreting adrenal lesions. KCNJ5 mutations were over-represented in aldosterone producing adenomas from women compared with men (63 versus 24 percent) and aldosterone-producing adenomas with KCNJ5 mutations were larger than those without (27.1 mm versus 17.1 mm) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22615/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a separate multicenter study, KCNJ5 sequencing was performed on somatic (aldosterone-producing adenoma, n = 380) and peripheral (aldosterone-producing adenoma, n = 344; bilateral adrenal hyperplasia, n = 174) DNA of patients with primary aldosteronism [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22615/abstract/30\">",
"     30",
"    </a>",
"    ]. Somatic KCNJ5 mutations (G151R or L168R) were found in 34 percent (129 of 380) of aldosterone-producing adenoma. They were significantly more prevalent in women (49 percent) than men (19 percent) (p&lt;0.001), associated with higher preoperative aldosterone levels, but not with therapeutic outcome after surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22615/abstract/30\">",
"     30",
"    </a>",
"    ]. Germline KCNJ5 mutations were found neither in patients with aldosterone-producing adenoma nor those with bilateral adrenal hyperplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22615/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H563371\">",
"    <span class=\"h2\">",
"     Clinical findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;FH type III is very rare and inherited as an autosomal dominant trait. The presence of FH type III should be suspected in children with primary aldosteronism and in patients with primary aldosteronism found to have massive adrenal hyperplasia. In the limited families described thus far, most have had severe and refractory primary aldosteronism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H563379\">",
"    <span class=\"h2\">",
"     Evaluation and diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Commercially available testing for germline KCNJ5 mutations is not yet available. This rare subtype of primary aldosteronism should be suspected in children with hyperaldosteronism and in families with more than one member with primary aldosteronism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/13/5338?source=see_link\">",
"     \"Approach to the patient with hypertension and hypokalemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37911?source=see_link\">",
"     \"Clinical features of primary aldosteronism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The subtype evaluation of patients with FH type III should be identical to patients with apparent sporadic primary aldosteronism (",
"    <a class=\"graphic graphic_algorithm graphicRef76673 \" href=\"UTD.htm?35/23/36222\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22615/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/13/5338?source=see_link&amp;anchor=H17#H17\">",
"     \"Approach to the patient with hypertension and hypokalemia\", section on 'Subtype classification'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Adrenal CT may show massive or milder bilateral hyperplasia. Adrenal venous sampling, if performed, would show bilateral aldosterone hypersecretion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H563387\">",
"    <span class=\"h2\">",
"     Therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of patients with FH type III should be identical to patients with apparent sporadic primary aldosteronism (",
"    <a class=\"graphic graphic_algorithm graphicRef76673 \" href=\"UTD.htm?35/23/36222\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22615/abstract/22\">",
"     22",
"    </a>",
"    ]. However, in selected cases of refractory disease associated with massive bilateral adrenal hyperplasia, bilateral laparoscopic adrenalectomy may need to be considered. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/16/40199?source=see_link\">",
"     \"Treatment of primary aldosteronism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Glucocorticoid-remediable aldosteronism (GRA) or familial hyperaldosteronism type I is an inherited form (autosomal dominant) of hyperaldosteronism and is usually associated with bilateral adrenal hyperplasia. (See",
"      <a class=\"local\" href=\"#H563247\">",
"       'Familial hyperaldosteronism type I or glucocorticoid-remediable aldosteronism (GRA)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The mutation in patients with GRA is fusion of the promoter region of the gene for CYP11B1 and the coding sequence of CYP11B2; these patients are biochemically unique in having markedly increased levels of 18-oxocortisol and 18-hydroxycortisol. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      GRA should be suspected as the cause of primary aldosteronism when there is a positive family history and the onset of hypertension is before age 21. More than one-half of patients are normokalemic at the time of diagnosis, although they may develop marked hypokalemia after the administration of a thiazide diuretic. Patients with GRA are at increased risk for hemorrhagic stroke, due primarily to ruptured intracranial aneurysms. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical characteristics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest treating GRA with physiologic doses of a glucocorticoid (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). This will correct the overproduction of aldosterone by suppressing ACTH and will usually lower the blood pressure toward or to normal and correct hypokalemia (if present). Mineralocorticoid receptor antagonists may be equally effective. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Familial hyperaldosteronism type II should be considered in all patients with primary aldosteronism who have family members with hypertension. The hypertensive family members should be offered case detection testing with measurement of plasma aldosterone concentration and plasma renin activity. (See",
"      <a class=\"local\" href=\"#H563331\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Familial hyperaldosteronism type II appears to be transmitted in an autosomal dominant fashion. FH type II has been localized to chromosome 7p22 in some families, but exact location of mutation(s) is unknown to date. (See",
"      <a class=\"local\" href=\"#H563323\">",
"       'Possible mutations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with familial hyperaldosteronism type II should be treated exactly the same as patients with sporadic primary aldosteronism. (See",
"      <a class=\"local\" href=\"#H563347\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Familial hyperaldosteronism type III is caused by germline mutations in the potassium channel subunit KCNJ5. In addition, somatic mutations in KCNJ5 have been identified in aldosterone producing adenomas. (See",
"      <a class=\"local\" href=\"#H563363\">",
"       'Mutations in KCNJ5 gene'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Commercially available testing for germline KCNJ5 mutations is not yet available. This rare subtype of primary aldosteronism should be suspected in children with hyperaldosteronism and in families with more than one member with primary aldosteronism. (See",
"      <a class=\"local\" href=\"#H563379\">",
"       'Evaluation and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      FH type III appears to have a variable clinical phenotype. However, in selected cases of refractory disease associated with massive bilateral adrenal hyperplasia, bilateral laparoscopic adrenalectomy may need to be considered. (See",
"      <a class=\"local\" href=\"#H563387\">",
"       'Therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22615/abstract/1\">",
"      Sutherland DJ, Ruse JL, Laidlaw JC. Hypertension, increased aldosterone secretion and low plasma renin activity relieved by dexamethasone. Can Med Assoc J 1966; 95:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22615/abstract/2\">",
"      Lifton RP, Dluhy RG, Powers M, et al. A chimaeric 11 beta-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature 1992; 355:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22615/abstract/3\">",
"      Rich GM, Ulick S, Cook S, et al. Glucocorticoid-remediable aldosteronism in a large kindred: clinical spectrum and diagnosis using a characteristic biochemical phenotype. Ann Intern Med 1992; 116:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22615/abstract/4\">",
"      McMahon GT, Dluhy RG. Glucocorticoid-remediable aldosteronism. Cardiol Rev 2004; 12:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22615/abstract/5\">",
"      Torpy DJ, Gordon RD, Lin JP, et al. Familial hyperaldosteronism type II: description of a large kindred and exclusion of the aldosterone synthase (CYP11B2) gene. J Clin Endocrinol Metab 1998; 83:3214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22615/abstract/6\">",
"      Mulatero P, Tizzani D, Viola A, et al. Prevalence and characteristics of familial hyperaldosteronism: the PATOGEN study (Primary Aldosteronism in TOrino-GENetic forms). Hypertension 2011; 58:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22615/abstract/7\">",
"      Lifton RP, Dluhy RG, Powers M, et al. Hereditary hypertension caused by chimaeric gene duplications and ectopic expression of aldosterone synthase. Nat Genet 1992; 2:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22615/abstract/8\">",
"      Litchfield WR, Coolidge C, Silva P, et al. Impaired potassium-stimulated aldosterone production: a possible explanation for normokalemic glucocorticoid-remediable aldosteronism. J Clin Endocrinol Metab 1997; 82:1507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22615/abstract/9\">",
"      Fallo F, Pilon C, Williams TA, et al. Coexistence of different phenotypes in a family with glucocorticoid-remediable aldosteronism. J Hum Hypertens 2004; 18:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22615/abstract/10\">",
"      Litchfield WR, Anderson BF, Weiss RJ, et al. Intracranial aneurysm and hemorrhagic stroke in glucocorticoid-remediable aldosteronism. Hypertension 1998; 31:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22615/abstract/11\">",
"      Botero-Velez M, Curtis JJ, Warnock DG. Brief report: Liddle's syndrome revisited--a disorder of sodium reabsorption in the distal tubule. N Engl J Med 1994; 330:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22615/abstract/12\">",
"      Jamieson A, Inglis GC, Campbell M, et al. Rapid diagnosis of glucocorticoid suppressible hyperaldosteronism in infants and adolescents. Arch Dis Child 1994; 71:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22615/abstract/13\">",
"      Jonsson JR, Klemm SA, Tunny TJ, et al. A new genetic test for familial hyperaldosteronism type I aids in the detection of curable hypertension. Biochem Biophys Res Commun 1995; 207:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22615/abstract/14\">",
"      Mulatero P, Veglio F, Pilon C, et al. Diagnosis of glucocorticoid-remediable aldosteronism in primary aldosteronism: aldosterone response to dexamethasone and long polymerase chain reaction for chimeric gene. J Clin Endocrinol Metab 1998; 83:2573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22615/abstract/15\">",
"      Gates LJ, Benjamin N, Haites NE, et al. Is random screening of value in detecting glucocorticoid-remediable aldosteronism within a hypertensive population? J Hum Hypertens 2001; 15:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22615/abstract/16\">",
"      Dluhy RG, Anderson B, Harlin B, et al. Glucocorticoid-remediable aldosteronism is associated with severe hypertension in early childhood. J Pediatr 2001; 138:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22615/abstract/17\">",
"      Funder JW, Carey RM, Fardella C, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008; 93:3266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22615/abstract/18\">",
"      Stowasser M, Bachmann AW, Huggard PR, et al. Treatment of familial hyperaldosteronism type I: only partial suppression of adrenocorticotropin required to correct hypertension. J Clin Endocrinol Metab 2000; 85:3313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22615/abstract/19\">",
"      Pallauf A, Schirpenbach C, Zwermann O, et al. The prevalence of familial hyperaldosteronism in apparently sporadic primary aldosteronism in Germany: a single center experience. Horm Metab Res 2012; 44:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22615/abstract/20\">",
"      Sukor N, Mulatero P, Gordon RD, et al. Further evidence for linkage of familial hyperaldosteronism type II at chromosome 7p22 in Italian as well as Australian and South American families. J Hypertens 2008; 26:1577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22615/abstract/21\">",
"      Carss KJ, Stowasser M, Gordon RD, O'Shaughnessy KM. Further study of chromosome 7p22 to identify the molecular basis of familial hyperaldosteronism type II. J Hum Hypertens 2011; 25:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22615/abstract/22\">",
"      Young WF. Primary aldosteronism: renaissance of a syndrome. Clin Endocrinol (Oxf) 2007; 66:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22615/abstract/23\">",
"      Geller DS, Zhang J, Wisgerhof MV, et al. A novel form of human mendelian hypertension featuring nonglucocorticoid-remediable aldosteronism. J Clin Endocrinol Metab 2008; 93:3117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22615/abstract/24\">",
"      Choi M, Scholl UI, Yue P, et al. K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. Science 2011; 331:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22615/abstract/25\">",
"      Charmandari E, Sertedaki A, Kino T, et al. A novel point mutation in the KCNJ5 gene causing primary hyperaldosteronism and early-onset autosomal dominant hypertension. J Clin Endocrinol Metab 2012; 97:E1532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22615/abstract/26\">",
"      Mussa A, Camilla R, Monticone S, et al. Polyuric-polydipsic syndrome in a pediatric case of non-glucocorticoid remediable familial hyperaldosteronism. Endocr J 2012; 59:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22615/abstract/27\">",
"      Mulatero P, Tauber P, Zennaro MC, et al. KCNJ5 mutations in European families with nonglucocorticoid remediable familial hyperaldosteronism. Hypertension 2012; 59:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22615/abstract/28\">",
"      Scholl UI, Nelson-Williams C, Yue P, et al. Hypertension with or without adrenal hyperplasia due to different inherited mutations in the potassium channel KCNJ5. Proc Natl Acad Sci U S A 2012; 109:2533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22615/abstract/29\">",
"      &Aring;kerstr&ouml;m T, Crona J, Delgado Verdugo A, et al. Comprehensive re-sequencing of adrenal aldosterone producing lesions reveal three somatic mutations near the KCNJ5 potassium channel selectivity filter. PLoS One 2012; 7:e41926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22615/abstract/30\">",
"      Boulkroun S, Beuschlein F, Rossi GP, et al. Prevalence, clinical, and molecular correlates of KCNJ5 mutations in primary aldosteronism. Hypertension 2012; 59:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22615/abstract/31\">",
"      Azizan EA, Murthy M, Stowasser M, et al. Somatic mutations affecting the selectivity filter of KCNJ5 are frequent in 2 large unselected collections of adrenal aldosteronomas. Hypertension 2012; 59:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22615/abstract/32\">",
"      Xekouki P, Hatch MM, Lin L, et al. KCNJ5 mutations in the National Institutes of Health cohort of patients with primary hyperaldosteronism: an infrequent genetic cause of Conn's syndrome. Endocr Relat Cancer 2012; 19:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22615/abstract/33\">",
"      Monticone S, Hattangady NG, Nishimoto K, et al. Effect of KCNJ5 mutations on gene expression in aldosterone-producing adenomas and adrenocortical cells. J Clin Endocrinol Metab 2012; 97:E1567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22615/abstract/34\">",
"      Azizan EA, Lam BY, Newhouse SJ, et al. Microarray, qPCR, and KCNJ5 sequencing of aldosterone-producing adenomas reveal differences in genotype and phenotype between zona glomerulosa- and zona fasciculata-like tumors. J Clin Endocrinol Metab 2012; 97:E819.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 122 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-8189A37D88-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_5_22615=[""].join("\n");
var outline_f22_5_22615=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H563247\">",
"      FAMILIAL HYPERALDOSTERONISM TYPE I OR GLUCOCORTICOID-REMEDIABLE ALDOSTERONISM (GRA)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Pathophysiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Clinical characteristics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H563315\">",
"      FAMILIAL HYPERALDOSTERONISM TYPE II (FH TYPE II)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H563323\">",
"      Possible mutations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H563331\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H563339\">",
"      Approach to diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H563347\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H563355\">",
"      FAMILIAL HYPERALDOSTERONISM TYPE III (FH TYPE III)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H563363\">",
"      Mutations in KCNJ5 gene",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H563371\">",
"      Clinical findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H563379\">",
"      Evaluation and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H563387\">",
"      Therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/122\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/122|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?35/23/36222\" title=\"algorithm 1\">",
"      Subtype eval primary aldo",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/122|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/7/123\" title=\"figure 1\">",
"      Adrenal steroid synthesis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/46/28391?source=related_link\">",
"      Adrenal steroid biosynthesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/13/5338?source=related_link\">",
"      Approach to the patient with hypertension and hypokalemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/20/2376?source=related_link\">",
"      Chapter 6C: Aldosterone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37911?source=related_link\">",
"      Clinical features of primary aldosteronism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/33/30233?source=related_link\">",
"      Extrarenal manifestations of autosomal dominant polycystic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/51/25399?source=related_link\">",
"      Genetic disorders of the collecting tubule sodium channel: Liddle's syndrome and pseudohypoaldosteronism type 1",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/16/40199?source=related_link\">",
"      Treatment of primary aldosteronism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_5_22616="Clinical manifestations and pathogenesis of disorders of the androgen receptor";
var content_f22_5_22616=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and pathogenesis of disorders of the androgen receptor",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/5/22616/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/5/22616/contributors\">",
"     James E Griffin, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/5/22616/contributors\">",
"     Jean D Wilson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/5/22616/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/5/22616/contributors\">",
"     Peter J Snyder, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/5/22616/contributors\">",
"     Alvin M Matsumoto, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/5/22616/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/5/22616/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/5/22616/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 23, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Loss of function mutations of the gene that encodes the androgen-receptor result in several distinct phenotypes in 46,XY males with testes and normal testosterone formation. These phenotypes vary from women and men with 46,XY disorders of sexual development (DSD) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22616/abstract/1\">",
"     1",
"    </a>",
"    ] to men with undervirilization or infertility. In contrast to the variability in phenotypic expression, the disorders have similar endocrine, pathophysiologic, and genetic features. The pathophysiology will be reviewed here, while diagnosis and therapy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/44/17096?source=see_link\">",
"     \"Diagnosis and treatment of disorders of the androgen receptor\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Complete androgen insensitivity (CAIS)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complete androgen insensitivity syndrome (CAIS; formerly called complete testicular feminization) is due to mutations that cause severe impairment of androgen receptor function. The typical presentation is a phenotypic woman seen for primary amenorrhea and found to have little or no axillary and pubic hair, testes, no uterus, a 46,XY karyotype, and serum testosterone concentrations in the adult male range. Affected women have unambiguously female external genitalia. The labia and clitoris are normal or slightly underdeveloped, and the vagina is either absent or short and blind-ending.",
"   </p>",
"   <p>",
"    Testes may be located in the abdomen, the inguinal canals, or the labia majora and have the histologic appearance of undescended testes with a normal or increased number of Leydig cells and no spermatogenesis. The urogenital tract is characterized by absence or near absence of m&uuml;llerian structures; rarely, uterine remnants are present [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22616/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Epididymides and vasa deferentia are usually absent, but in one study, the epididymis and vas deferens were identified histologically adjacent to the testes in 10 of 33 affected children (average age six years) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22616/abstract/3\">",
"     3",
"    </a>",
"    ]. Tumors may develop in the cryptorchid testes [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22616/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/25/2457?source=see_link\">",
"     \"Epidemiology of and risk factors for testicular germ cell tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/27/42425?source=see_link\">",
"     \"Testicular intratubular germ cell neoplasia, unclassified (testicular carcinoma in situ, testicular intraepithelial neoplasia)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Growth pattern follows that of normal girls, but final height is closer to that of normal boys [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22616/abstract/5\">",
"     5",
"    </a>",
"    ]. Breast development is that of a normal woman, and overall body habitus is female (",
"    <a class=\"graphic graphic_picture graphicRef80831 \" href=\"UTD.htm?22/50/23330\">",
"     picture 1",
"    </a>",
"    ). Axillary and pubic hair is markedly decreased or absent. These women are taller (average height 172 cm) and heavier than normal women [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22616/abstract/6,7\">",
"     6,7",
"    </a>",
"    ], suggesting that the Y chromosome has somatic effects not mediated by the androgen receptor. Psychologic development is feminine, including typical maternal instincts [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22616/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Although many patients report satisfactory outcome after vaginoplasty, including normal libido and ability to achieve orgasm [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22616/abstract/10\">",
"     10",
"    </a>",
"    ], women in whom the vagina remains small may experience sexual problems [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22616/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence of CAIS may be as high as 1 in 20,000. In one study, it was the third most frequent cause of primary amenorrhea (after gonadal dysgenesis and congenital absence of the vagina) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22616/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Partial androgen insensitivity (PAIS)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Less severe defects in androgen action cause a variety of forms of 46,XY DSD that vary from women with mild degrees of virilization to fertile but undervirilized men. The various phenotypes were originally thought to be separate syndromes, and the recognition that they are due to defects of varying severity in androgen receptor function came from family studies [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22616/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. In one family, three severely affected persons were females whereas another had perineoscrotal hypospadias and bifid scrotum typical of the Reifenstein phenotype [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22616/abstract/15\">",
"     15",
"    </a>",
"    ]. In a second family, manifestations varied from male infertility with hypospadias to fertile, undervirilized men [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22616/abstract/16\">",
"     16",
"    </a>",
"    ]. The various phenotypes sometimes cluster within individual families.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H346304724\">",
"    <span class=\"h3\">",
"     Phenotypic women with mild virilization",
"    </span>",
"    &nbsp;&mdash;&nbsp;This form of PAIS, formerly called incomplete testicular feminization, encompasses women who resemble those with complete androgen insensitivity but with normal body hair and partial virilization of the external genitalia and who both virilize and feminize at the time of expected puberty [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22616/abstract/17\">",
"     17",
"    </a>",
"    ]. The external genitalia typically exhibit partial fusion of the labioscrotal folds",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    clitoromegaly. The vagina is short and ends blindly. The internal urogenital tract is characterized by absent m&uuml;llerian structures, but the Wolffian duct derivatives (epididymides, vasa deferentia, seminal vesicles, and ejaculatory ducts) are male in character but incompletely developed. The testes are similar to those in complete testicular feminization in location and histology.",
"   </p>",
"   <p>",
"    Breast development and body habitus are those of normal women (",
"    <a class=\"graphic graphic_picture graphicRef80831 \" href=\"UTD.htm?22/50/23330\">",
"     picture 1",
"    </a>",
"    ) and the axillary and pubic hair are normal, in contrast to the paucity of body hair in women with CAIS. Psychologic orientation is feminine. The prevalence of this disorder is uncertain, but in our experience, it is about one-tenth as common as CAIS.",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H346304813\">",
"    <span class=\"h3\">",
"     Reifenstein syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reifenstein syndrome is a form of PAIS in 46,XY DSD men who have a predominant male phenotype and variable defects in virilization [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22616/abstract/13\">",
"     13",
"    </a>",
"    ]. The incidence of Reifenstein syndrome is not certain, perhaps due to the difficulty of diagnosis in the absence of a positive family history. In our experience, it is about as common as CAIS. The usual phenotype is an infertile man with perineoscrotal hypospadias and a bifid scrotum, but the external genitalia can vary from microphallus with a normal penile urethra to complete failure of scrotal fusion and a pseudovagina. Other genital tract findings include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Wolffian duct derivatives are male in character, and m&uuml;llerian duct derivatives are absent.",
"     </li>",
"     <li>",
"      The vas deferens may be incomplete, and the lower ejaculatory duct system and seminal vesicles have been characterized in only a few patients.",
"     </li>",
"     <li>",
"      The urogenital sinus may be partially virilized, but a true prostate does not develop.",
"     </li>",
"     <li>",
"      The testes may be cryptorchid or normally descended and usually are small.",
"     </li>",
"     <li>",
"      Germinal epithelium is present in the testes but usually with a maturation arrest. Infertility is primarily due to impairment in spermatogenesis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The body habitus is male, but gynecomastia usually develops at the time of expected puberty (",
"    <a class=\"graphic graphic_picture graphicRef80831 \" href=\"UTD.htm?22/50/23330\">",
"     picture 1",
"    </a>",
"    ). Axillary and pubic hair is normal, but chest and facial hair are absent or sparse. Subjects raised as males usually have unambiguous male gender",
"    <span class=\"nowrap\">",
"     identity/role",
"    </span>",
"    behavior, while gender identity is usually female in those raised as females [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22616/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In subjects raised as males, the frequency of sexual dysfunction has been reported to be high in comparison with normal men [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22616/abstract/19\">",
"     19",
"    </a>",
"    ], whereas in a study of adult 46,XY individuals with ambiguous genitalia of various causes, the assessment of satisfaction with sexual function was similar in those raised as men or women, namely 2.5 and 2.7 out of a maximum of 5, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22616/abstract/20\">",
"     20",
"    </a>",
"    ].",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H346304823\">",
"    <span class=\"h3\">",
"     Infertile male syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some affected 46,XY men in Reifenstein families have only infertility, undermasculinization, and gynecomastia. Subsequently, men with azoospermia or severe oligospermia but without a family history of Reifenstein syndrome were found to have defects in the androgen receptor (see below) similar to those in men with Reifenstein syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22616/abstract/21\">",
"     21",
"    </a>",
"    ]. This mildest form of PAIS has been termed the infertile male syndrome. The external genitalia (",
"    <a class=\"graphic graphic_picture graphicRef80831 \" href=\"UTD.htm?22/50/23330\">",
"     picture 1",
"    </a>",
"    ) and internal urogenital tract are those of normal men. The testes are usually descended, and testicular histology varies from complete absence of germinal elements to maturation arrest of spermatogenesis.",
"   </p>",
"   <p>",
"    The overall body habitus is male and facial and body hair growth is usually fully masculine. Some men have gynecomastia. The frequency of the disorder as a cause of male infertility is not established. In two series of men with idiopathic azoospermia or severe oligospermia, approximately 10 percent had PAIS [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22616/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H346304830\">",
"    <span class=\"h3\">",
"     Undervirilized fertile male syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based on the clinical syndromes described above, it was assumed that infertility might be a consistent manifestation of androgen receptor disorders. However, rare undervirilized men with PAIS have normal sperm density [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22616/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. The external genitalia are those of a normal man, except that the penis may be small. The internal urogenital tract is normal. The testes are descended, sperm density is usually normal, and ejaculate volume is decreased. Some affected men are fertile [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22616/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The overall body habitus is male with decreased beard and body hair; gynecomastia may be present. Gender orientation is male. The frequency of the disorder is unknown because only a few families have been described.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ENDOCRINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hormonal profile is similar in all the syndromes associated with defects of androgen receptor function, but the endocrine features have been studied most extensively in women with CAIS [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22616/abstract/26-29\">",
"     26-29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These women have serum testosterone concentrations in the normal male range or somewhat higher. Serum sex hormone-binding globulin (SHBG) concentrations and testosterone production rates are increased. The testes are the source of testosterone production.",
"   </p>",
"   <p>",
"    The increased testosterone production is secondary to increases in serum luteinizing hormone (LH) concentrations, which in turn are due to resistance to the feedback effect of androgens on LH secretion at the hypothalamic-pituitary level [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22616/abstract/28,30\">",
"     28,30",
"    </a>",
"    ]. Both the frequency and amplitude of pulses of LH secretion are increased [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22616/abstract/28\">",
"     28",
"    </a>",
"    ]. Serum follicle-stimulating hormone (FSH) concentrations are usually normal.",
"   </p>",
"   <p>",
"    Estrogen production is increased, the mean estrone and estradiol production rates being about 70 percent higher than those of normal men [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22616/abstract/29\">",
"     29",
"    </a>",
"    ]. Most of the increase in estradiol production is due to direct secretion by the testes. The high serum estrogen concentrations blunt the elevation in LH secretion, and gonadectomy or antiestrogen treatment causes serum LH concentrations to rise even further [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22616/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The hormone levels in PAIS women with mild virilization or PAIS men with the Reifenstein syndrome are similar to those in women with CAIS [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22616/abstract/13,31\">",
"     13,31",
"    </a>",
"    ]; hormone levels in the infertile male syndrome are less abnormal [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22616/abstract/21\">",
"     21",
"    </a>",
"    ]. In a family with the undervirilized fertile male syndrome, all three men studied had high serum testosterone concentrations, two had high serum estradiol, and all had normal serum LH [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22616/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Production of dihydrotestosterone is decreased in some patients with CAIS, presumably due to the decreased mass of the male urogenital tract tissues, which are major sites of dihydrotestosterone production [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22616/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recognition that patients with CAIS have profound resistance to the action of androgen came from studies in which affected women were found to be resistant to the virilizing action of exogenous androgen [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22616/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This hormone resistance was deduced to be due to defects in androgen receptor function as a result of studies of women with CAIS who had no detectable androgen receptor binding [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22616/abstract/34-36\">",
"     34-36",
"    </a>",
"    ], qualitatively abnormal androgen receptor binding [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22616/abstract/37-39\">",
"     37-39",
"    </a>",
"    ], or decreased amounts of qualitatively normal receptor binding [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22616/abstract/37,40\">",
"     37,40",
"    </a>",
"    ]. Similar findings were described in patients with the less severe phenotypes [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22616/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Involvement of the androgen receptor in these disorders was confirmed when the encoding gene was cloned and specific molecular defects were defined (see below).",
"   </p>",
"   <p>",
"    The variable feminization in the different syndromes is thought to depend on the severity of the androgen resistance rather than on the amount of estrogen produced. For example, two men with Reifenstein syndrome had more estrogen production than women with CAIS or PAIS with mild virilization [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22616/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Genetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early studies of families with CAIS [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22616/abstract/41\">",
"     41",
"    </a>",
"    ] or with PAIS manifested by the Reifenstein syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22616/abstract/13-15\">",
"     13-15",
"    </a>",
"    ], or mild virilization in phenotypic women [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22616/abstract/37\">",
"     37",
"    </a>",
"    ] suggested that the disorder is inherited as a X-linked recessive or male-limited autosomal dominant trait [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22616/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    X-linkage of the androgen receptor gene was established when the human cDNA was cloned from an X-chromosome library [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22616/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. The androgen receptor is a member of the steroid-thyroid-retinoid superfamily of nuclear receptors with a C-terminal region containing hormone-binding and DNA-binding domains and a N-terminal region important in transactivation (",
"    <a class=\"graphic graphic_figure graphicRef61536 \" href=\"UTD.htm?34/56/35724\">",
"     figure 1",
"    </a>",
"    ). Specific mutations of the receptor cDNA have been identified in many patients with androgen insensitivity syndromes.",
"   </p>",
"   <p>",
"    Most of the mutations that have been characterized are in women with CAIS. The mutations in families with androgen receptor abnormalities included deletions, splicing abnormalities, premature termination codons, and missense mutations that cause amino-acid substitutions [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22616/abstract/44\">",
"     44",
"    </a>",
"    ]. Eighty percent of these women had missense mutations. Splicing abnormalities and premature termination codons were found in 2 and 7 percent, respectively. Partial deletions were found in 7 percent and complete deletions of the androgen-receptor gene in only 1 percent.",
"   </p>",
"   <p>",
"    Approximately 40 percent of patients with CAIS have a negative family history. As an example, in a study of 30 families in which a mutation of the androgen receptor was identified in only one individual, the mothers and grandmothers were heterozygous carriers in 22 of the 30 families, indicating that the mutation in these families had occurred remotely and had been passed through several generations before becoming manifest [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22616/abstract/45\">",
"     45",
"    </a>",
"    ]. In 8 of 30 families de novo mutations were identified, some present in mosaic form [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22616/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although loss of function mutations of the androgen receptor can be identified in most women with CAIS, mutations of the coding sequence of the androgen receptor are found in only about 20 percent of the individuals with the diagnosis of PAIS and a negative family history [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22616/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Genotype-phenotype correlations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Major deletions or premature termination codons have been found only in patients with CAIS. Amino acid-substitutions can cause the entire spectrum of phenotypes from infertile men to CAIS. About 80 percent of the amino acid substitutions are in the hormone-binding domain, and many of the remaining 20 percent are in the DNA-binding domain. DNA-binding domain mutations are usually associated with normal androgen binding but defective ability to activate androgen responsive genes [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22616/abstract/47\">",
"     47",
"    </a>",
"    ]. Understanding how one amino acid substitution leads to a greater impairment in receptor function than another will require knowledge of the crystal structure of the androgen-androgen receptor complex. Interestingly, mutations in exon 1 turn out to be more common than originally thought, indicating that this exon should probably be sequenced routinely [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22616/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mutations characterized in patients with the infertile male syndrome and the undervirilized fertile male syndrome cause amino acid substitutions in the hormone-binding domain [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22616/abstract/49,50\">",
"     49,50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In some patients with PAIS due to amino acid substitutions in the hormone-binding domain, the hormone resistance can be overcome in part by supraphysiological doses of androgen [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22616/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In some families with clearcut androgen resistance, no mutation has been identified in the androgen receptor gene or in its flanking sequences. In one mutational analysis in 102 patients with AIS, no abnormality was found in 12 of 69 (17 percent) subjects with CAIS and 31 of 43 (72 percent) subjects with PAIS [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22616/abstract/51\">",
"     51",
"    </a>",
"    ]. At least three mechanisms may underlie the failure to find an androgen receptor mutation. In two unrelated families, mutations located deep within the intronic sequences (beyond the regions ordinarily sequenced) impaired the efficiency of the splicing process by which mature mRNA is formed [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22616/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. In another family, the defect appeared to impair a coactivator protein necessary for function of the androgen-androgen receptor complex [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22616/abstract/54\">",
"     54",
"    </a>",
"    ]. Mosaicism due to a somatic mutation of the androgen receptor may also be associated with a normal androgen receptor sequence in some tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22616/abstract/55,56\">",
"     55,56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is more difficult to understand why in some families affected individuals with the same mutation have different phenotypes and how the same mutation can produce different phenotypes in different families [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22616/abstract/57\">",
"     57",
"    </a>",
"    ]. In one study, phenotypic variation was seen in three of nine families with PAIS but in none of the families with CAIS [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22616/abstract/58\">",
"     58",
"    </a>",
"    ]. Variable timing of receptor expression or differences in testosterone synthesis or metabolism could have an impact on the expression of a mutation in a given patient. Alternatively, variations in unidentified proteins, such as other members of the transcription regulatory complex, may alter the activity of the androgen receptor. Similarly, differences in the lengths of the polyglutamine and polyglycine repeat sequences in the N-terminal domain of the protein can influence the effect of given mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22616/abstract/59,60\">",
"     59,60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Spinobulbar muscular atrophy",
"    </span>",
"    &nbsp;&mdash;&nbsp;An unanticipated variation of androgen-receptor gene structure occurs in men with spinobulbar muscular atrophy (Kennedy syndrome) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22616/abstract/61\">",
"     61",
"    </a>",
"    ]. This X-linked disorder is characterized by progressive degeneration of anterior motor neurons and is associated with late-onset gynecomastia, defective spermatogenesis, and a hormonal profile consistent with androgen resistance. The androgen-receptor gene in these men contains an expansion in the number of glutamine repeats in the N-terminal region (",
"    <a class=\"graphic graphic_figure graphicRef61536 \" href=\"UTD.htm?34/56/35724\">",
"     figure 1",
"    </a>",
"    ) from the usual 20 glutamines to more than twice that number [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22616/abstract/62\">",
"     62",
"    </a>",
"    ]. In vitro studies of transactivation of a reporter gene by a mutant receptor with the expanded glutamine repeats indicate that receptor function is impaired [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22616/abstract/63\">",
"     63",
"    </a>",
"    ] and the severity of this impairment correlates with the length of expansion of the CAG repeat [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22616/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two transgenic models of Kennedy syndrome have been developed: one type in mice and the other in Drosophila. In both of these models, even when homozygous, the disease does not develop in females. In males, it can be prevented or reversed by castration [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22616/abstract/65\">",
"     65",
"    </a>",
"    ]. It had been uncertain whether the abnormal androgen receptor complex was working directly by the canonical androgen receptor or by some other process. It is now known that the androgen-androgen receptor complex is sufficient in itself, but it must enter the nucleus and interact with DNA [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22616/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H904842\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disorders of the androgen receptor are one form of 46,XY disorders of sexual development (DSD). Loss of function mutations in the androgen receptor lead to variable defects in virilization or infertility in 46,XY males with testes and normal testosterone formation. Clinical presentation ranges from phenotypic women with decreased or absent axillary and pubic hair (complete androgen insensitivity syndrome, CAIS) through individuals with partial androgen insensitivity (PAIS), including women with partial virilization, to phenotypic men with variable defects in virilization to men with isolated infertility.",
"   </p>",
"   <p>",
"    The androgen receptor is coded by a gene on the X-chromosome. Loss of function mutations in the coding sequence of the androgen receptor can be found in most women with CAIS, but only in about 20 percent of subjects with PAIS. In some families with PAIS, affected individuals with the same mutation have different phenotypes, and the same mutation can produce different phenotypes in different families.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22616/abstract/1\">",
"      Hughes IA, Houk C, Ahmed SF, et al. Consensus statement on management of intersex disorders. Arch Dis Child 2006; 91:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22616/abstract/2\">",
"      Dodge ST, Finkelston MS, Miyazawa K. Testicular feminization with incomplete M&uuml;llerian regression. Fertil Steril 1985; 43:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22616/abstract/3\">",
"      Hannema SE, Scott IS, Hodapp J, et al. Residual activity of mutant androgen receptors explains wolffian duct development in the complete androgen insensitivity syndrome. J Clin Endocrinol Metab 2004; 89:5815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22616/abstract/4\">",
"      MORRIS JM. The syndrome of testicular feminization in male pseudohermaphrodites. Am J Obstet Gynecol 1953; 65:1192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22616/abstract/5\">",
"      Papadimitriou DT, Linglart A, Morel Y, Chaussain JL. Puberty in subjects with complete androgen insensitivity syndrome. Horm Res 2006; 65:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22616/abstract/6\">",
"      Varrela J, Alvesalo L, Vinkka H. Body size and shape in 46,XY females with complete testicular feminization. Ann Hum Biol 1984; 11:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22616/abstract/7\">",
"      Danilovic DL, Correa PH, Costa EM, et al. Height and bone mineral density in androgen insensitivity syndrome with mutations in the androgen receptor gene. Osteoporos Int 2007; 18:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22616/abstract/8\">",
"      Money J, Ehrhardt AA, Masica DN. Fetal feminization induced by androgen insensitivity in the testicular feminizing syndrome: effect on marriage and maternalism. Johns Hopkins Med J 1968; 123:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22616/abstract/9\">",
"      Hines M, Ahmed SF, Hughes IA. Psychological outcomes and gender-related development in complete androgen insensitivity syndrome. Arch Sex Behav 2003; 32:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22616/abstract/10\">",
"      Wisniewski AB, Migeon CJ, Meyer-Bahlburg HF, et al. Complete androgen insensitivity syndrome: long-term medical, surgical, and psychosexual outcome. J Clin Endocrinol Metab 2000; 85:2664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22616/abstract/11\">",
"      Minto CL, Liao KL, Conway GS, Creighton SM. Sexual function in women with complete androgen insensitivity syndrome. Fertil Steril 2003; 80:157.",
"     </a>",
"    </li>",
"    <li>",
"     Ross GT. Disorders of the ovary and female reproductive tract. In: Williams Textbook of Endocrinology, Wilson JD, Foster DW (Eds), Saunders, Philadelphia 1985. p.206.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22616/abstract/13\">",
"      Wilson JD, Harrod MJ, Goldstein JL, et al. Familial incomplete male pseudohermaphroditism, type 1. Evidence for androgen resistance and variable clinical manifestations in a family with the Reifenstein syndrome. N Engl J Med 1974; 290:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22616/abstract/14\">",
"      Walker AC, Stack EM, Horsfall WA. Familial male pseudohermaphroditism. Med J Aust 1970; 1:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22616/abstract/15\">",
"      Gard&oacute; S, Papp Z. Clinical variations of testicular intersexuality in a family. J Med Genet 1974; 11:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22616/abstract/16\">",
"      Chu J, Zhang R, Zhao Z, et al. Male fertility is compatible with an Arg(840)Cys substitution in the AR in a large Chinese family affected with divergent phenotypes of AR insensitivity syndrome. J Clin Endocrinol Metab 2002; 87:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22616/abstract/17\">",
"      MORRIS JM, MAHESH VB. FURTHER OBSERVATIONS ON THE SYNDROME, \"TESTICULAR FEMINIZATION\". Am J Obstet Gynecol 1963; 87:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22616/abstract/18\">",
"      Melo KF, Mendonca BB, Billerbeck AE, et al. Clinical, hormonal, behavioral, and genetic characteristics of androgen insensitivity syndrome in a Brazilian cohort: five novel mutations in the androgen receptor gene. J Clin Endocrinol Metab 2003; 88:3241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22616/abstract/19\">",
"      Bouvattier C, Mignot B, Lef&egrave;vre H, et al. Impaired sexual activity in male adults with partial androgen insensitivity. J Clin Endocrinol Metab 2006; 91:3310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22616/abstract/20\">",
"      Migeon CJ, Wisniewski AB, Gearhart JP, et al. Ambiguous genitalia with perineoscrotal hypospadias in 46,XY individuals: long-term medical, surgical, and psychosexual outcome. Pediatrics 2002; 110:e31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22616/abstract/21\">",
"      Aiman J, Griffin JE, Gazak JM, et al. Androgen insensitivity as a cause of infertility in otherwise normal men. N Engl J Med 1979; 300:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22616/abstract/22\">",
"      Aiman J, Griffin JE. The frequency of androgen receptor deficiency in infertile men. J Clin Endocrinol Metab 1982; 54:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22616/abstract/23\">",
"      Morrow AF, Gyorki S, Warne GL, et al. Variable androgen receptor levels in infertile men. J Clin Endocrinol Metab 1987; 64:1115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22616/abstract/24\">",
"      Grino PB, Griffin JE, Cushard WG Jr, Wilson JD. A mutation of the androgen receptor associated with partial androgen resistance, familial gynecomastia, and fertility. J Clin Endocrinol Metab 1988; 66:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22616/abstract/25\">",
"      Pinsky L, Kaufman M, Killinger DW. Impaired spermatogenesis is not an obligate expression of receptor-defective androgen resistance. Am J Med Genet 1989; 32:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22616/abstract/26\">",
"      GRIFFITHS K, GRANT JK, WHYTE WG. STEROID BIOSYNTHESIS IN VITRO BY CRYPTORCHID TESTES FROM A CASE OF TESTICULAR FEMINIZATION. J Clin Endocrinol Metab 1963; 23:1044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22616/abstract/27\">",
"      Tremblay RR, Foley TP Jr, Corvol P, et al. Plasma concentration of testosterone, dihydrotestosterone, testosterone-oestradiol binding globulin, and pituitary gonadotrophins in the syndrome of male pseudo-hermaphroditism with testicular feminization. Acta Endocrinol (Copenh) 1972; 70:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22616/abstract/28\">",
"      Boyar RM, Moore RJ, Rosner W, et al. Studies of gonadotropin-gonadal dynamics in patients with androgen insensitivity. J Clin Endocrinol Metab 1978; 47:1116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22616/abstract/29\">",
"      MacDonald PC, Madden JD, Brenner PF, et al. Origin of estrogen in normal men and in women with testicular feminization. J Clin Endocrinol Metab 1979; 49:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22616/abstract/30\">",
"      Faiman C, Winter JS. The control of gonadotropin secretion in complete testicular feminization. J Clin Endocrinol Metab 1974; 39:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22616/abstract/31\">",
"      Madden JD, Walsh PC, MacDonald PC, Wilson JD. Clinical and endocrinologic characterization of a patients with the syndrome of incomplete testicular feminization. J Clin Endocrinol Metab 1975; 41:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22616/abstract/32\">",
"      Imperato-McGinley J, Peterson RE, Gautier T, et al. Hormonal evaluation of a large kindred with complete androgen insensitivity: evidence for secondary 5 alpha-reductase deficiency. J Clin Endocrinol Metab 1982; 54:931.",
"     </a>",
"    </li>",
"    <li>",
"     Wilkins L. Abnormal sex differentiation: Hermaphroditism and gonadal dysgenesis. In: The Diagnosis and Treatment of Endocrine Disorders in Childhood and Adolescence, Charles C Thomas Pub Ltd, Springfield, IL 1957. p.258.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22616/abstract/34\">",
"      Keenan BS, Meyer WJ 3rd, Hadjian AJ, et al. Syndrome of androgen insensitivity in man: absence of 5 alpha-dihydrotestosterone binding protein in skin fibroblasts. J Clin Endocrinol Metab 1974; 38:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22616/abstract/35\">",
"      Griffin JE, Punyashthiti K, Wilson JD. Dihydrotestosterone binding by cultured human fibroblasts. Comparison of cells from control subjects and from patients with hereditary male pseudohermaphroditism due to androgen resistance. J Clin Invest 1976; 57:1342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22616/abstract/36\">",
"      Kaufman M, Straisfeld C, Pinsky L. Male pseudohermaphroditism presumably due to target organ unresponsiveness to androgens. Deficient 5alpha-dihydrotestosterone binding in cultured skin fibroblasts. J Clin Invest 1976; 58:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22616/abstract/37\">",
"      Griffin JE. Testicular feminization associated with a thermolabile androgen receptor in culutred human fibroblasts. J Clin Invest 1979; 64:1624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22616/abstract/38\">",
"      Pinsky L, Kaufman M, Killinger DW, et al. Human minimal androgen insensitivity with normal dihydrotestosterone-binding capacity in cultured genital skin fibroblasts: evidence for an androgen-selective qualitative abnormality of the receptor. Am J Hum Genet 1984; 36:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22616/abstract/39\">",
"      Brown TR, Maes M, Rothwell SW, Migeon CJ. Human complete androgen insensitivity with normal dihydrotestosterone receptor binding capacity in cultured genital skin fibroblasts: evidence for a qualitative abnormality of the receptor. J Clin Endocrinol Metab 1982; 55:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22616/abstract/40\">",
"      Griffin JE. Androgen resistance--the clinical and molecular spectrum. N Engl J Med 1992; 326:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22616/abstract/41\">",
"      Pettersson, G, Bonnier, G. Inherited sex-mosaic in man. Hereditas 1937; 23:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22616/abstract/42\">",
"      Chang CS, Kokontis J, Liao ST. Molecular cloning of human and rat complementary DNA encoding androgen receptors. Science 1988; 240:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22616/abstract/43\">",
"      Lubahn DB, Joseph DR, Sullivan PM, et al. Cloning of human androgen receptor complementary DNA and localization to the X chromosome. Science 1988; 240:327.",
"     </a>",
"    </li>",
"    <li>",
"     Griffin JE, McPhaul MJ, Russell DW, Wilson JD. The androgen resistance syndromes: steroid 5 alpha-reductase 2 deficiency, testicular feminization, and related disorders. In: The Metabolic and Molecular Bases of Inherited Disease, 8th, Scriver CR, Beaudet AL, Sly WS, Valle D (Eds), McGraw-Hill, New York 2001. p.4117.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22616/abstract/45\">",
"      Hiort O, Sinnecker GH, Holterhus PM, et al. Inherited and de novo androgen receptor gene mutations: investigation of single-case families. J Pediatr 1998; 132:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22616/abstract/46\">",
"      Deeb A, Mason C, Lee YS, Hughes IA. Correlation between genotype, phenotype and sex of rearing in 111 patients with partial androgen insensitivity syndrome. Clin Endocrinol (Oxf) 2005; 63:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22616/abstract/47\">",
"      McPhaul MJ, Marcelli M, Zoppi S, et al. Genetic basis of endocrine disease. 4. The spectrum of mutations in the androgen receptor gene that causes androgen resistance. J Clin Endocrinol Metab 1993; 76:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22616/abstract/48\">",
"      Philibert P, Audran F, Pienkowski C, et al. Complete androgen insensitivity syndrome is frequently due to premature stop codons in exon 1 of the androgen receptor gene: an international collaborative report of 13 new mutations. Fertil Steril 2010; 94:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22616/abstract/49\">",
"      Yong EL, Ng SC, Roy AC, et al. Pregnancy after hormonal correction of severe spermatogenic defect due to mutation in androgen receptor gene. Lancet 1994; 344:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22616/abstract/50\">",
"      Tsukada T, Inoue M, Tachibana S, et al. An androgen receptor mutation causing androgen resistance in undervirilized male syndrome. J Clin Endocrinol Metab 1994; 79:1202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22616/abstract/51\">",
"      Ahmed SF, Cheng A, Dovey L, et al. Phenotypic features, androgen receptor binding, and mutational analysis in 278 clinical cases reported as androgen insensitivity syndrome. J Clin Endocrinol Metab 2000; 85:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22616/abstract/52\">",
"      Ris-Stalpers C, Verleun-Mooijman MC, de Blaeij TJ, et al. Differential splicing of human androgen receptor pre-mRNA in X-linked Reifenstein syndrome, because of a deletion involving a putative branch site. Am J Hum Genet 1994; 54:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22616/abstract/53\">",
"      Br&uuml;ggenwirth HT, Boehmer AL, Ramnarain S, et al. Molecular analysis of the androgen-receptor gene in a family with receptor-positive partial androgen insensitivity: an unusual type of intronic mutation. Am J Hum Genet 1997; 61:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22616/abstract/54\">",
"      Adachi M, Takayanagi R, Tomura A, et al. Androgen-insensitivity syndrome as a possible coactivator disease. N Engl J Med 2000; 343:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22616/abstract/55\">",
"      Holterhus PM, Br&uuml;ggenwirth HT, Hiort O, et al. Mosaicism due to a somatic mutation of the androgen receptor gene determines phenotype in androgen insensitivity syndrome. J Clin Endocrinol Metab 1997; 82:3584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22616/abstract/56\">",
"      K&ouml;hler B, Lumbroso S, Leger J, et al. Androgen insensitivity syndrome: somatic mosaicism of the androgen receptor in seven families and consequences for sex assignment and genetic counseling. J Clin Endocrinol Metab 2005; 90:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22616/abstract/57\">",
"      McPhaul MJ, Marcelli M, Zoppi S, et al. Mutations in the ligand-binding domain of the androgen receptor gene cluster in two regions of the gene. J Clin Invest 1992; 90:2097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22616/abstract/58\">",
"      Boehmer AL, Brinkmann O, Br&uuml;ggenwirth H, et al. Genotype versus phenotype in families with androgen insensitivity syndrome. J Clin Endocrinol Metab 2001; 86:4151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22616/abstract/59\">",
"      McPhaul MJ, Marcelli M, Tilley WD, et al. Molecular basis of androgen resistance in a family with a qualitative abnormality of the androgen receptor and responsive to high-dose androgen therapy. J Clin Invest 1991; 87:1413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22616/abstract/60\">",
"      Gao T, Marcelli M, McPhaul MJ. Transcriptional activation and transient expression of the human androgen receptor. J Steroid Biochem Mol Biol 1996; 59:9.",
"     </a>",
"    </li>",
"    <li>",
"     Pinsky L, Beitel LK, Trifiro MA. Spinobulbar muscular atrophy. In: The Metabolic and Molecular Bases of Inherited Disease, 8th, Scriver CR, Beaudet AL, Sly WS, Valle D (Eds), McGraw-Hill, New York 2001. p.4147.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22616/abstract/62\">",
"      La Spada AR, Wilson EM, Lubahn DB, et al. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 1991; 352:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22616/abstract/63\">",
"      Chamberlain NL, Driver ED, Miesfeld RL. The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res 1994; 22:3181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22616/abstract/64\">",
"      Dejager S, Bry-Gauillard H, Bruckert E, et al. A comprehensive endocrine description of Kennedy's disease revealing androgen insensitivity linked to CAG repeat length. J Clin Endocrinol Metab 2002; 87:3893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22616/abstract/65\">",
"      Orr HT, Zoghbi HY. Trinucleotide repeat disorders. Annu Rev Neurosci 2007; 30:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22616/abstract/66\">",
"      Nedelsky NB, Pennuto M, Smith RB, et al. Native functions of the androgen receptor are essential to pathogenesis in a Drosophila model of spinobulbar muscular atrophy. Neuron 2010; 67:936.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7458 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-33D61AF354-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_5_22616=[""].join("\n");
var outline_f22_5_22616=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H904842\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Complete androgen insensitivity (CAIS)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Partial androgen insensitivity (PAIS)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H346304724\">",
"      - Phenotypic women with mild virilization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H346304813\">",
"      - Reifenstein syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H346304823\">",
"      - Infertile male syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H346304830\">",
"      - Undervirilized fertile male syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ENDOCRINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Genetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Genotype-phenotype correlations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Spinobulbar muscular atrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H904842\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/7458\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7458|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/56/35724\" title=\"figure 1\">",
"      Androgen receptor domains",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7458|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/50/23330\" title=\"picture 1\">",
"      Disorders androgen receptor",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/44/17096?source=related_link\">",
"      Diagnosis and treatment of disorders of the androgen receptor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/25/2457?source=related_link\">",
"      Epidemiology of and risk factors for testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/27/42425?source=related_link\">",
"      Testicular intratubular germ cell neoplasia, unclassified (testicular carcinoma in situ, testicular intraepithelial neoplasia)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_5_22617="Clinical manifestations and diagnosis of peritonitis in peritoneal dialysis";
var content_f22_5_22617=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and diagnosis of peritonitis in peritoneal dialysis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/5/22617/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/5/22617/contributors\">",
"     John M Burkart, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/5/22617/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/5/22617/contributors\">",
"     Thomas A Golper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/5/22617/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/5/22617/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/5/22617/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peritonitis is a common complication of peritoneal dialysis (PD). Peritonitis is associated with significant morbidity, catheter loss, transfer to hemodialysis, transient loss of ultrafiltration, possible permanent membrane damage, and occasionally death [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22617/abstract/1-6\">",
"     1-6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will review the clinical presentation and diagnosis of peritonitis in patients undergoing PD. Most of the discussion relates to the presentation and diagnosis of bacterial peritonitis, although a few specific issues unique to fungal and tuberculosis peritonitis are also addressed. Prevention and treatment are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/40/26248?source=see_link\">",
"     \"Pathophysiology and prevention of peritonitis in peritoneal dialysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/11/17594?source=see_link\">",
"     \"Microbiology and therapy of peritonitis in continuous peritoneal dialysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8631?source=see_link\">",
"     \"Fungal peritonitis in continuous peritoneal dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2065221487\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among PD patients, peritonitis may be PD-related or secondary (enteric). PD-related peritonitis is due to touch contamination with pathogenic skin bacteria or to catheter-related infection. Secondary peritonitis is caused by underlying pathology of the gastrointestinal tract.",
"   </p>",
"   <p>",
"    Conditions that may lead to secondary peritonitis include cholecystitis, appendicitis, ruptured diverticulum, treatment of severe constipation, perforation during endoscopy, bowel ischemia,",
"    <strong>",
"    </strong>",
"    and incarcerated hernia. Secondary peritonitis is less common than PD-related peritonitis. As an example, in one review, intra-abdominal pathology was responsible for fewer than six percent of cases of peritonitis in CAPD patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22617/abstract/7\">",
"     7",
"    </a>",
"    ]. Secondary peritonitis may also be caused by seeding from the blood or vagina but this is less common compared with the intra-abdominal causes listed above.",
"   </p>",
"   <p>",
"    The clinical outcome is much worse in cases of secondary peritonitis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22617/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. In one report, 11 of 26 patients with secondary peritonitis died [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22617/abstract/8\">",
"     8",
"    </a>",
"    ] compared with an overall peritonitis-associated mortality of approximately 2 to 3 percent among all PD patients with peritonitis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22617/abstract/11\">",
"     11",
"    </a>",
"    ]. In the study of secondary peritonitis, mortality correlated with the specific causes of peritonitis (particularly infarcted bowel), the time to diagnosis and definitive surgical intervention. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/31/20986?source=see_link\">",
"     \"Gastrointestinal disease in dialysis patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2065221708\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Usually patients are unaware of an antecedent event that led to peritonitis, although occasionally there is a history of possible contamination",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    breaks in sterile technique. There may be a history of recent or ongoing tunnel or exit site infection. Patients with secondary peritonitis may have a history of constipation, diarrhea",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    change in bowel habits, or have a known history of a hernia. Some patients have a past medical history of prior episodes of peritonitis.",
"   </p>",
"   <p>",
"    The most common symptoms and signs of peritonitis among PD patients are abdominal pain and cloudy peritoneal effluent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22617/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Other symptoms and signs include fever, nausea, diarrhea, abdominal tenderness, rebound tenderness, and occasionally systemic signs, including hypotension.",
"   </p>",
"   <p>",
"    Historical reviews of peritonitis among PD patients reported the following frequency of symptoms and signs [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22617/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Abdominal pain &mdash; 79 to 88 percent",
"     </li>",
"     <li>",
"      Fever (greater than 37.5&ordm;C) &mdash; 29 to 53 percent",
"     </li>",
"     <li>",
"      Nausea or vomiting &mdash; 31 to 51 percent",
"     </li>",
"     <li>",
"      Cloudy effluent &mdash; 84 percent",
"     </li>",
"     <li>",
"      Hypotension &mdash; 18 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical presentation may vary depending upon whether the patient has PD-related or secondary peritonitis but these distinctions are not absolute. In general, patients with secondary peritonitis are more likely to have systemic manifestations of sepsis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22617/abstract/14\">",
"     14",
"    </a>",
"    ]. There may be more precise localization of pain or tenderness among patients with specific underlying pathology resulting in secondary peritonitis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22617/abstract/15\">",
"     15",
"    </a>",
"    ]. As an example, patients with abdominal wall hernias (femoral, inguinal, incisional, and pericatheter), and who develop peritonitis as a result of ischemic bowel or an incarcerated hernia may have a tender hernia site.",
"   </p>",
"   <p>",
"    By comparison, signs and symptoms due directly to inflammation of the abdominal wall and viscera are observed with equal frequency among patients with PD-related and secondary peritonitis.",
"   </p>",
"   <p>",
"    The severity of abdominal pain varies depending upon the culprit organism [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22617/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Streptococcal and fungal peritonitis are associated with particularly severe pain. However, the character of the abdominal pain is not specific and cannot be differentiated from other causes of abdominal pain. Abdominal tenderness is frequently associated with rebound, but rarely guarding.",
"   </p>",
"   <p>",
"    As noted above, patients usually, though not always, describe cloudy peritoneal dialysate fluid. The cause of the cloudy fluid is the presence of peritoneal fluid white cell counts above 100",
"    <span class=\"nowrap\">",
"     cells/mm3.",
"    </span>",
"    Occasionally patients with peritonitis will have white cell counts less than 100",
"    <span class=\"nowrap\">",
"     cells/mm3;",
"    </span>",
"    among such patients, the fluid does not appear cloudy. The onset of pain and the appearance of cloudy fluid may not occur at the same time. In some cases, pain is the presenting symptom and the dialysate fluid is initially clear, becoming cloudy after the next exchange or on the next day [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22617/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    By contrast with patients undergoing chronic ambulatory peritoneal dialysis (CAPD), patients undergoing automated peritoneal dialysis (APD) who develop peritonitis commonly present without a history of cloudy abdominal fluid. This is because the patient may not notice that the dialysate is cloudy since it is drained overnight into the toilet, sink, or bathtub, and not into a bag. Thus, the clinician has to have a high index of suspicion for peritonitis if a patient undergoing APD has abdominal pain, fever,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    other gastrointestinal complaints. To visualize the spent dialysate among such patients, the drained fluid must be diverted into a specimen bag if on the cycler. In some cases, cloudy fluid may also be noted during the initial drain at night or, among patients who use a daytime exchange, during a daytime drain.",
"   </p>",
"   <p>",
"    Certain clinical features may suggest whether peritonitis is PD-related or secondary. As an example, among patients with PD-related peritonitis, the catheter exit site may show purulent drainage and the tunnel sinus may be tender or swollen since catheter-related infection is an important cause of PD-related peritonitis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22617/abstract/17\">",
"     17",
"    </a>",
"    ]. Patients with a bowel perforation causing secondary or enteric peritonitis may have stool in the dialysate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41061?source=see_link\">",
"     \"Abdominal hernias in continuous peritoneal dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The response to treatment may also provide a clue as to whether the patient has PD-related or secondary peritonitis. Among patients with secondary peritonitis, if the underlying intra-abdominal pathology is left untreated, there tends to be little improvement in symptoms with antibiotics alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Laboratory manifestations",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Peritoneal fluid cell count",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major laboratory finding in peritonitis is an increase in the peritoneal fluid white cell count to above 100",
"    <span class=\"nowrap\">",
"     cells/mm3.",
"    </span>",
"    By comparison, uninfected patients typically have fewer than 8 white blood",
"    <span class=\"nowrap\">",
"     cells/mm3",
"    </span>",
"    in the dialysate [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22617/abstract/18\">",
"     18",
"    </a>",
"    ]. The high white cell count is due to the migration of host defense cells as part of the inflammatory response.",
"   </p>",
"   <p>",
"    However, approximately 10 percent of PD patients with bacterial peritonitis have dialysate white cell counts below",
"    <span class=\"nowrap\">",
"     100/mm3.",
"    </span>",
"    A low white cell count with peritonitis may be due to the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A short length of the dwell. As an example, the dwell time is significantly less among patients on APD who present at night, resulting in significant fewer white cells in the effluent. In this setting, the differential cell count is as, if not more, important than the absolute cell count. Among APD patients, the presence of greater than 50 percent polymorphonuclear cells strongly suggests peritonitis, independent of the absolute white cell count [",
"      <a class=\"abstract\" href=\"UTD.htm?22/5/22617/abstract/15,17\">",
"       15,17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A poor host immune response, which results in a delayed or diminished increase in the peritoneal fluid neutrophil count. Most CAPD patients who present with low white cell counts will eventually have counts above",
"      <span class=\"nowrap\">",
"       100/mm3.",
"      </span>",
"      As an example, in one study of 60 patients who presented with abdominal pain, positive PD fluid cultures and PD fluid white cell counts below",
"      <span class=\"nowrap\">",
"       100/mm3,",
"      </span>",
"      67 percent of patients eventually developed a PD fluid cell count above",
"      <span class=\"nowrap\">",
"       100/mm3",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?22/5/22617/abstract/19\">",
"       19",
"      </a>",
"      ]. Twenty seven percent achieved cell counts of 30 to",
"      <span class=\"nowrap\">",
"       100/mm3,",
"      </span>",
"      and only 7 percent of patients never achieved a PD fluid cell count greater than",
"      <span class=\"nowrap\">",
"       30/mm3.",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    During an episode of peritonitis, usually more than 50 percent of the cells in the peritoneal fluid are neutrophils [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22617/abstract/17,20\">",
"     17,20",
"    </a>",
"    ]. A predominance of lymphocytes may be seen with fungal and mycobacterial infections [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22617/abstract/21\">",
"     21",
"    </a>",
"    ], however neutrophils generally predominate even in these infections [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22617/abstract/22-25\">",
"     22-25",
"    </a>",
"    ]. Thus, neither the number of white cells in the dialysate nor the differential is useful in predicting the causative microorganism [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22617/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some patients have a predominance of eosinophils (or eosinophilic peritonitis) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22617/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. In general a patient with a large number of eosinophils is more likely to have a non-bacterial cause of peritonitis (such as drug or allergy-related) compared with patients who present with a high neutrophil count. However, eosinophilic peritonitis is also commonly due to infection.",
"   </p>",
"   <p>",
"    This was shown in one review of 465 cases of peritonitis that occurred in PD patients over a 15 year period and included 42 cases of eosinophilic peritonitis (defined by having over 10 percent eosinophils on presentation) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22617/abstract/30\">",
"     30",
"    </a>",
"    ]. Among the patients with eosinophilic peritonitis, 20 were culture negative and 22 had a bacterial pathogen identified. There was no difference in the spectrum of bacterial pathogens identified between patients with eosinophilic bacterial peritonitis and those with non-eosinophilic bacterial peritonitis. Among patients with eosinophilic nonbacterial peritonitis compared with eosinophilic bacterial peritonitis, there was a slight statistical, but clinically insignificant, increase in the percentage of blood and dialysate eosinophil counts on initial presentation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Peritoneal fluid amylase and lipase levels",
"    </span>",
"    &nbsp;&mdash;&nbsp;The peritoneal fluid amylase and lipase concentrations are occasionally elevated among patients with secondary peritonitis, but not (or only mildly so) among patients with PD-related peritonitis in whom peritoneal fluid amylase levels rarely increase to concentrations greater than 50",
"    <span class=\"nowrap\">",
"     IU/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22617/abstract/31-33\">",
"     31-33",
"    </a>",
"    ]. This characteristic may help to distinguish between PD-related and secondary peritonitis. (See",
"    <a class=\"local\" href=\"#H2240666541\">",
"     'Evaluation after diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Among patients with secondary peritonitis, the elevated amylase concentration may be due to a leak from a bowel perforation or directly from an inflamed pancreas. The amylase concentration is generally not elevated among patients with PD-related peritonitis because amylase is a large molecule and diffuses very slowly in the setting of mild inflammation which is generally the case with PD-related peritonitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2084603937\">",
"    <span class=\"h3\">",
"     Peritoneal fluid cultures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peritoneal fluid culture is positive in approximately 80 to 95 percent of peritonitis cases providing proper culture technique is followed [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22617/abstract/12,15,17\">",
"     12,15,17",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2240666438\">",
"     'Correct technique for obtaining peritoneal fluid for culture'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The organisms that are cultured from peritoneal fluid are generally different in PD-related and secondary peritonitis. In PD-related peritonitis, gram positive organisms, in particular coagulase negative Staphylococcus species, are the most common organisms whereas enteric organisms (such as Bacteroides) or multiple enteric organisms are often observed in secondary peritonitis. The identification of the PD-cultured organism may help to distinguish between PD-related and secondary peritonitis. (See",
"    <a class=\"local\" href=\"#H2240666541\">",
"     'Evaluation after diagnosis'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/11/17594?source=see_link&amp;anchor=H2#H2\">",
"     \"Microbiology and therapy of peritonitis in continuous peritoneal dialysis\", section on 'Microbiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2084604360\">",
"    <span class=\"h3\">",
"     Peripheral white cell count",
"    </span>",
"    &nbsp;&mdash;&nbsp;A peripheral leukocytosis of 10,000 to",
"    <span class=\"nowrap\">",
"     15,000/mm3",
"    </span>",
"    is often seen in infected patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2065221804\">",
"    <span class=\"h3\">",
"     Blood cultures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blood cultures are generally negative among patients with both PD-related and secondary peritonitis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22617/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2065221781\">",
"    <span class=\"h2\">",
"     Radiographic findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiographic manifestations of peritonitis are nonspecific and such studies are not routinely performed among patients with suspected PD-related peritonitis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22617/abstract/15\">",
"     15",
"    </a>",
"    ]. However, imaging studies may show specific abnormalities among patients with secondary peritonitis and are often obtained when secondary peritonitis is suspected. (See",
"    <a class=\"local\" href=\"#H2240666541\">",
"     'Evaluation after diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H615481923\">",
"    <span class=\"h2\">",
"     Establishing the diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of peritonitis should be suspected in a PD patient with a characteristic clinical presentation. (See",
"    <a class=\"local\" href=\"#H2065221708\">",
"     'Clinical manifestations'",
"    </a>",
"    above.) A presumptive diagnosis is made if the peritoneal fluid white count is greater than 100",
"    <span class=\"nowrap\">",
"     cells/mm3",
"    </span>",
"    and the percentage of neutrophils is greater than 50 percent.",
"   </p>",
"   <p>",
"    However, as described above, peritoneal leukocytosis is not seen at presentation in all patients, in particular, patients on automated peritoneal dialysis (APD). Among such patients, a presumptive diagnosis may be made in the presence of greater than 50 percent polymorphonuclear cells, independent of the absolute white cell count [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22617/abstract/15,17\">",
"     15,17",
"    </a>",
"    ]. This is in part because the total white cell count is often low in APD patients because of the rapid exchanges and short dwell times as described above. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Peritoneal fluid cell count'",
"    </a>",
"    above.) In addition, although a few white blood cells are commonly observed in the effluent of a short dwell, these cells are usually macrophages. Polymorphonuclear cells are rarely found in the peritoneal fluid in the absence of infection, thus a high percentage of these cells strongly suggests infection [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22617/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    To enhance the recovery of peritoneal cells in APD patients who do not use a daytime exchange, we generally infuse one liter of dialysate and allow it to dwell for a minimum of one to two hours; the dialysate is then drained and examined for turbidity and sent for cell count, cell differential, and culture [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22617/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among patients who are not on APD, (ie CAPD patients), a presumptive diagnosis of peritonitis may also be made if there is a consistent clinical history and physical, even if the peritoneal white cell count is low, providing other causes of abdominal pathology have been excluded. This is because a small percentage of CAPD patients with infectious peritonitis do not have cloudy effluent and it is important to make an early presumptive diagnosis of peritonitis and initiate antibiotics in order to prevent serious sequelae.",
"   </p>",
"   <p>",
"    In this setting, however, clinical judgment is essential. Some clinicians would observe such a patient in clinic for a few hours and repeat the cell count and differential. In many such cases, the dialysate becomes cloudy on subsequent exchanges. During this observation period, the patient should be closely monitored and antibiotics initiated if signs, symptoms and a repeat cell count are consistent with peritonitis. If this observation period cannot be conducted, the patient should be presumed to have peritonitis and empiric antibiotics initiated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/11/17594?source=see_link&amp;anchor=H11#H11\">",
"     \"Microbiology and therapy of peritonitis in continuous peritoneal dialysis\", section on 'Empiric initial therapy for peritonitis'",
"    </a>",
"    .)",
"    <br/>",
"   </p>",
"   <p>",
"    Among all patients, the diagnosis of peritonitis is confirmed by a positive dialysate culture. The culture is positive in approximately 80 to 95 percent of cases if proper culture technique is followed [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22617/abstract/12,15,17\">",
"     12,15,17",
"    </a>",
"    ]. Issues surrounding culture techniques and negative culture results in patients with infectious peritonitis are discussed below. (See",
"    <a class=\"local\" href=\"#H2240666438\">",
"     'Correct technique for obtaining peritoneal fluid for culture'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    However, if the dialysate effluent culture is negative, but clinical signs and symptoms are otherwise consistent, the presumptive diagnosis of peritonitis may still be made. If the patient truly has an infectious cause of peritonitis, the culture may be negative for one or more of the following reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The culture is obtained early in the course, before colony counts are high enough for isolation.",
"     </li>",
"     <li>",
"      Microbiologic culture technique is incorrect, usually consisting of the collection of too little effluent [",
"      <a class=\"abstract\" href=\"UTD.htm?22/5/22617/abstract/35\">",
"       35",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H2240666438\">",
"       'Correct technique for obtaining peritoneal fluid for culture'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Antibiotics are present, having been given for other reasons and not appreciated at the time of culturing [",
"      <a class=\"abstract\" href=\"UTD.htm?22/5/22617/abstract/35,36\">",
"       35,36",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2240666438\">",
"    <span class=\"h2\">",
"     Correct technique for obtaining peritoneal fluid for culture",
"    </span>",
"    &nbsp;&mdash;&nbsp;An optimal technique for obtaining peritoneal fluid for culture is the combination of sediment culturing of 50 mL effluent and bedside inoculation of 5 to 10 mL of effluent dialysate in each of two blood culture bottles [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22617/abstract/15\">",
"     15",
"    </a>",
"    ]. To perform sediment culturing, 50 ml of dialysate fluid is centrifuged at 3000 G for fifteen minutes and the supernatant decanted off. The sediment is resuspended in 3 to 5 mL of sterile saline and the suspension is inoculated on solid culture medium and into standard blood culture bottles, which should be expeditiously transported to the microbiology laboratory. This method has been shown to be that most likely to identify the causative organism [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22617/abstract/37-39\">",
"     37-39",
"    </a>",
"    ]. The solid media may be incubated in aerobic, microaerobic and anaerobic environments. This technique generally results in a culture negative rate of 20 percent or less.",
"    <br/>",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of peritonitis in PD patients includes all the causes of abdominal pain without peritonitis in the general population and all the causes of non-infectious cloudy peritoneal fluid, in the absence of, or with variable amounts of abdominal pain.",
"   </p>",
"   <p>",
"    Among patients with abdominal pain without peritonitis, the patient may have physical examination findings localized to the abdomen, but the peritoneal fluid is unremarkable. In these instances, one must evaluate for other causes of gastrointestinal pathology such as constipation, irritable bowel, ischemic bowel, or a myriad of other causes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/30/16874?source=see_link\">",
"     \"Differential diagnosis of abdominal pain in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among patients who present with cloudy peritoneal effluent (with varying degrees of abdominal pain), the differential diagnosis is also broad since multiple conditions may result in cloudy effluent. Conditions that cause cloudy effluent may be classified according to the noncellular or cellular substance. The differential diagnosis can thus be considerably narrowed based upon analysis of the effluent. The following conditions should be considered among patients who have cloudy effluent but few cells [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22617/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Excessive fibrin production &mdash; May occur at initiation of PD and at times after peritonitis.",
"     </li>",
"     <li>",
"      Effluent was obtained after a prolonged period of peritoneal rest (ie, no PD).",
"     </li>",
"     <li>",
"      Triglyceride or lipid leakage (chylous ascites) &mdash; Related to lymphatic obstruction due to malignancy (especially lymphoma), acute pancreatis, superior vena cava syndrome, and use of dihydropyridine calcium channel blockers [",
"      <a class=\"abstract\" href=\"UTD.htm?22/5/22617/abstract/42-45\">",
"       42-45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Severe constipation and a prolonged dwell time [",
"      <a class=\"abstract\" href=\"UTD.htm?22/5/22617/abstract/40-42\">",
"       40-42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A low number of white cells in the effluent may also be due to tunnel infection, rather than peritonitis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/60/3018?source=see_link\">",
"       \"Tunnel and peritoneal catheter exit site infections in continuous peritoneal dialysis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Excessive fibrin may be recognized by the appearance of filaments that eventually form a clot in the dialysis bag [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22617/abstract/40\">",
"     40",
"    </a>",
"    ]. The presence of lipids can frequently be verified with inspection by an experienced clinician. The fluid can also be sent for triglyceride",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    lipid analysis.",
"   </p>",
"   <p>",
"    A cloudy effluent may also be caused by the presence of a large number of cells of virtually any type in the absence or presence of infection. Cellular causes of cloudy effluent are classified based upon the type of cell which is generally quickly identified by the cytology or hematology laboratory:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Atypical cells &mdash; lymphoma or other malignancy.",
"     </li>",
"     <li>",
"      Neutrophils &mdash; Bacterial infection, exposure to certain drugs (amphotericin,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      ), well-differentiated renal cell carcinoma (perhaps from perinephric inflammation) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/5/22617/abstract/41,46,47\">",
"       41,46,47",
"      </a>",
"      ], pancreatitis and other retroperitoneal disease, leukemia, intra-abdominal disease, lymphoma [",
"      <a class=\"abstract\" href=\"UTD.htm?22/5/22617/abstract/41\">",
"       41",
"      </a>",
"      ] and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/36/44612?source=see_link\">",
"       icodextrin",
"      </a>",
"      dialysate [",
"      <a class=\"abstract\" href=\"UTD.htm?22/5/22617/abstract/48-51\">",
"       48-51",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Eosinophils &mdash; Bacterial infection, fungal and viral infections, allergic reactions, drug effects (such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      ), early after catheter placement as a result of CO2 insufflation during laparoscopy, following peritonitis [",
"      <a class=\"abstract\" href=\"UTD.htm?22/5/22617/abstract/27,28\">",
"       27,28",
"      </a>",
"      ], and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/36/44612?source=see_link\">",
"       icodextrin",
"      </a>",
"      dialysate [",
"      <a class=\"abstract\" href=\"UTD.htm?22/5/22617/abstract/30,48-51\">",
"       30,48-51",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Monocytes &mdash; Bacterial infection, mycobacterial infection, eosinophilia and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/36/44612?source=see_link\">",
"       icodextrin",
"      </a>",
"      dialysate.",
"     </li>",
"     <li>",
"      Erythrocytes &mdash; The most common causes of bloody dialysate are trauma during placement of the dialysis catheter and gynecologic disorders, ovulation, or menses. Bloody dialysate can occasionally occur with routine infectious peritonitis, though is usually associated with pathologic conditions. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24245?source=see_link\">",
"       \"Bloody peritoneal dialysate (hemoperitoneum)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Among patients with cloudy effluent, the predominant cell type is generally quickly identified by cellular analysis of the fluid. Atypical cells of malignancy are excluded by the cytology laboratory. Once malignancy is excluded, the presumptive diagnosis is bacterial peritonitis until cultures return. The diagnosis of bacterial or fungal culture is confirmed by a positive culture result. Patients with a high peritoneal white blood cell count and negative culture are considered to have sterile peritonitis.",
"   </p>",
"   <p>",
"    Sterile peritonitis is a term used to describe to condition characterized by symptoms of peritonitis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    an increased peritoneal effluent cell count in the absence of a positive culture. Thus the term is not used upon presentation but only after the effluent cell count and differential have been determined and correctly obtained cultures are negative. Since up to 20 percent of patients who have bacterial peritonitis have negative cultures [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22617/abstract/12,15,17\">",
"     12,15,17",
"    </a>",
"    ], sterile peritonitis includes culture negative infectious (ie, bacterial, fungal or tuberculous) peritonitis as well as drug-toxicity, allergic reactions, or reaction to intraperitoneal or retroperitoneal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22617/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/36/44612?source=see_link\">",
"     Icodextrin",
"    </a>",
"    dialysate has been associated with sterile peritonitis that occurs either immediately or after several months of exposure and is associated with a predominance of neutrophils and less commonly eosinophils or monocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22617/abstract/48-51\">",
"     48-51",
"    </a>",
"    ]. In most reports, patients presented with mild abdominal pain, no systemic symptoms, cloudy effluent, and sterile cultures [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22617/abstract/51\">",
"     51",
"    </a>",
"    ]. Aseptic peritonitis in this setting was subsequently recognized to be due to peptidoglycan contamination [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22617/abstract/52\">",
"     52",
"    </a>",
"    ]. After suspected batches were recalled and corrective actions were undertaken, the frequency of peritonitis resulting from the clinical use of this agent markedly decreased. However cases of icodextrin-related sterile peritonitis continue to be reported, even with batches with a \"safe\" level of peptidoglycan [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22617/abstract/53\">",
"     53",
"    </a>",
"    ]. The underlying mechanism in this setting is unclear. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/12/18632?source=see_link\">",
"     \"Peritoneal dialysis solutions\"",
"    </a>",
"    .)",
"    <br/>",
"   </p>",
"   <p>",
"    It can be difficult to distinguish between culture negative bacterial peritonitis and non-bacterial sterile peritonitis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22617/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. Our approach is to manage such patients as if they have bacterial peritonitis and use the response to antibiotics as the defining feature. Patients with culture negative bacterial peritonitis show clinical improvement and a decrease in the peritoneal fluid cell count within two to three days after initiation of antibiotics. By comparison, patients with non-bacterial sterile peritonitis show little decrease in the peritoneal fluid cell count after starting antibiotics; the elevated white cell count tends to slowly resolve either spontaneously or, among patients with drug- or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/36/44612?source=see_link\">",
"     icodextrin",
"    </a>",
"    -related allergic sterile peritonitis, when the offending agent is stopped. In general, by contrast with patients with bacterial peritonitis, patients with nonbacterial peritonitis do not look especially ill.",
"   </p>",
"   <p>",
"    At our center, we treat patients with sterile peritonitis with two weeks of broad spectrum antibiotics. We check peritoneal white blood counts every two to three days. Among patients who have a persistently elevated peritoneal white cell count, we repeat cultures (bacterial, mycobacterium, and fungal) every week for one month or more. If the culture remains negative and the patient looks well, we stop antibiotics after two weeks while continuing to obtain weekly cultures off antibiotics. It is important to stop all agents (such as amphotericin and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    ) that may be causing the high peritoneal white blood cells count. If the patient improves clinically and the remainder of the evaluation is negative, one could stop obtaining PD fluid analysis at one month; however, some clinicians repeat cultures until a diagnosis is obtained or the elevated count resolves.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2240666541\">",
"    <span class=\"h1\">",
"     EVALUATION AFTER DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once a presumptive diagnosis of peritonitis has been made based upon the clinical manifestations and peritoneal fluid absolute",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    differential white cell count, other tests are performed in order to identify culprit organisms as early as possible (especially fungus) and to determine if possible, whether peritonitis is PD-related or secondary. If secondary peritonitis is suspected, it is important to quickly identify the underlying cause. These tests are often done at the time of the initial evaluation even before the peritonitis diagnosis has been established. The following tests are generally done at the time of the initial evaluation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Peritoneal fluid amylase and lipase levels. As described previously, increased serum amylase and lipase concentrations suggest secondary rather than PD-related peritonitis. Among PD patients who have peritonitis, peritoneal fluid amylase levels above 50",
"      <span class=\"nowrap\">",
"       IU/L",
"      </span>",
"      suggest the presence of underlying intra-abdominal disease. Peritoneal fluid lipase levels above 15",
"      <span class=\"nowrap\">",
"       IU/L",
"      </span>",
"      suggest pancreatitis or perforation near the duodenum as the cause of peritonitis [",
"      <a class=\"abstract\" href=\"UTD.htm?22/5/22617/abstract/56\">",
"       56",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      One should note, however, that most of the studies that examined amylase concentrations among PD patients with peritonitis were performed prior to the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/36/44612?source=see_link\">",
"       icodextrin",
"      </a>",
"      -containing PD fluids. Icodextrin is known to interfere with amylase determinations, giving a falsely low level. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/12/18632?source=see_link\">",
"       \"Peritoneal dialysis solutions\"",
"      </a>",
"      .). There are no data that have examined the utility of peritoneal fluid amylase levels in the diagnosis of secondary peritonitis among patients using icodextrin solutions. Nevertheless, elevated amylase",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      lipase concentration among patients using icodextrin would likely represent the presence of intraabdominal pathology. Furthermore, among patients on icodextrin, a low level is less likely to exclude intraabdominal pathology. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/12/18632?source=see_link\">",
"       \"Peritoneal dialysis solutions\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Gram stain of the peritoneal fluid should be performed. Although it is usually negative, the identification of any organisms is a helpful guide to therapy, since the gram stain is predictive of the culture results [",
"      <a class=\"abstract\" href=\"UTD.htm?22/5/22617/abstract/26\">",
"       26",
"      </a>",
"      ]. Gram stain may be particularly useful in the early diagnosis of fungal peritonitis.",
"     </li>",
"     <li>",
"      Culture of purulent drainage from the exit site should be performed since isolation of the same organism as from peritoneal fluid suggests that the exit site infection may be the cause of peritonitis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/60/3018?source=see_link\">",
"       \"Tunnel and peritoneal catheter exit site infections in continuous peritoneal dialysis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Blood cultures should be obtained if there are systemic symptoms, although they are seldom positive [",
"      <a class=\"abstract\" href=\"UTD.htm?22/5/22617/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Further evaluation is necessary among patients suspected of having secondary peritonitis. Such patients should undergo an acute abdominal series and a computed tomographic scan of the abdomen. If feculent material is noted in the drained dialysate, surgical consultation should be obtained immediately. Surgical consultation should also be obtained if the peritoneal amylase concentration is markedly elevated or multiple organisms are identified by culture or gram stain. Emergency laparotomy may be indicated if a surgically-treatable source of infection is documented [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22617/abstract/57\">",
"     57",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/0/12296?source=see_link&amp;anchor=H17#H17\">",
"     \"Diagnosis of spontaneous bacterial peritonitis\", section on 'Imaging studies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We perform additional tests among patients who develop systemic symptoms, have fungal peritonitis, fail to respond to initial therapy by day three, or relapse after therapy is completed.",
"    <br/>",
"    <br/>",
"    We most commonly start with an acute abdominal series and a CT of the abdomen. If an acute abdominal series is ordered, one should remember that small amounts of free intraperitoneal air can occasionally be seen in asymptomatic patients on peritoneal dialysis; it is probably due to leakage of air through the insertion site or air that is infused during fill and is not pathognomonic of a perforated viscus (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef66170 \" href=\"UTD.htm?14/6/14446\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22617/abstract/58\">",
"     58",
"    </a>",
"    ]. However, free air should lead to consideration of perforation in the presence of peritonitis and systemic symptoms.",
"    <br/>",
"    <br/>",
"    CT scan, magnetic resonance imaging (MRI) or radionuclide scanning may be used to see if the patient has pathology such as an abscess, peritoneal fluid leak, incarcerated hernia, ascending cholangitis, pancreatitis, appendicitis, diverticulitis, perforated bowel, and others, all of which can masquerade as PD related peritonitis. However, among patients with moderate to severe kidney disease (dialysis-dependent or estimated GFR less than 30",
"    <span class=\"nowrap\">",
"     mL/min),",
"    </span>",
"    the administration of gadolinium has been associated with the potentially severe syndrome of nephrogenic systemic fibrosis. In such patients, gadolinium should be avoided if possible. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/22/31082?source=see_link\">",
"     \"Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some data suggest that abdominal CT scanning may not be accurate in identifying collections of fluid in PD patients with peritonitis. In a retrospective study of 133 patients with peritonitis, 19 patients underwent 26 contrast CT scans due to severe abdominal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22617/abstract/59\">",
"     59",
"    </a>",
"    ]. Of the 12 laparotomies that were performed, six operations uncovered a drainable collection that had not been observed with the CT scan. Thus, a negative CT scan in this setting does NOT exclude the possibility of a pathologic process that requires a surgical procedure.",
"    <br/>",
"    <br/>",
"    In elderly patients in whom we suspect ischemic bowel, we obtain Doppler studies of mesenteric vessels",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    other vascular directed imaging studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Peritonitis is a common complication of peritoneal dialysis (PD). Peritonitis may be PD-related or secondary (enteric). PD-related peritonitis is due to touch contamination with pathogenic skin bacteria or to catheter-related infection. Secondary peritonitis is caused by underlying pathology of the gastrointestinal tract. Secondary peritonitis is less common and is associated with a worse outcome compared with PD-related peritonitis. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2065221487\">",
"       'Definitions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most common symptoms and signs of peritonitis among PD patients are abdominal pain and cloudy peritoneal effluent. Other symptoms and signs include fever, nausea, diarrhea, abdominal tenderness, rebound tenderness, and occasionally systemic signs, including hypotension. Patients with secondary peritonitis are more likely to have systemic manifestations of sepsis. (See",
"      <a class=\"local\" href=\"#H2065221708\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients on chronic ambulatory peritoneal dialysis (CAPD) usually describe cloudy peritoneal dialysate fluid, which is caused by peritoneal fluid white cell counts above 100",
"      <span class=\"nowrap\">",
"       cells/mm3.",
"      </span>",
"      Patients who are undergoing automated peritoneal dialysis (APD) may not develop cloudy fluid with peritonitis. Thus, the clinician has to have a high index of suspicion for peritonitis among APD patients who present with abdominal pain, fever,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      other gastrointestinal complaints. (See",
"      <a class=\"local\" href=\"#H2065221708\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The major laboratory finding in peritonitis is an increased peritoneal fluid white cell count above 100",
"      <span class=\"nowrap\">",
"       cells/mm3,",
"      </span>",
"      usually with greater than 50 percent neutrophils. However, approximately 10 percent of PD patients have dialysate white cell counts below",
"      <span class=\"nowrap\">",
"       100/mm3",
"      </span>",
"      due to either a short dwell time or a poor host response. Peritoneal fluid culture is positive in approximately 80 to 95 percent of peritonitis cases providing proper culture technique is followed. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Laboratory manifestations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A presumptive diagnosis of peritonitis is made if the peritoneal fluid white count is greater than 100",
"      <span class=\"nowrap\">",
"       cells/mm3",
"      </span>",
"      and the percentage of neutrophils is greater than 50 percent. Among APD patients, a presumptive diagnosis is made if greater than 50 percent polymorphonuclear cells are present, independent of the absolute white cell count. Among all PD patients, a presumptive diagnosis may be made if there is a consistent clinical history and physical exam, even if the patient has a relatively low peritoneal white cell count, providing other causes of abdominal pathology have been excluded. The diagnosis of peritonitis is confirmed by a positive dialysate culture. If the dialysate effluent culture is negative, but clinical signs and symptoms are otherwise consistent, the presumptive diagnosis of peritonitis may still be made. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis includes all the causes of abdominal pain in the general population and all the causes of non-infectious cloudy peritoneal fluid. Conditions that cause cloudy effluent may be classified according to the noncellular or cellular substance. The differential diagnosis can thus be considerably narrowed based upon analysis of the effluent. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Differential diagnosis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/30/16874?source=see_link\">",
"       \"Differential diagnosis of abdominal pain in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Once a presumptive diagnosis of peritonitis has been, other tests may be performed to identify culprit organisms as early as possible and to determine whether peritonitis is PD-related or secondary. Among all patients, we measure peritoneal fluid amylase and lipase levels, perform a gram stain of the peritoneal fluid and culture any purulent drainage from the peritoneal catheter exit site. We obtain blood cultures among patients with systemic symptoms. (See",
"      <a class=\"local\" href=\"#H2240666541\">",
"       'Evaluation after diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among patients suspected of having secondary peritonitis, we obtain radiographic studies including an acute abdominal series and a computed tomographic scan of the abdomen. Surgical consultation should be obtained immediately if feculent material is noted in the drained dialysate. Surgical consultation should also be obtained if the peritoneal amylase concentration is markedly elevated or multiple organisms are identified by culture or gram stain. (See",
"      <a class=\"local\" href=\"#H2240666541\">",
"       'Evaluation after diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We generally obtain an acute abdominal series and a CT of the abdomen among patients who develop systemic symptoms, have fungal peritonitis, fail to respond to initial therapy by day three, or relapse after therapy is completed. (See",
"      <a class=\"local\" href=\"#H2240666541\">",
"       'Evaluation after diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22617/abstract/1\">",
"      Holley, HL, Piraino, BM. Complications of peritoneal dialysis: Diagnosis and management. Semin Dial 1990; 3:245.",
"     </a>",
"    </li>",
"    <li>",
"     Schreiber, M, Burkart, JM, et al. Peritonitis remains the leading cause of transfer from PD to HD (abstract). Perit Dial Int 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22617/abstract/3\">",
"      Woodrow G, Turney JH, Brownjohn AM. Technique failure in peritoneal dialysis and its impact on patient survival. Perit Dial Int 1997; 17:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22617/abstract/4\">",
"      P&eacute;rez Fontan M, Rodr&iacute;guez-Carmona A, Garc&iacute;a-Naveiro R, et al. Peritonitis-related mortality in patients undergoing chronic peritoneal dialysis. Perit Dial Int 2005; 25:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22617/abstract/5\">",
"      Sipahioglu MH, Aybal A, Unal A, et al. Patient and technique survival and factors affecting mortality on peritoneal dialysis in Turkey: 12 years' experience in a single center. Perit Dial Int 2008; 28:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22617/abstract/6\">",
"      Bunke CM, Brier ME, Golper TA. Outcomes of single organism peritonitis in peritoneal dialysis: gram negatives versus gram positives in the Network 9 Peritonitis Study. Kidney Int 1997; 52:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22617/abstract/7\">",
"      Tzamaloukas AH, Obermiller LE, Gibel LJ, et al. Peritonitis associated with intra-abdominal pathology in continuous ambulatory peritoneal dialysis patients. Perit Dial Int 1993; 13 Suppl 2:S335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22617/abstract/8\">",
"      Tzamaloukas AH, Murata GH, Fox L. Peritoneal catheter loss and death in continuous ambulatory peritoneal dialysis peritonitis: correlation with clinical and biochemical parameters. Perit Dial Int 1993; 13 Suppl 2:S338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22617/abstract/9\">",
"      Harwell CM, Newman LN, Cacho CP, et al. Abdominal catastrophe: visceral injury as a cause of peritonitis in patients treated by peritoneal dialysis. Perit Dial Int 1997; 17:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22617/abstract/10\">",
"      Kern EO, Newman LN, Cacho CP, et al. Abdominal catastrophe revisited: the risk and outcome of enteric peritoneal contamination. Perit Dial Int 2002; 22:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22617/abstract/11\">",
"      Ghali JR, Bannister KM, Brown FG, et al. Microbiology and outcomes of peritonitis in Australian peritoneal dialysis patients. Perit Dial Int 2011; 31:651.",
"     </a>",
"    </li>",
"    <li>",
"     Vas, SI. Peritonitis. In: Peritoneal Dialysis, 3rd ed, Nolph, KD (Eds), Kluwer Academic Publishers, Dordrecht 1989. p.261.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22617/abstract/13\">",
"      Oliveira LG, Luengo J, Caramori JC, et al. Peritonitis in recent years: clinical findings and predictors of treatment response of 170 episodes at a single Brazilian center. Int Urol Nephrol 2012; 44:1529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22617/abstract/14\">",
"      Shrestha BM, Brown P, Wilkie M. Surgical peritonitis in patients on peritoneal dialysis. Perit Dial Int 2008; 28:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22617/abstract/15\">",
"      Li PK, Szeto CC, Piraino B, et al. Peritoneal dialysis-related infections recommendations: 2010 update. Perit Dial Int 2010; 30:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22617/abstract/16\">",
"      Voinescu CG, Khanna R. Peritonitis in peritoneal dialysis. Int J Artif Organs 2002; 25:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22617/abstract/17\">",
"      Piraino B, Bailie GR, Bernardini J, et al. Peritoneal dialysis-related infections recommendations: 2005 update. Perit Dial Int 2005; 25:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22617/abstract/18\">",
"      Tranaeus A, Heimb&uuml;rger O, Lindholm B. Peritonitis in continuous ambulatory peritoneal dialysis (CAPD): diagnostic findings, therapeutic outcome and complications. Perit Dial Int 1989; 9:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22617/abstract/19\">",
"      Koopmans JG, Boeschoten EW, Pannekeet MM, et al. Impaired initial cell reaction in CAPD-related peritonitis. Perit Dial Int 1996; 16 Suppl 1:S362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22617/abstract/20\">",
"      Flanigan MJ, Freeman RM, Lim VS. Cellular response to peritonitis among peritoneal dialysis patients. Am J Kidney Dis 1985; 6:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22617/abstract/21\">",
"      Twardowski ZJ, Schreiber MJ Jr, Burkart JM. A 55-year-old man with hematuria and blood-tinged dialysate. Perit Dial Int 1992; 12:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22617/abstract/22\">",
"      Eisenberg ES, Leviton I, Soeiro R. Fungal peritonitis in patients receiving peritoneal dialysis: experience with 11 patients and review of the literature. Rev Infect Dis 1986; 8:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22617/abstract/23\">",
"      Cheng IK, Fang GX, Chan TM, et al. Fungal peritonitis complicating peritoneal dialysis: report of 27 cases and review of treatment. Q J Med 1989; 71:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22617/abstract/24\">",
"      Holley HP Jr, Tucker CT, Moffatt TL, et al. Tuberculous peritonitis in patients undergoing chronic home peritoneal dialysis. Am J Kidney Dis 1982; 1:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22617/abstract/25\">",
"      Dunmire, RB, Breyer, JA. Nontuberculous mycobacterial peritonitis during CAPD: Case report and review of diagnostic and therapeutic strategies. Am J Kidney Dis 1991; 18:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22617/abstract/26\">",
"      Keane WF, Bailie GR, Boeschoten E, et al. Adult peritoneal dialysis-related peritonitis treatment recommendations: 2000 update. Perit Dial Int 2000; 20:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22617/abstract/27\">",
"      Johnson CA. Intraperitoneal vancomycin administration. Perit Dial Int 1991; 11:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22617/abstract/28\">",
"      Charney DI, Gouge SF. Chemical peritonitis secondary to intraperitoneal vancomycin. Am J Kidney Dis 1991; 17:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22617/abstract/29\">",
"      Ejaz AA, Fitzpatrick PM, Durkin AJ, et al. Pathophysiology of peritoneal fluid eosinophilia in peritoneal dialysis patients. Nephron 1999; 81:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22617/abstract/30\">",
"      Font&aacute;n MP, Rodr&iacute;guez-Carmona A, Galed I, et al. Incidence and significance of peritoneal eosinophilia during peritoneal dialysis-related peritonitis. Perit Dial Int 2003; 23:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22617/abstract/31\">",
"      Caruana RJ, Burkart J, Segraves D, et al. Serum and peritoneal fluid amylase levels in CAPD. Normal values and clinical usefulness. Am J Nephrol 1987; 7:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22617/abstract/32\">",
"      Burkart JM, Khanna R. A 69-year-old male with elevated amylase in bloody and cloudy dialysate. Perit Dial Int 1993; 13:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22617/abstract/33\">",
"      Teitelbaum I, Burkart J. Peritoneal dialysis. Am J Kidney Dis 2003; 42:1082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22617/abstract/34\">",
"      Morduchowicz G, van Dyk DJ, Wittenberg C, et al. Bacteremia complicating peritonitis in peritoneal dialysis patients. Am J Nephrol 1993; 13:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22617/abstract/35\">",
"      Szeto CC, Wong TY, Chow KM, et al. The clinical course of culture-negative peritonitis complicating peritoneal dialysis. Am J Kidney Dis 2003; 42:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22617/abstract/36\">",
"      Eisele G, Adewunni C, Bailie GR, et al. Surreptitious use of antimicrobial agents by CAPD patients. Perit Dial Int 1993; 13:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22617/abstract/37\">",
"      Sewell DL, Golper TA, Hulman PB, et al. Comparison of large volume culture to other methods for isolation of microorganisms from dialysate. Perit Dial Int 1990; 10:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22617/abstract/38\">",
"      Lye WC, Wong PL, Leong SO, Lee EJ. Isolation of organisms in CAPD peritonitis: a comparison of two techniques. Adv Perit Dial 1994; 10:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22617/abstract/39\">",
"      Alfa MJ, Degagne P, Olson N, Harding GK. Improved detection of bacterial growth in continuous ambulatory peritoneal dialysis effluent by use of BacT/Alert FAN bottles. J Clin Microbiol 1997; 35:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22617/abstract/40\">",
"      Rocklin MA, Teitelbaum I. Noninfectious causes of cloudy peritoneal dialysate. Semin Dial 2001; 14:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22617/abstract/41\">",
"      de Freitas DG, Gokal R. Sterile peritonitis in the peritoneal dialysis patient. Perit Dial Int 2005; 25:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22617/abstract/42\">",
"      Yoshimoto K, Saima S, Nakamura Y, et al. Dihydropyridine type calcium channel blocker-induced turbid dialysate in patients undergoing peritoneal dialysis. Clin Nephrol 1998; 50:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22617/abstract/43\">",
"      Bargman JM, Zent R, Ellis P, et al. Diagnosis of lymphoma in a continuous ambulatory peritoneal dialysis patient by peritoneal fluid cytology. Am J Kidney Dis 1994; 23:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22617/abstract/44\">",
"      P&eacute;rez Font&aacute;n M, Pombo F, Soto A, et al. Chylous ascites associated with acute pancreatitis in a patient undergoing continuous ambulatory peritoneal dialysis. Nephron 1993; 63:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22617/abstract/45\">",
"      Rocklin MA, Quinn MJ, Teitelbaum I. Cloudy dialysate as a presenting feature of superior vena cava syndrome. Nephrol Dial Transplant 2000; 15:1455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22617/abstract/46\">",
"      Streather CP, Carr P, Barton IK. Carcinoma of the kidney presenting as sterile peritonitis in a patient on continuous ambulatory peritoneal dialysis. Nephron 1991; 58:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22617/abstract/47\">",
"      Vlahakos D, Rudders R, Simon G, Canzanello VJ. Lymphoma-mimicking peritonitis in a patient on continuous ambulatory peritoneal dialysis (CAPD). Perit Dial Int 1990; 10:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22617/abstract/48\">",
"      MacGinley R, Cooney K, Alexander G, et al. Relapsing culture-negative peritonitis in peritoneal dialysis patients exposed to icodextrin solution. Am J Kidney Dis 2002; 40:1030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22617/abstract/49\">",
"      Tintillier M, Pochet JM, Christophe JL, et al. Transient sterile chemical peritonitis with icodextrin: clinical presentation, prevalence, and literature review. Perit Dial Int 2002; 22:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22617/abstract/50\">",
"      Boer WH, Vos PF, Fieren MW. Culture-negative peritonitis associated with the use of icodextrin-containing dialysate in twelve patients treated with peritoneal dialysis. Perit Dial Int 2003; 23:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22617/abstract/51\">",
"      Glorieux G, Lameire N, Van Biesen W, et al. Specific characteristics of peritoneal leucocyte populations during sterile peritonitis associated with icodextrin CAPD fluids. Nephrol Dial Transplant 2003; 18:1648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22617/abstract/52\">",
"      Martis L, Patel M, Giertych J, et al. Aseptic peritonitis due to peptidoglycan contamination of pharmacopoeia standard dialysis solution. Lancet 2005; 365:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22617/abstract/53\">",
"      Rozenberg R, Magen E, Weissgarten J, Korzets Z. Icodextrin-induced sterile peritonitis: the Israeli experience. Perit Dial Int 2006; 26:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22617/abstract/54\">",
"      Bunke M, Brier ME, Golper TA. Culture-negative CAPD peritonitis: the Network 9 Study. Adv Perit Dial 1994; 10:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22617/abstract/55\">",
"      Choi P, Nemati E, Banerjee A, et al. Peritoneal dialysis catheter removal for acute peritonitis: a retrospective analysis of factors associated with catheter removal and prolonged postoperative hospitalization. Am J Kidney Dis 2004; 43:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22617/abstract/56\">",
"      Royse VL, Jensen DM, Corwin HL. Pancreatic enzymes in chronic renal failure. Arch Intern Med 1987; 147:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22617/abstract/57\">",
"      Akriviadis EA, Runyon BA. Utility of an algorithm in differentiating spontaneous from secondary bacterial peritonitis. Gastroenterology 1990; 98:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22617/abstract/58\">",
"      Suresh KR, Port FK. Air under the diaphragm in patients undergoing continuous ambulatory peritoneal dialysis (CAPD). Perit Dial Int 1989; 9:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22617/abstract/59\">",
"      Yehia M, de Zoysa JR, Collins JF. Is computerized tomography useful in identifying abdominal catastrophes in patients presenting with peritonitis? Perit Dial Int 2008; 28:385.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1869 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-218.189.88.190-7920B88E07-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_5_22617=[""].join("\n");
var outline_f22_5_22617=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2065221487\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2065221708\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Laboratory manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Peritoneal fluid cell count",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Peritoneal fluid amylase and lipase levels",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2084603937\">",
"      - Peritoneal fluid cultures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2084604360\">",
"      - Peripheral white cell count",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2065221804\">",
"      - Blood cultures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2065221781\">",
"      Radiographic findings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H615481923\">",
"      Establishing the diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2240666438\">",
"      Correct technique for obtaining peritoneal fluid for culture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2240666541\">",
"      EVALUATION AFTER DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/1869\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/1869|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?14/6/14446\" title=\"diagnostic image 1\">",
"      Pneumoperitoneum Plain film showing free air",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41061?source=related_link\">",
"      Abdominal hernias in continuous peritoneal dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24245?source=related_link\">",
"      Bloody peritoneal dialysate (hemoperitoneum)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/0/12296?source=related_link\">",
"      Diagnosis of spontaneous bacterial peritonitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/30/16874?source=related_link\">",
"      Differential diagnosis of abdominal pain in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8631?source=related_link\">",
"      Fungal peritonitis in continuous peritoneal dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/31/20986?source=related_link\">",
"      Gastrointestinal disease in dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/11/17594?source=related_link\">",
"      Microbiology and therapy of peritonitis in continuous peritoneal dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/22/31082?source=related_link\">",
"      Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/40/26248?source=related_link\">",
"      Pathophysiology and prevention of peritonitis in peritoneal dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/12/18632?source=related_link\">",
"      Peritoneal dialysis solutions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/60/3018?source=related_link\">",
"      Tunnel and peritoneal catheter exit site infections in continuous peritoneal dialysis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_5_22618="Clinical features, diagnosis, and management of von Hippel-Lindau disease";
var content_f22_5_22618=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical features, diagnosis, and management of von Hippel-Lindau disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/5/22618/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/5/22618/contributors\">",
"     Sharon E Plon, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/5/22618/contributors\">",
"     Eric Jonasch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/5/22618/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/5/22618/contributors\">",
"     Michael B Atkins, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/5/22618/contributors\">",
"     Helen V Firth, DM, FRCP, DCH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/5/22618/contributors\">",
"     John L Kirkland, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/5/22618/contributors\">",
"     Ronald D Perrone, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/5/22618/contributors\">",
"     Amar Gajjar, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/5/22618/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/5/22618/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/5/22618/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;von Hippel-Lindau (VHL) disease is an inherited, autosomal dominant syndrome manifested by a variety of benign and malignant tumors. A VHL gene abnormality is present in about 1 in 36,000 individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22618/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The initial manifestations of disease can occur in childhood, adolescence, or adulthood, with a mean age at initial presentation of about 26 years [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22618/abstract/1\">",
"     1",
"    </a>",
"    ]. The spectrum of VHL-associated tumors includes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hemangioblastomas of the brain (cerebellum) and spine",
"     </li>",
"     <li>",
"      Retinal angiomas",
"     </li>",
"     <li>",
"      Clear cell renal cell carcinomas (RCCs)",
"     </li>",
"     <li>",
"      Pheochromocytomas",
"     </li>",
"     <li>",
"      Endolymphatic sac tumors of the middle ear",
"     </li>",
"     <li>",
"      Serous cystadenomas and neuroendocrine tumors of the pancreas",
"     </li>",
"     <li>",
"      Papillary cystadenomas of the epididymis and broad ligament",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The different types of VHL disease, their clinical manifestations and management, the genetic diagnosis of VHL, and appropriate surveillance protocols will be reviewed here. The molecular biology and pathogenesis of VHL disease are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/21/14678?source=see_link\">",
"     \"Molecular biology and pathogenesis of von Hippel-Lindau disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TYPES OF VHL DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Families with VHL disease have been divided into types 1 and 2, based upon the likelihood of developing pheochromocytoma [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22618/abstract/4\">",
"     4",
"    </a>",
"    ]. Type 2 families are more likely to carry a missense mutation in the VHL gene.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1759621\">",
"    <span class=\"h2\">",
"     Type 1",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients in kindreds with type 1 disease have a substantially lower risk of developing pheochromocytomas, although they are at high risk for the other VHL-associated lesions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1759629\">",
"    <span class=\"h2\">",
"     Type 2",
"    </span>",
"    &nbsp;&mdash;&nbsp;Kindreds with type 2 disease are at high risk for developing pheochromocytoma. Type 2 disease is subdivided based upon the risk of developing of renal cell carcinoma (RCC). Type 2A and 2B families have a low and high incidence of RCC, respectively, while type 2C kindreds are characterized by the development of pheochromocytomas only, without RCC or hemangioblastoma. These subclassifications should be used as a guide and are not absolute. Continued surveillance for other VHL related lesions should continue, for example, in individuals who present with type 2C characteristics. &nbsp;",
"   </p>",
"   <p>",
"    The goal of improving survival and quality of life in patients with VHL disease has been aided by a better understanding of the natural history of VHL-associated tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22618/abstract/5\">",
"     5",
"    </a>",
"    ]. As a result, surveillance strategies have been developed for affected individuals, which have led to the detection of small, asymptomatic tumors prior to the development of metastases or other complications. In addition, therapeutic advances (eg, renal-sparing surgery in RCC) have improved outcomes by decreasing the incidence of renal failure when therapy is required. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/26/5546?source=see_link&amp;anchor=H20#H20\">",
"     \"Surgical management of localized renal cell carcinoma\", section on 'Nephron-sparing approaches'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The molecular pathogenesis of VHL disease is discussed elsewhere. A \"two-hit\" model appears to apply to this disorder. Affected patients have a germline mutation that inactivates one copy of the VHL gene in all cells. For disease to occur there must be loss of expression of the second, normal allele through somatic mutation or deletion of the second allele, or through hypermethylation of its promoter. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/21/14678?source=see_link\">",
"     \"Molecular biology and pathogenesis of von Hippel-Lindau disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1986453\">",
"    <span class=\"h1\">",
"     OCCURRENCE AND AGE OF ONSET OF VHL RELATED LESIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;VHL related lesions occur over a wide range of ages, as outlined in the table (",
"    <a class=\"graphic graphic_table graphicRef83902 \" href=\"UTD.htm?28/20/29004\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22618/abstract/6\">",
"     6",
"    </a>",
"    ]. Age of onset of screening varies by lesion, with screening for retinal lesions commencing at a very young age, and screening for other lesions starting slightly later. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Surveillance protocols'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     HEMANGIOBLASTOMAS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemangioblastomas are well-circumscribed, capillary-vessel-rich benign neoplasms, which do not invade locally or metastasize. However, they can cause symptoms through pressure on adjacent structures and through hemorrhage, due to either the hemangioblastoma itself or cyst formation around the lesion. The clinical presentation and management of sporadic hemangioblastomas are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/43/695?source=see_link\">",
"     \"Hemangioblastoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hemangioblastomas are the most common lesions associated with VHL disease, affecting 60 to 84 percent of patients and typically occur in the cerebellum or spinal cord [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22618/abstract/1,2,7\">",
"     1,2,7",
"    </a>",
"    ]. Patients with VHL-associated hemangioblastomas tend to be younger than those with sporadic hemangioblastomas with a mean age at diagnosis in one series of 29 years, and a range of 9 to 78 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22618/abstract/1\">",
"     1",
"    </a>",
"    ]. While sporadic hemangioblastomas usually are solitary and generally do not recur after surgery, lesions in patients with VHL tend to be infratentorial and multiple [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22618/abstract/8\">",
"     8",
"    </a>",
"    ]. In a detailed analysis of 160 patients with VHL and hemangioblastoma, 655 discrete tumors were identified, of which 51 percent were in the spinal cord, 38 percent in the cerebellum, 10 percent in the brainstem, and 2 percent supratentorial [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22618/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We recommend that all patients with either a retinal or CNS hemangioblastoma be tested for VHL germline mutations, even in the case of a single lesion. Where access to genetic investigations is limited, it would be reasonable to focus testing on patients with solitary lesions presenting under the age of 50 years since the likelihood of identifying a germline VHL mutation is inversely correlated with the age of the patient. In a cohort of 188 consecutive patients presenting with a seemingly sporadic hemangioblastoma, no family history of VHL, and no other evidence of the disease, VHL germline mutations were present in 5 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22618/abstract/9\">",
"     9",
"    </a>",
"    ]. Of those who tested negative, 5 percent developed a VHL-related lesion in the ensuing years, which may result from being mosaic for a VHL mutation. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Somatic mosaicism'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Because hemangioblastomas often initially develop in the second decade, routine screening with magnetic resonance imaging (MRI) of the brain and spinal cord is recommended in patients with VHL disease starting after the age of ten (see",
"    <a class=\"local\" href=\"#H23\">",
"     'Surveillance protocols'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemangioblastomas can remain dormant for unpredictable periods of time or can present with accelerated growth [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22618/abstract/7,10\">",
"     7,10",
"    </a>",
"    ]. Currently there are no clinical (eg, age, gender, location), radiographic, or specific molecular markers (ie, underlying mutations) that can predict the natural history of a given lesion, and regular follow-up with imaging and observation of clinical signs and symptoms is necessary.",
"   </p>",
"   <p>",
"    Therapeutic efforts should focus on avoiding treatment-related morbidity by minimizing the frequency of surgical interventions because of the frequent development of multiple lesions. Small asymptomatic lesions can be followed with careful surveillance. Although surgery usually can successfully remove lesions in the spinal cord, brainstem, and cerebellum, intervention is reserved until lesions become symptomatic or they display accelerated growth [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22618/abstract/7,8,11,12\">",
"     7,8,11,12",
"    </a>",
"    ]. Patients who demonstrate progression by neural imaging should be followed at more frequent intervals for evidence of clinical symptoms.",
"   </p>",
"   <p>",
"    Stereotactic radiosurgery (SRS) and conventional fractionated radiation therapy (RT) may play a role in treating lesions that are not readily accessible by surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22618/abstract/13\">",
"     13",
"    </a>",
"    ]. There are no randomized prospective studies that compare the long-term efficacy and safety of SRS with conventional radiation therapy for hemangioblastomas. In a prospective observational study performed at the National Institutes of Health, diminishing tumor control over time was observed in lesions treated with SRS [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22618/abstract/13\">",
"     13",
"    </a>",
"    ]. On the basis of these findings, prophylactic treatment of asymptomatic hemangioblastomas with SRS is not recommended, and surgery is still considered the standard of care when feasible.",
"   </p>",
"   <p>",
"    At this time, no effective systemic therapy has been validated for hemangioblastomas. A prospective clinical trial with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    , an antiangiogenic agent, failed to demonstrate response in hemangioblastomas [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22618/abstract/14\">",
"     14",
"    </a>",
"    ]. Preclinical data suggested that fibroblast growth factor receptor (FGFR) inhibitors may provide some value in the management of hemangioblastomas. Based on these findings, a case report of response to the antiangiogenic agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/2/1064?source=see_link\">",
"     pazopanib",
"    </a>",
"    , which possesses modest FGFR blocking activity, was reported [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22618/abstract/15\">",
"     15",
"    </a>",
"    ]. Further work needs to be done to define the value of specific antiangiogenic agents for hemangioblastomas. &nbsp;",
"   </p>",
"   <p>",
"    Outcomes with different therapeutic approaches for the management of hemangioblastoma are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/43/695?source=see_link&amp;anchor=H9#H9\">",
"     \"Hemangioblastoma\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     RETINAL CAPILLARY HEMANGIOBLASTOMAS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retinal capillary hemangioblastomas (RCH) are typically found either in the peripheral retina",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the juxtapapillary region. Visual loss from retinal capillary hemangioblastomas is generally caused by exudation from the tumor, causing retinal edema or by tractional effects, in which glial proliferation on the surface of the tumor induces retinal striae and distortion [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22618/abstract/16\">",
"     16",
"    </a>",
"    ]. In addition, retinal capillary hemangioblastomas can hemorrhage, leading to retinal detachment, glaucoma, and loss of vision.",
"   </p>",
"   <p>",
"    Retinal capillary hemangioblastomas are found in up to 70 percent of VHL patients by age 60 years; they are often multifocal and bilateral. Compared to patients with sporadic retinal angiomas, patients with VHL are much younger and more likely to have multiple lesions. In one series of 31 patients with VHL and 37 patients without VHL, the VHL patients were younger (18 versus 36 years of age, respectively), had an average of four tumors, and were more likely to develop new tumors than those without the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22618/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a study of 890 patients with VHL, of whom 335 patients had a retinal capillary hemangioblastoma in at least one eye, lesions were detected unilaterally in 42 percent and bilaterally in 58 percent of patients. No correlation was detected between the age, gender, or laterality of involvement. Of involved eyes, 87 percent had tumors that could be individually visualized; of these, tumors were commonly found in the peripheral retina (85 percent) only, and less commonly in the juxtapapillary area (15 percent). The tumor count in the periphery averaged",
"    <span class=\"nowrap\">",
"     2.5+/-1.8",
"    </span>",
"    per eye, with 25 percent of eyes having more than one quadrant of retinal involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22618/abstract/18\">",
"     18",
"    </a>",
"    ]. An assessment of the genotype-phenotype relationship in retinal capillary hemangioblastoma suggested that 15 percent of individuals with complete deletions of VHL protein had hemangioblastoma development versus an overall prevalence in the patient population of 37 percent. The risk of vision loss was found to increase with age although tumor number did not increase significantly as a function of age.",
"   </p>",
"   <p>",
"    As is the case with seemingly sporadic hemangioblastomas, any patient presenting with a retinal capillary hemangioblastoma (particularly if prior to age 40) should have a complete evaluation for the presence of VHL. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Clinical manifestations'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Routine surveillance for retinal capillary hemangioblastoma is recommended for patients with VHL disease because of their high frequency. The frequent onset of such lesions during childhood makes it important to initiate ophthalmic surveillance in the pediatric population. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Surveillance protocols'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The treatment of retinal capillary hemangioblastoma requires that the benefits of treatment be balanced against potential treatment-related complications. Whether the smallest lesions can be carefully observed without specific treatment until there is any evidence of growth or symptoms is controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22618/abstract/19\">",
"     19",
"    </a>",
"    ]. Some groups recommend that retinal capillary hemangioblastoma be treated immediately upon detection in order to prevent growth and complications, whereas others wait for some change in size before initiating treatment.",
"   </p>",
"   <p>",
"    Laser photocoagulation and cryotherapy are effective in over 70 percent of cases, generally with a single treatment, and are the preferred methods of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22618/abstract/19\">",
"     19",
"    </a>",
"    ]. An exception is that hemangioblastomas of the optic nerve should not be treated with these methods, because of the deleterious side effects on the normal retina. Photodynamic therapy can also be considered as an option in the treatment of retinal capillary hemangioblastoma, although limited data exist on its efficacy. External beam RT may have a role for salvage therapy if other modalities have failed [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22618/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Investigational approaches have focused on interfering with angiogenesis. The experimental vascular endothelial growth factor (VEGF) receptor inhibitor SU5146 was reported to successfully reduce peritumoral edema and improve vision in six patients with VHL, although the drug did not reduce the actual tumor size itself [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22618/abstract/21-24\">",
"     21-24",
"    </a>",
"    ]. This agent is not commercially available.",
"   </p>",
"   <p>",
"    In a study assessing impact of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    on VHL related lesions, the very small number of individuals with retinal lesions did not show signs of improvement [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22618/abstract/14\">",
"     14",
"    </a>",
"    ]. In a small study of five patients, the VEGF-binding monoclonal antibody",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/40/33413?source=see_link\">",
"     ranibizumab",
"    </a>",
"    produced only a minimal effect in one of five patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22618/abstract/25\">",
"     25",
"    </a>",
"    ]. These investigational approaches may be useful to reduce the symptoms generated from hemangioblastomas of the optic nerve that are difficult to treat. Further studies need to be performed to better understand the biology of the hemangioblastoma cell of origin and its endothelium and to develop more effective systemic therapies. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     RENAL CELL CARCINOMAS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Clinical presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with VHL disease are at risk for developing multiple renal cysts and renal cell carcinomas (RCC), which occur in approximately two-thirds of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22618/abstract/1\">",
"     1",
"    </a>",
"    ]. Virtually all VHL-associated RCCs are clear cell tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22618/abstract/2\">",
"     2",
"    </a>",
"    ]. RCCs of predominant papillary, chromophobe, or oncocytic histology are not associated with VHL disease, but can be associated with other cancer susceptibility syndromes [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22618/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/4/35910?source=see_link\">",
"     \"Hereditary kidney cancer syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis of RCC is rare in VHL disease prior to age 20 and occur with increasing frequency thereafter; thus screening is initiated in adolescence [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22618/abstract/1,2,28\">",
"     1,2,28",
"    </a>",
"    ]. The mean age at onset in one large series was 44 years and it was estimated that 69 percent of patients surviving to age 60 would develop RCC [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22618/abstract/1\">",
"     1",
"    </a>",
"    ]. The incidence of RCC is lower in patients who carry missense mutations in the VHL gene in which pheochromocytoma is prominent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22618/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Types of VHL disease'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    RCCs are often multicentric and bilateral, arising both in conjunction with cysts or de novo from noncystic renal parenchyma. Although renal cysts may be benign, they are thought to represent a premalignant lesion; solid components within otherwise benign-appearing renal cysts almost always contain RCC [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22618/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/3/27704?source=see_link\">",
"     \"Simple and complex renal cysts in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Histopathologic changes in the renal parenchyma are widespread and are not limited to renal cysts [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22618/abstract/30\">",
"     30",
"    </a>",
"    ]. Systematic microscopic analysis identified numerous clear cell abnormalities, which are thought to be precursors for clear cell RCC. Similar clear cell precursors were not seen in the renal parenchyma from patients with sporadic RCC or from patients without RCC.",
"   </p>",
"   <p>",
"    Growth kinetics of RCC in VHL patients was described in a series of 96 renal tumors in 64 VHL patients with analyzed germline mutation (54 out of 64 treated, 10 out of 64 active surveillance) over a mean follow-up of 55 months [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22618/abstract/31\">",
"     31",
"    </a>",
"    ]. In this series, the mean growth rate of 96 tumors was 4.4",
"    <span class=\"nowrap\">",
"     mm/year",
"    </span>",
"    (SD 3.2, median 4.1",
"    <span class=\"nowrap\">",
"     mm/year),",
"    </span>",
"    mean volume doubling time was 25.7 months (SD 20.2, median 22.2 months). Obviously, patients with larger lesions or faster growth rates need to have a tailored approach to their follow-up. &nbsp;",
"   </p>",
"   <p>",
"    The recommended surveillance strategy for early detection of suspicious renal cystic lesions in patients with VHL disease is discussed below (see",
"    <a class=\"local\" href=\"#H23\">",
"     'Surveillance protocols'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The therapeutic approach to RCC in patients with VHL has shifted from radical nephrectomy to nephron-sparing approaches (observation for small lesions, partial nephrectomy, cryotherapy, radiofrequency ablation), with the goal of preserving as much renal parenchyma as possible [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22618/abstract/28,32-34\">",
"     28,32-34",
"    </a>",
"    ]. Patients diagnosed with VHL should be aware of these recommendations and should seek care from a urologist familiar with VHL guidelines if a renal mass is discovered. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/26/5546?source=see_link&amp;anchor=H20#H20\">",
"     \"Surgical management of localized renal cell carcinoma\", section on 'Nephron-sparing approaches'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several factors have contributed to this change:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Improved imaging modalities (eg, CT, MRI, and ultrasound), combined with regular surveillance programs, have led to the identification of more RCCs at an early stage.",
"     </li>",
"     <li>",
"      Solid renal tumors &lt;3 cm in diameter generally have a low metastatic potential and can be safely monitored as long as they remain stable. In one study, for example, serial imaging studies were performed in 96 patients with VHL syndrome and small renal tumors [",
"      <a class=\"abstract\" href=\"UTD.htm?22/5/22618/abstract/33\">",
"       33",
"      </a>",
"      ]. Surgery was performed in 52 when a tumor reached a threshold size of 3 cm in diameter. Only two patients required nephrectomy, and none developed metastatic disease at a median follow up of 60 months. In the other 44 patients, this size threshold was not used as an indication for immediate surgery. In this group, 12 patients required nephrectomy, and 11 developed metastatic disease with a median follow-up of 66 months. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/9/2200?source=see_link\">",
"       \"Diagnostic approach, differential diagnosis, and treatment of a small renal mass\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Partial nephrectomy appears to be as effective as total nephrectomy for early stage RCC. Repeated partial nephrectomies may be feasible in carefully selected patients to preserve renal parenchyma and avoid dialysis [",
"      <a class=\"abstract\" href=\"UTD.htm?22/5/22618/abstract/34\">",
"       34",
"      </a>",
"      ]. The rationale and results with partial nephrectomy for patients with RCC are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/26/5546?source=see_link&amp;anchor=H21#H21\">",
"       \"Surgical management of localized renal cell carcinoma\", section on 'Partial nephrectomy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Other nephron-sparing approaches, particularly cryoablation and radiofrequency ablation, may permit the eradication of multiple small tumors while minimizing damage to the normal kidney. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/44/26310?source=see_link\">",
"       \"Radiofrequency ablation and cryoablation for renal cell carcinoma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Continued close surveillance is required after treatment of RCC in VHL patients. New renal tumors are detected in approximately 30 percent of patients by five years and 85 percent by 10 years. The risk of metastatic disease appears to be low as long as the patient is carefully monitored. However, in one report of 21 such patients, two developed metastatic disease at a median follow-up of 29 months [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22618/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Renal transplantation has been used in VHL patients who required bilateral nephrectomy for RCC or developed end-stage renal disease. Experience is limited, because of concerns that immunosuppressive therapy might enhance the risk of tumor recurrence. However, this concern was not borne out in at least one study of 32 patients with VHL receiving renal transplants and 32 matched transplant recipients without the disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22618/abstract/35\">",
"     35",
"    </a>",
"    ]. At an average follow-up of four years, no differences were observed between the two groups in graft and patient survival or renal function.",
"   </p>",
"   <p>",
"    Systemic therapy options are being studied in patients with VHL and RCC. With the advent of molecularly targeted therapy that can decrease the size of RCC lesions, it may be possible to decrease frequency of surgical intervention through chronic or intermittent use of currently available agents. A clinical trial assessing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    in 15 VHL patients showed a 33 percent partial response rate [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22618/abstract/14\">",
"     14",
"    </a>",
"    ]. An ongoing clinical trial is testing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/2/1064?source=see_link\">",
"     pazopanib",
"    </a>",
"    in the same patient population (NCT01436227).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     PHEOCHROMOCYTOMAS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pheochromocytomas are seen both sporadically and in association with a number of genetic syndromes, including VHL disease, multiple endocrine neoplasia type 2, neurofibromatosis type 1, and mutations of the succinate dehydrogenase (SDH) subunits B, D, and C. The different familial syndromes manifesting pheochromocytomas are discussed in detail elsewhere. All patients with pheochromocytoma should have a genetic evaluation to identify the underlying syndrome (found in 40 percent of patients) so that the proper surveillance is initiated for other tumors for which the patient is at risk. The presence of pheochromocytomas is used to define types 2A-C VHL disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/54/21351?source=see_link\">",
"     \"Pheochromocytoma in genetic disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pheochromocytomas in VHL disease tend to be seen in younger patients, are often multiple, may be extraadrenal, and are less likely to be associated with symptoms or biochemical evidence of catecholamine production compared to those occurring in patients without VHL [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22618/abstract/36-38\">",
"     36-38",
"    </a>",
"    ]. Pediatric cases are not infrequent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22618/abstract/39,40\">",
"     39,40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two large series illustrate the clinical characteristics of pheochromocytomas in patients with VHL disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a report from the National Institutes of Health of 64 patients with VHL disease and pheochromocytomas, a total of 106 tumors were identified [",
"      <a class=\"abstract\" href=\"UTD.htm?22/5/22618/abstract/38\">",
"       38",
"      </a>",
"      ]. Of these, 12 percent originated outside the adrenal gland and 35 percent of patients were asymptomatic, without hypertension or evidence of increased catecholamine production.",
"     </li>",
"     <li>",
"      In the Mayo Clinic experience, 20 of 109 patients with VHL disease (18 percent) had a pheochromocytoma at a median age of 30 years, including three originating outside the adrenal gland [",
"      <a class=\"abstract\" href=\"UTD.htm?22/5/22618/abstract/37\">",
"       37",
"      </a>",
"      ]. Detailed analysis of these patients failed to reveal evidence of catecholamine production in one-third.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Tumors that produce catecholamines may be associated with the typical clinical signs and symptoms of pheochromocytomas, including hypertension, diaphoresis, tachycardia, and apparent mood changes. In addition, the possibility of an occult pheochromocytoma needs to be considered whenever a patient with VHL type 2 disease requires surgery, because of the risk of sympathetic overactivity and severe hypertension.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9384130\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pheochromocytomas can be detected with radiographic imaging, via urine",
"    <span class=\"nowrap\">",
"     metanephrine/normetanephrine",
"    </span>",
"    testing, and with plasma",
"    <span class=\"nowrap\">",
"     metanephrine/normetanephrine",
"    </span>",
"    testing. Conventional imaging may not be sufficient because of the potential for extraadrenal lesions, referred to as paragangliomas. Studies with",
"    <sup>",
"     18",
"    </sup>",
"    F-DOPA PET provide some context and suggest that MIBG scanning is not effective at detecting pheochromocytomas in patients with VHL:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A pilot study of",
"      <sup>",
"       18",
"      </sup>",
"      F-DOPA PET in seven patients with VHL indicated a high detection rate (7 out of 7) as did CT scan. On the other hand",
"      <span class=\"nowrap\">",
"       [(123/131)I]",
"      </span>",
"      -MIBG scintigraphy failed to detect 4 of the 7 lesions [",
"      <a class=\"abstract\" href=\"UTD.htm?22/5/22618/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      These data were confirmed in an independent study of 48 patients with hereditary and nonhereditary cases [",
"      <a class=\"abstract\" href=\"UTD.htm?22/5/22618/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      In a prospective study assessing adrenal imaging of 52 patients with VHL, 390 lesions were identified by computed tomography (n = 139), MRI (n = 117), (18)F-fluorodeoxyglucose PET (n = 94), and",
"      <sup>",
"       18",
"      </sup>",
"      F-DOPA PET (n = 40).",
"      <sup>",
"       18",
"      </sup>",
"      F-DOPA PET identified 20 pancreatic and 20 extrapancreatic tumors, including lesions in the adrenal gland (n = 11), kidney (n = 3), liver (n = 4), lung (n = 1), and cervical paraganglioma (n = 1). These tumor sites were not seen by conventional imaging studies in 9.6 percent of patients and 4.4 percent of lesions [",
"      <a class=\"abstract\" href=\"UTD.htm?22/5/22618/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Measurement of plasma metanephrines and normetanephrines provides important diagnostic information.",
"   </p>",
"   <p>",
"    In a study of patients with VHL and multiple endocrine neoplasia type 2 (MEN-2), measurements of plasma normetanephrines and metanephrines provided a sensitivity of 97 percent, and specificity of 96 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22618/abstract/44\">",
"     44",
"    </a>",
"    ]. VHL patients almost exclusively produced normetanephrines (indicating norepinephrine production), and so a high normetanephrine to metanephrine ratio is expected in patients with VHL.",
"   </p>",
"   <p>",
"    A significant proportion of patients with seemingly sporadic pheochromocytoma have an underlying cancer susceptibility syndrome, including VHL. This issue was addressed in a review of 271 patients with apparently sporadic pheochromocytoma (no other tumors or family history of the disease) from population-based registries in Germany and Poland; all were tested for germline mutations in VHL and three other genes (Ret, NF1, SDHB, SDHD) that have been implicated in familial pheochromocytoma [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22618/abstract/45\">",
"     45",
"    </a>",
"    ]. A germline VHL mutation was identified in 30 patients overall (11 percent) and in 42 percent of those who presented at age 18 or younger. A positive family history had been established at last follow-up in 12 of the 30 patients and at least four others had a de novo germline VHL mutation since both parents tested negative. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/14/23786?source=see_link\">",
"     \"Clinical presentation and diagnosis of pheochromocytoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The recommended surveillance testing for pheochromocytoma in patients with VHL disease is discussed below (see",
"    <a class=\"local\" href=\"#H23\">",
"     'Surveillance protocols'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Treatment of choice for symptomatic pheochromocytomas is surgical removal after appropriate alpha-adrenoreceptor blockade and other supportive measures if needed [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22618/abstract/46\">",
"     46",
"    </a>",
"    ]. It is critical to follow established protocols to suppress catecholamine production in the preoperative period, and following patients carefully perioperatively and postoperatively for several weeks to ensure that endocrine and cardiovascular function has not been compromised by prolonged overproduction of catecholamines. &nbsp;",
"   </p>",
"   <p>",
"    Additional information on the pharmacologic management of patients with pheochromocytoma prior to surgery is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/14/23786?source=see_link\">",
"     \"Clinical presentation and diagnosis of pheochromocytoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/14/38121?source=see_link\">",
"     \"Pheochromocytoma in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     ENDOLYMPHATIC SAC TUMORS OF THE MIDDLE EAR",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Papillary cystadenomas of the endolymphatic sac are highly vascular lesions arising within the posterior temporal bone [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22618/abstract/47\">",
"     47",
"    </a>",
"    ]. Common clinical manifestations include hearing loss, tinnitus, vertigo, and less often, facial muscle weakness [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22618/abstract/47-50\">",
"     47-50",
"    </a>",
"    ]. Radiologic findings include retrolabyrinthine location, intratumoral calcification on CT scan, hyperintense focal signals on T1-weighted (noncontrast-enhanced) MRI, and a heterogeneous signal on T2-weighted MRI scan [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22618/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. Visualization of these lesions requires dedicated images, and endolymphatic sac tumors (ELSTs) will often be missed on brain MRI scans ordered for surveillance of cerebellar hemangioblastoma.",
"   </p>",
"   <p>",
"    ELSTs have been associated with mutations in the VHL gene and with other manifestations of VHL disease [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22618/abstract/48,49,53-55\">",
"     48,49,53-55",
"    </a>",
"    ]. In two studies that included a total of 250 patients with VHL disease, detailed evaluation revealed ELSTs in 34 (14 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22618/abstract/47,48\">",
"     47,48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although these tumors also occur sporadically, they arise at a younger age in VHL patients, in whom they are often bilateral. In one series, for example, bilateral tumors were present in 28 percent of the patients with VHL versus 1 percent in the patients without VHL [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22618/abstract/49\">",
"     49",
"    </a>",
"    ]. In two other reports in VHL patients, 5 of 34 tumors (15 percent) were bilateral [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22618/abstract/47,48\">",
"     47,48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Three mechanisms have been described to account for the hearing loss and other symptoms associated with ELSTs [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22618/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tumors can invade the otic capsule, resulting in destruction of the membranous labyrinth and disruption of endolymphatic flow.",
"     </li>",
"     <li>",
"      Sudden, irreversible hearing loss may be due to intralabyrinthine hemorrhage.",
"     </li>",
"     <li>",
"      Gradual onset of hearing loss, tinnitus, and vertigo can be caused by blockage of endolymphatic sac resorption of fluid (hydrops).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    ELSTs may be difficult to detect with a single modality. In a prospective 40 patient study, endolymphatic sac tumors were suspected based on audiovestibular symptoms, audiometry, and magnetic resonance imaging in 34, 30, and 12.5 percent of subjects, respectively. In total, more than 90 percent of radiologically diagnosed endolymphatic sac tumors were associated with abnormal audiometric findings [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22618/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with VHL should be questioned annually about any auditory or vestibular symptoms with routine audiology performed for surveillance. Any patient with abnormalities in auditory tests should be screened for the presence of these tumors by CT of the skull base or MRI with fine cuts temporal bones [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22618/abstract/47\">",
"     47",
"    </a>",
"    ]. These lesions can be very difficult to see radiographically. Whether surgery is indicated for patients with an asymptomatic tumor is controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22618/abstract/50\">",
"     50",
"    </a>",
"    ], and additional studies are required to assess the risk of acute hearing loss in such patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of ELSTs needs to consider the presence and severity of symptoms, their generally slow growth rate, and the potential complications associated with surgery. Treatment of ELST is primarily surgical; if the lesions can be completely excised, surgery is curative [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22618/abstract/57-59\">",
"     57-59",
"    </a>",
"    ]. Stereotactic radiosurgery may have a role for recurrent disease [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22618/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cochlear implants may be an option for patients with hearing loss due to bilateral ELSTs [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22618/abstract/61\">",
"     61",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/24/39300?source=see_link\">",
"     \"Hearing amplification in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     PANCREATIC TUMORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pancreatic abnormalities are common in patients with VHL disease. In a multi-institutional study of 158 consecutive patients from 94 affected families, 77 percent had lesions in the pancreas, including cysts (70 percent), serous cystadenomas (9 percent), and neuroendocrine tumors (9 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22618/abstract/62\">",
"     62",
"    </a>",
"    ]. In another series of 633 patients with VHL disease, neuroendocrine tumors were identified in 108 (17 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22618/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Simple pancreatic cysts and serous cystadenomas may be asymptomatic even when the radiologic presentation is dramatic. However, such lesions can cause epigastric pain and discomfort [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22618/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. Pancreatitis and pancreatic failure are exceedingly rare complications, although some degree of exocrine pancreatic dysfunction has been reported. Asking about change in stool characteristics and digestive patterns should be part of a comprehensive review of systems with VHL patients who have pancreatic cysts. Mucinous cysts of the pancreas are not seen in association with VHL disease, and VHL patients do not have an increased risk of pancreatic adenocarcinoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/20/15686?source=see_link\">",
"     \"Classification of pancreatic cysts\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Neuroendocrine tumors of the pancreas can metastasize to the liver and may produce symptoms due to secreted peptides (eg, diarrhea with vasoactive intestinal peptide and hypoglycemic episodes with insulin) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22618/abstract/62\">",
"     62",
"    </a>",
"    ]. In one series of 108 patients with neuroendocrine tumors, 9 (8 percent) had metastatic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22618/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, most of these tumors are asymptomatic and grow slowly for prolonged periods without producing symptoms of peptide overproduction. In two combined series, none of 25 patients had symptoms related to peptide hormone secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22618/abstract/62,66\">",
"     62,66",
"    </a>",
"    ]. As a result, many of these lesions are diagnosed incidentally during surveillance for renal lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22618/abstract/63\">",
"     63",
"    </a>",
"    ]&nbsp;(see",
"    <a class=\"local\" href=\"#H23\">",
"     'Surveillance protocols'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Management of pancreatic neuroendocrine tumors is surgical. Resection is generally reserved for lesions greater than 3 cm in diameter in the body or tail of the pancreas, or 2 cm in diameter in the head of the pancreas [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22618/abstract/63,67\">",
"     63,67",
"    </a>",
"    ]. Smaller asymptomatic lesions may be monitored with imaging at yearly intervals. In a study of 108 VHL patients with pancreatic neuroendocrine tumors, tumors &lt;3 cm, with a doubling time &gt;500 days, and mutations in VHL gene exons 1 or 2, had a minimal risk for metastasis, suggesting that such patients could be managed with observation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22618/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     PAPILLARY CYSTADENOMAS OF THE EPIDIDYMIS AND BROAD LIGAMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Papillary cystadenomas occur in both the epididymis in men and the broad ligament in women [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22618/abstract/68\">",
"     68",
"    </a>",
"    ]. Single epididymal cysts are common in the general population and should not raise suspicion for VHL disease in the absence of other VHL-related findings. On the other hand, bilateral papillary cystadenomas are almost pathognomonic of VHL disease [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22618/abstract/2,69\">",
"     2,69",
"    </a>",
"    ]. In one series of 56 patients with VHL who were screened with both ultrasound and physical examination, 30 had epididymal abnormalities, two-thirds of which were bilateral. Papillary cystadenomas are benign and generally asymptomatic and no treatment is required [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22618/abstract/69\">",
"     69",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/51/5942?source=see_link\">",
"     \"Evaluation of nonacute scrotal pathology in adult men\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Papillary cystadenomas in the broad ligament in women are also asymptomatic in most patients, and thus the true incidence of these lesions is unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22618/abstract/70,71\">",
"     70,71",
"    </a>",
"    ]. Symptoms that have been reported include pain, dyspareunia, and menorrhagia; treatment is symptomatic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     VHL MUTATIONS IN SPORADIC TUMORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sporadic RCCs, pheochromocytomas, ELST, and hemangioblastomas frequently have acquired somatic (as opposed to germline) abnormalities involving the VHL gene, supporting a role for the VHL gene in tumorigenesis in sporadic cases [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22618/abstract/26,55,72-76\">",
"     26,55,72-76",
"    </a>",
"    ]. As noted above, two hits appear to be required in VHL disease in both the hereditary and sporadic tumors. The hits can result from inherited mutations, somatic mutations followed by loss of heterozygosity, or loss of gene expression caused by promoter hypermethylation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/21/14678?source=see_link\">",
"     \"Molecular biology and pathogenesis of von Hippel-Lindau disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following observations illustrate the frequency with which this occurs:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Somatic mutations of the VHL gene",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      allelic deletion may be present in as many as 50 percent of sporadic hemangioblastomas. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/43/695?source=see_link&amp;anchor=H8#H8\">",
"       \"Hemangioblastoma\", section on 'Molecular biology'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Abnormalities of the VHL gene are also found in 50 to 60 percent of patients with sporadic RCC, suggesting that the VHL gene has a role in pathogenesis in this setting as well. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/52/18250?source=see_link&amp;anchor=H403325303#H403325303\">",
"       \"Epidemiology, pathology, and pathogenesis of renal cell carcinoma\", section on 'Von Hippel Lindau gene'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      VHL abnormalities in apparently sporadic pheochromocytoma are observed less commonly (4 percent of benign lesions and in 17 percent of malignant tumors in a series of 72 patients) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/5/22618/abstract/74\">",
"       74",
"      </a>",
"      ]. However, some of these patients actually have germline mutations and therefore VHL disease [",
"      <a class=\"abstract\" href=\"UTD.htm?22/5/22618/abstract/45\">",
"       45",
"      </a>",
"      ]&nbsp;(see",
"      <a class=\"local\" href=\"#H10\">",
"       'Pheochromocytomas'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Genetic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although clinical criteria were originally developed for the diagnosis of VHL primarily based upon the finding of more than one VHL-associated tumor, detection of a germline mutation in the VHL gene now is typically used to establish the diagnosis, particularly in patients with a single manifestation of the condition [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22618/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Genetic testing, which is typically performed on peripheral blood lymphocytes, involves DNA sequencing and dosage analysis using MLPA or Southern blot analysis of the VHL gene. The sensitivity and specificity of these methods are nearly 100 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22618/abstract/77\">",
"     77",
"    </a>",
"    ]. Germline mutations in the VHL gene can be inherited or arise de novo. The latter occurs in about 20 percent of kindreds. Rare patients may have the clinical features of VHL without a detectable mutation, due to mosaicism for the VHL mutation (see",
"    <a class=\"local\" href=\"#H21\">",
"     'Somatic mosaicism'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Patients suspected of having VHL disease should be referred to specialized centers for evaluation, genetic counseling, and definitive diagnosis, even if there is no family history of VHL disease. Approved VHL Clinical Care Centers are listed at",
"    <a class=\"external\" href=\"file://www.vhl.org/ccc/index.php.\">",
"     file://www.vhl.org/ccc/index.php.",
"    </a>",
"    These centers have been approved for standards of care that were developed by the VHL Family Alliance&rsquo;s Medical Advisory Board.",
"   </p>",
"   <p>",
"    Comprehensive genetic testing of the VHL gene should be based on the presence of one or more characteristic lesions. The specific criteria used at the Massachusetts General Hospital VHL Clinic are summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef57447 \" href=\"UTD.htm?41/27/42427\">",
"     table 2",
"    </a>",
"    ). Testing for a specific familial VHL mutation should then be performed for at-risk relatives based upon having a blood relative with an established diagnosis of VHL.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Somatic mosaicism",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a patient with somatic mosaicism, a mutation occurs during embryonic development after fertilization; in these circumstances, some cells will be normal while others carry the mutation. In contrast to finding germline mutations, diagnostic difficulties are more likely [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22618/abstract/78,79\">",
"     78,79",
"    </a>",
"    ]. Although an individual with somatic mosaicism may present with classic VHL disease, the mutation may not be detectable in the peripheral blood because the hematologic stem cells do not carry the mutation.",
"   </p>",
"   <p>",
"    Thus the possibility of mosaicism should be considered in patients presenting with VHL-associated tumors and a negative VHL genetic test based upon peripheral blood. The disease manifestations in such patients are dependent upon when the de novo mutation event occurred in embryogenesis. The earlier the new mutation occurred, the more tissue types are likely to be affected.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Genetic counseling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should be referred for appropriate genetic counseling in conjunction with testing for VHL mutations. VHL disease is inherited in an autosomal dominant fashion, and affected individuals have a 50 percent probability of transmitting the VHL mutation to each offspring.",
"   </p>",
"   <p>",
"    Among patients with somatic mosaicism, the risk to offspring depends upon whether or not the germ tissue carries the mutation, although that cannot be determined clinically. Thus, patients with documented mosaicism should be counseled that their risk of having an affected child may be as high as 50 percent and the affected child will inherit the mutation in 100 percent of their cells and potentially have more severe manifestations of the disease. Testing of multiple tumors from the same patient with mosaicism can sometimes provide information on the causative mutation but should be interpreted by an experienced geneticist or genetic counselor.",
"   </p>",
"   <p>",
"    The diagnosis of VHL in a child of unaffected parents can be very alarming, and the concept of de novo mutations should be carefully explained. In particular, parents should be reassured and potential guilt alleviated by explaining that the mutation is unlikely to be the result of any action that occurred immediately prior to or during the pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9384234\">",
"    <span class=\"h1\">",
"     PREGNANCY AND VHL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prospective parents planning or carrying a pregnancy at risk for VHL face different options for learning the carrier status of the fetus. The couple may choose not to know until after the child is born. Alternatively, a couple may choose prenatal diagnosis, utilizing a sample obtained by amniocentesis or chorionic villus sampling. Some couples that choose prenatal diagnosis wish to know the carrier status prior to birth in order to prepare, while others may elect to terminate a pregnancy if the fetus is affected. If prenatal genetic testing is not performed, then all at-risk children should be tested for the VHL mutation found in the affected parent in order to determine whether or not the VHL surveillance regimen is required.",
"   </p>",
"   <p>",
"    Prospective parents should also be provided with information about reproductive technologies that greatly lower their risk of having a child with VHL, such as sperm or oocyte donation (depending on which parent is affected), and preimplantation genetic diagnosis. Preimplantation genetic diagnosis involves testing embryos fertilized in vitro for the familial VHL mutation, usually on a single cell of a blastocyst, and selecting unaffected embryos for implantation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22618/abstract/80\">",
"     80",
"    </a>",
"    ]. The various reproductive options available to prospective parents require thoughtful discussion and genetic counseling. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/56/23431?source=see_link\">",
"     \"Preimplantation genetic diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    VHL related lesions may demonstrate accelerated growth in some women during pregnancy. Particular care needs to be taken during follow-up of these individuals, especially if they have a prior history of pheochromocytomas, CNS lesions, or retinal lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22618/abstract/81,82\">",
"     81,82",
"    </a>",
"    ]. All women with pheochromocytomas need to have these surgically removed before attempting to become pregnant. Growth or development of pheochromocytomas can have catastrophic consequences during pregnancy and delivery, so plasma metanephrine testing during early and late pregnancy is warranted.",
"   </p>",
"   <p>",
"    Women with existing retinal, brain, and spinal cord lesions may be at increased risk for tumor growth during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22618/abstract/82,83\">",
"     82,83",
"    </a>",
"    ]. Eyes should be checked regularly throughout the pregnancy, and a noncontrast MRI may be considered in the fourth month to follow-up on CNS lesions. Delivery via cesarian section should be considered, to lower the probability of developing increased intracranial pressure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26218926\">",
"    <span class=\"h1\">",
"     ADDITIONAL RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Summary information concerning VHL may be useful for counseling patients and affected families. The following organization can provide such information:",
"   </p>",
"   <p>",
"    VHL Family Alliance",
"   </p>",
"   <p>",
"    2001 Beacon Street, Suite 208",
"   </p>",
"   <p>",
"    Boston, MA 02135 &nbsp;",
"   </p>",
"   <p>",
"    Telephone: 617-277-5667",
"   </p>",
"   <p>",
"    Toll free number in the United States and Canada: 800-767-4VHL",
"   </p>",
"   <p>",
"    FAX: 858-712-8712",
"   </p>",
"   <p>",
"    <a class=\"external\" href=\"mailto:info@vhl.org\">",
"     info@vhl.org",
"    </a>",
"   </p>",
"   <p>",
"    <a class=\"external\" href=\"file://www.vhl.org/\">",
"     www.vhl.org",
"    </a>",
"   </p>",
"   <p>",
"    The VHL Handbook is available in eight languages as a download on the web",
"    <a class=\"external\" href=\"file://info@vhl.org/\">",
"     info@vhl.org",
"    </a>",
"    or through the VHL Family Alliance office. The handbook is a reference guide for patients and their healthcare teams. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SURVEILLANCE PROTOCOLS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Morbidity and mortality in patients with VHL disease have decreased substantially due to an improved understanding of the natural history of the serious clinical manifestations of VHL disease, better imaging techniques, and improvements in therapy. Surveillance is important not only to detect new lesions at an early stage, but also to monitor small asymptomatic lesions for evidence of progression.",
"   </p>",
"   <p>",
"    Surveillance has focused primarily on hemangioblastomas (including retinal angiomas), RCCs, and pheochromocytomas, the three manifestations most often resulting in severe disability or death. Surveillance recommendations need to be adapted to the individual patient, taking into account the presence of previously diagnosed asymptomatic disease and disease manifestations in other members of the family. However, there is variability within families and patients should understand that they may develop manifestations of VHL that were not seen in their affected relatives.",
"   </p>",
"   <p>",
"    There is some controversy concerning the optimal frequency for various imaging and screening procedures, which attempt to balance the risks and costs versus the potential for a delayed diagnosis. The following summarizes recommendations made by the VHL Family Alliance in conjunction with their medical advisory board.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26218941\">",
"    <span class=\"h2\">",
"     Ages 1 to 4",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H420144150\">",
"    <span class=\"h3\">",
"     Annually",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       Eye/retinal",
"      </span>",
"      examination with indirect ophthalmoscope by an ophthalmologist skilled in diagnosis and management of retinal disease, especially for children known to carry the VHL mutation.",
"     </li>",
"     <li>",
"      Pediatrician to look for signs of neurological disturbance, nystagmus, strabismus, white pupil, and abnormalities in blood pressure, vision, or hearing.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9386088\">",
"    <span class=\"h2\">",
"     Ages 5 to 15",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H420144158\">",
"    <span class=\"h3\">",
"     Annually",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Physical examination and neurological assessment by pediatrician informed about VHL, with particular attention to blood pressure, lying and standing, hearing issues, neurological disturbance, nystagmus, strabismus, white pupil, and other signs which might indicate a referral to a retinal specialist.",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Eye/retinal",
"      </span>",
"      examination with indirect ophthalmoscope by ophthalmologist informed about VHL, using a dilated exam.",
"     </li>",
"     <li>",
"      Test for plasma metanephrines, or urinary metanephrines using 24-hour urine test.",
"     </li>",
"     <li>",
"      Abdominal ultrasonography annually from eight years or earlier if indicated. Abdominal MRI or functional imaging scan only if biochemical abnormalities found.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H420144166\">",
"    <span class=\"h3\">",
"     Every 2 to 3 years",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complete audiology assessment by an audiologist. Annually if any hearing loss, tinnitus, or vertigo is found.",
"     </li>",
"     <li>",
"      In the case of repeated ear infections, MRI with contrast of the internal auditory canal using thin slices, to check for a possible endolymphatic sac tumor (ELST).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9386097\">",
"    <span class=\"h2\">",
"     Ages 16 and beyond",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H420144174\">",
"    <span class=\"h3\">",
"     Annually",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       Eye/retinal",
"      </span>",
"      examination with indirect ophthalmoscope by ophthalmologist informed about VHL, using a dilated exam.",
"     </li>",
"     <li>",
"      Quality ultrasound, and at least every other year MRI scan of abdomen with and without contrast to assess kidneys, pancreas, adrenals, but",
"      <strong>",
"       not",
"      </strong>",
"      <em>",
"      </em>",
"      during pregnancy.",
"     </li>",
"     <li>",
"      Physical examination by physician informed about VHL.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Test for plasma metanephrines, or urinary metanephrines using 24-hour urine test.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H420144182\">",
"    <span class=\"h3\">",
"     Every 2 years",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      MRI with contrast of brain and cervical spine, with thin cuts through the posterior fossa, and attention to inner",
"      <span class=\"nowrap\">",
"       ear/petrous",
"      </span>",
"      temporal bone to rule out both ELST and hemangioblastomas of neuraxis.",
"     </li>",
"     <li>",
"      Audiology assessment by an audiologist.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9386105\">",
"    <span class=\"h3\">",
"     During pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A review of VHL progression during pregnancy at one VHL center in the Netherlands demonstrated that there appeared to be accelerated growth of cerebellar hemangioblastoma in the two years around pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22618/abstract/82\">",
"     82",
"    </a>",
"    ], although this was not observed in a second series [",
"    <a class=\"abstract\" href=\"UTD.htm?22/5/22618/abstract/83\">",
"     83",
"    </a>",
"    ]. In addition, there were a number of VHL-related pregnancy complications which suggest that women with VHL who are pregnant should have close follow-up.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Regular retinal checkup to anticipate potentially more rapid progression of lesions.",
"     </li>",
"     <li>",
"      Test for pheochromcytoma early, mid, and again late pregnancy to ensure no active pheochromcytoma during pregnancy or especially labor and delivery.",
"     </li>",
"     <li>",
"      During the fourth month of pregnancy, MRI &mdash; without contrast &mdash; to check on any known lesions of the brain and spine. If known retinal, brain, or spinal lesions, consider C-section [",
"      <a class=\"abstract\" href=\"UTD.htm?22/5/22618/abstract/84\">",
"       84",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;von Hippel-Lindau (VHL) disease is an inherited, autosomal dominant syndrome manifested by a variety of benign and malignant tumors. The spectrum of VHL-associated tumors includes hemangioblastomas (including retinal hemangioblastomas), clear cell renal cell carcinomas (RCCs), pheochromocytomas, endolymphatic sac tumors of the middle ear, serous cystadenomas and neuroendocrine tumors of the pancreas, and papillary cystadenomas of the epididymis and broad ligament.",
"   </p>",
"   <p>",
"    The primary goal of management for patients with VHL diagnosis is the early diagnosis and treatment of tumors that otherwise might cause severe disability or death:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The diagnosis of VHL disease is based upon the detection of a germline mutation in the VHL gene and rarely by multiple VHL-associated tumors in the absence of a germline mutation. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hemangioblastomas are the most common lesions in patients with VHL disease, and tend to be multiple and infratentorial. Annual retinal examinations should be initiated beginning in infancy or early childhood to diagnose and treat retinal angiomas at an early enough stage to preserve vision. Every other year imaging of the brain and spinal cord with MRI starting after the age of fifteen years is indicated to establish the diagnosis and minimize disease-related complications. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Hemangioblastomas'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H23\">",
"       'Surveillance protocols'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clear cell RCCs occur in approximately 70 percent of VHL patients who survive to 60 years of age. Annual imaging of the kidneys with MRI or CT is indicated to establish the diagnosis. For patients in whom an RCC is diagnosed, we recommend a nephron-sparing approach to remove lesions that are 3 cm or larger whenever possible (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Renal cell carcinomas'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/26/5546?source=see_link&amp;anchor=H20#H20\">",
"       \"Surgical management of localized renal cell carcinoma\", section on 'Nephron-sparing approaches'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/44/26310?source=see_link\">",
"       \"Radiofrequency ablation and cryoablation for renal cell carcinoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pheochromocytomas tend to be seen in younger patients, are often multiple or extraadrenal, and are less likely to be associated with symptoms or biochemical evidence of catecholamine production compared to those occurring in patients without VHL. Annual assessment of plasma metanephrines should begin with young children. Annual imaging of the abdomen for pheochromocytomas and pancreatic tumors should be initiated during adolescence. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Pheochromocytomas'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Endolymphatic sac tumors are slow growing lesions that can cause significant hearing loss and may be bilateral. Baseline ear, nose, and throat examination including audiometry should be carried out in adolescents. Retesting and appropriate imaging are indicated if there are symptoms of ringing, tinnitus, pain, or change of auditory acuity. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Endolymphatic sac tumors of the middle ear'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prospective parents planning or carrying a pregnancy at risk for VHL should be offered genetic counseling and should also be provided with information about reproductive technologies that lower their risk of having a child with VHL. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Genetic counseling'",
"      </a>",
"      above.) Additionally, women who plan to or become pregnant may need a much higher level of surveillance than usual (See",
"      <a class=\"local\" href=\"#H9384234\">",
"       'Pregnancy and VHL'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9386105\">",
"       'During pregnancy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22618/abstract/1\">",
"      Maher ER, Yates JR, Harries R, et al. Clinical features and natural history of von Hippel-Lindau disease. Q J Med 1990; 77:1151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22618/abstract/2\">",
"      Lonser RR, Glenn GM, Walther M, et al. von Hippel-Lindau disease. Lancet 2003; 361:2059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22618/abstract/3\">",
"      Maher ER, Kaelin WG Jr. von Hippel-Lindau disease. Medicine (Baltimore) 1997; 76:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22618/abstract/4\">",
"      Zbar B, Kishida T, Chen F, et al. Germline mutations in the Von Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan. Hum Mutat 1996; 8:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22618/abstract/5\">",
"      Choyke PL, Glenn GM, Walther MM, et al. von Hippel-Lindau disease: genetic, clinical, and imaging features. Radiology 1995; 194:629.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.vhl.org/.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22618/abstract/7\">",
"      Wanebo JE, Lonser RR, Glenn GM, Oldfield EH. The natural history of hemangioblastomas of the central nervous system in patients with von Hippel-Lindau disease. J Neurosurg 2003; 98:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22618/abstract/8\">",
"      Conway JE, Chou D, Clatterbuck RE, et al. Hemangioblastomas of the central nervous system in von Hippel-Lindau syndrome and sporadic disease. Neurosurgery 2001; 48:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22618/abstract/9\">",
"      Woodward ER, Wall K, Forsyth J, et al. VHL mutation analysis in patients with isolated central nervous system haemangioblastoma. Brain 2007; 130:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22618/abstract/10\">",
"      Ammerman JM, Lonser RR, Dambrosia J, et al. Long-term natural history of hemangioblastomas in patients with von Hippel-Lindau disease: implications for treatment. J Neurosurg 2006; 105:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22618/abstract/11\">",
"      Lonser RR, Weil RJ, Wanebo JE, et al. Surgical management of spinal cord hemangioblastomas in patients with von Hippel-Lindau disease. J Neurosurg 2003; 98:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22618/abstract/12\">",
"      Weil RJ, Lonser RR, DeVroom HL, et al. Surgical management of brainstem hemangioblastomas in patients with von Hippel-Lindau disease. J Neurosurg 2003; 98:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22618/abstract/13\">",
"      Asthagiri AR, Mehta GU, Zach L, et al. Prospective evaluation of radiosurgery for hemangioblastomas in von Hippel-Lindau disease. Neuro Oncol 2010; 12:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22618/abstract/14\">",
"      Jonasch E, McCutcheon IE, Waguespack SG, et al. Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease. Ann Oncol 2011; 22:2661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22618/abstract/15\">",
"      Kim BY, Jonasch E, McCutcheon IE. Pazopanib therapy for cerebellar hemangioblastomas in von Hippel-Lindau disease: case report. Target Oncol 2012; 7:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22618/abstract/16\">",
"      Singh AD, Shields CL, Shields JA. von Hippel-Lindau disease. Surv Ophthalmol 2001; 46:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22618/abstract/17\">",
"      Singh AD, Nouri M, Shields CL, et al. Retinal capillary hemangioma: a comparison of sporadic cases and cases associated with von Hippel-Lindau disease. Ophthalmology 2001; 108:1907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22618/abstract/18\">",
"      Wong WT, Agr&oacute;n E, Coleman HR, et al. Clinical characterization of retinal capillary hemangioblastomas in a large population of patients with von Hippel-Lindau disease. Ophthalmology 2008; 115:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22618/abstract/19\">",
"      Singh AD, Nouri M, Shields CL, et al. Treatment of retinal capillary hemangioma. Ophthalmology 2002; 109:1799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22618/abstract/20\">",
"      Raja D, Benz MS, Murray TG, et al. Salvage external beam radiotherapy of retinal capillary hemangiomas secondary to von Hippel-Lindau disease: visual and anatomic outcomes. Ophthalmology 2004; 111:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22618/abstract/21\">",
"      Aiello LP, George DJ, Cahill MT, et al. Rapid and durable recovery of visual function in a patient with von hippel-lindau syndrome after systemic therapy with vascular endothelial growth factor receptor inhibitor su5416. Ophthalmology 2002; 109:1745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22618/abstract/22\">",
"      Richard S, Croisille L, Yvart J, et al. Paradoxical secondary polycythemia in von Hippel-Lindau patients treated with anti-vascular endothelial growth factor receptor therapy. Blood 2002; 99:3851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22618/abstract/23\">",
"      Girmens JF, Erginay A, Massin P, et al. Treatment of von Hippel-Lindau retinal hemangioblastoma by the vascular endothelial growth factor receptor inhibitor SU5416 is more effective for associated macular edema than for hemangioblastomas. Am J Ophthalmol 2003; 136:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22618/abstract/24\">",
"      Schuch G, de Wit M, H&ouml;ltje J, et al. Case 2. Hemangioblastomas: diagnosis of von Hippel-Lindau disease and antiangiogenic treatment with SU5416. J Clin Oncol 2005; 23:3624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22618/abstract/25\">",
"      Wong WT, Liang KJ, Hammel K, et al. Intravitreal ranibizumab therapy for retinal capillary hemangioblastoma related to von Hippel-Lindau disease. Ophthalmology 2008; 115:1957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22618/abstract/26\">",
"      Foster K, Prowse A, van den Berg A, et al. Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma. Hum Mol Genet 1994; 3:2169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22618/abstract/27\">",
"      Thrash-Bingham CA, Tartof KD. aHIF: a natural antisense transcript overexpressed in human renal cancer and during hypoxia. J Natl Cancer Inst 1999; 91:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22618/abstract/28\">",
"      Chauveau D, Duvic C, Chr&eacute;tien Y, et al. Renal involvement in von Hippel-Lindau disease. Kidney Int 1996; 50:944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22618/abstract/29\">",
"      Choyke PL, Glenn GM, Walther MM, et al. The natural history of renal lesions in von Hippel-Lindau disease: a serial CT study in 28 patients. AJR Am J Roentgenol 1992; 159:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22618/abstract/30\">",
"      Walther MM, Lubensky IA, Venzon D, et al. Prevalence of microscopic lesions in grossly normal renal parenchyma from patients with von Hippel-Lindau disease, sporadic renal cell carcinoma and no renal disease: clinical implications. J Urol 1995; 154:2010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22618/abstract/31\">",
"      Jilg CA, Neumann HP, Gl&auml;sker S, et al. Growth kinetics in von Hippel-Lindau-associated renal cell carcinoma. Urol Int 2012; 88:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22618/abstract/32\">",
"      Steinbach F, Novick AC, Zincke H, et al. Treatment of renal cell carcinoma in von Hippel-Lindau disease: a multicenter study. J Urol 1995; 153:1812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22618/abstract/33\">",
"      Walther MM, Choyke PL, Glenn G, et al. Renal cancer in families with hereditary renal cancer: prospective analysis of a tumor size threshold for renal parenchymal sparing surgery. J Urol 1999; 161:1475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22618/abstract/34\">",
"      Bratslavsky G, Liu JJ, Johnson AD, et al. Salvage partial nephrectomy for hereditary renal cancer: feasibility and outcomes. J Urol 2008; 179:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22618/abstract/35\">",
"      Goldfarb DA, Neumann HP, Penn I, Novick AC. Results of renal transplantation in patients with renal cell carcinoma and von Hippel-Lindau disease. Transplantation 1997; 64:1726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22618/abstract/36\">",
"      Eisenhofer G, Walther MM, Huynh TT, et al. Pheochromocytomas in von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 display distinct biochemical and clinical phenotypes. J Clin Endocrinol Metab 2001; 86:1999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22618/abstract/37\">",
"      Baghai M, Thompson GB, Young WF Jr, et al. Pheochromocytomas and paragangliomas in von Hippel-Lindau disease: a role for laparoscopic and cortical-sparing surgery. Arch Surg 2002; 137:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22618/abstract/38\">",
"      Walther MM, Reiter R, Keiser HR, et al. Clinical and genetic characterization of pheochromocytoma in von Hippel-Lindau families: comparison with sporadic pheochromocytoma gives insight into natural history of pheochromocytoma. J Urol 1999; 162:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22618/abstract/39\">",
"      Reddy VS, O'Neill JA Jr, Holcomb GW 3rd, et al. Twenty-five-year surgical experience with pheochromocytoma in children. Am Surg 2000; 66:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22618/abstract/40\">",
"      Perel Y, Schlumberger M, Marguerite G, et al. Pheochromocytoma and paraganglioma in children: a report of 24 cases of the French Society of Pediatric Oncology. Pediatr Hematol Oncol 1997; 14:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22618/abstract/41\">",
"      Kaji P, Carrasquillo JA, Linehan WM, et al. The role of 6-[18F]fluorodopamine positron emission tomography in the localization of adrenal pheochromocytoma associated with von Hippel-Lindau syndrome. Eur J Endocrinol 2007; 156:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22618/abstract/42\">",
"      Fiebrich HB, Brouwers AH, Kerstens MN, et al. 6-[F-18]Fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to conventional imaging with (123)I-metaiodobenzylguanidine scintigraphy, computer tomography, and magnetic resonance imaging in localizing tumors causing catecholamine excess. J Clin Endocrinol Metab 2009; 94:3922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22618/abstract/43\">",
"      Weisbrod AB, Kitano M, Gesuwan K, et al. Clinical utility of functional imaging with &sup1;���F-FDOPA in Von Hippel-Lindau syndrome. J Clin Endocrinol Metab 2012; 97:E613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22618/abstract/44\">",
"      Eisenhofer G, Lenders JW, Linehan WM, et al. Plasma normetanephrine and metanephrine for detecting pheochromocytoma in von Hippel-Lindau disease and multiple endocrine neoplasia type 2. N Engl J Med 1999; 340:1872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22618/abstract/45\">",
"      Neumann HP, Bausch B, McWhinney SR, et al. Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med 2002; 346:1459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22618/abstract/46\">",
"      Pacak K. Preoperative management of the pheochromocytoma patient. J Clin Endocrinol Metab 2007; 92:4069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22618/abstract/47\">",
"      Manski TJ, Heffner DK, Glenn GM, et al. Endolymphatic sac tumors. A source of morbid hearing loss in von Hippel-Lindau disease. JAMA 1997; 277:1461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22618/abstract/48\">",
"      Choo D, Shotland L, Mastroianni M, et al. Endolymphatic sac tumors in von Hippel-Lindau disease. J Neurosurg 2004; 100:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22618/abstract/49\">",
"      Bambakidis NC, Megerian CA, Ratcheson RA. Differential grading of endolymphatic sac tumor extension by virtue of von Hippel-Lindau disease status. Otol Neurotol 2004; 25:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22618/abstract/50\">",
"      Butman JA, Kim HJ, Baggenstos M, et al. Mechanisms of morbid hearing loss associated with tumors of the endolymphatic sac in von Hippel-Lindau disease. JAMA 2007; 298:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22618/abstract/51\">",
"      Patel NP, Wiggins RH 3rd, Shelton C. The radiologic diagnosis of endolymphatic sac tumors. Laryngoscope 2006; 116:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22618/abstract/52\">",
"      Mukherji SK, Albernaz VS, Lo WW, et al. Papillary endolymphatic sac tumors: CT, MR imaging, and angiographic findings in 20 patients. Radiology 1997; 202:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22618/abstract/53\">",
"      Lonser RR, Kim HJ, Butman JA, et al. Tumors of the endolymphatic sac in von Hippel-Lindau disease. N Engl J Med 2004; 350:2481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22618/abstract/54\">",
"      Vortmeyer AO, Choo D, Pack SD, et al. von Hippel-Lindau disease gene alterations associated with endolymphatic sac tumor. J Natl Cancer Inst 1997; 89:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22618/abstract/55\">",
"      Vortmeyer AO, Huang SC, Koch CA, et al. Somatic von Hippel-Lindau gene mutations detected in sporadic endolymphatic sac tumors. Cancer Res 2000; 60:5963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22618/abstract/56\">",
"      Poulsen ML, Gimsing S, Kosteljanetz M, et al. von Hippel-Lindau disease: surveillance strategy for endolymphatic sac tumors. Genet Med 2011; 13:1032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22618/abstract/57\">",
"      Devaney KO, Ferlito A, Rinaldo A. Endolymphatic sac tumor (low-grade papillary adenocarcinoma) of the temporal bone. Acta Otolaryngol 2003; 123:1022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22618/abstract/58\">",
"      Hansen MR, Luxford WM. Surgical outcomes in patients with endolymphatic sac tumors. Laryngoscope 2004; 114:1470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22618/abstract/59\">",
"      Kim HJ, Butman JA, Brewer C, et al. Tumors of the endolymphatic sac in patients with von Hippel-Lindau disease: implications for their natural history, diagnosis, and treatment. J Neurosurg 2005; 102:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22618/abstract/60\">",
"      Ferreira MA, Feiz-Erfan I, Zabramski JM, et al. Endolymphatic sac tumor: unique features of two cases and review of the literature. Acta Neurochir (Wien) 2002; 144:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22618/abstract/61\">",
"      Jagannathan J, Lonser RR, Stanger RA, et al. Cochlear implantation for hearing loss associated with bilateral endolymphatic sac tumors in von Hippel-Lindau disease. Otol Neurotol 2007; 28:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22618/abstract/62\">",
"      Hammel PR, Vilgrain V, Terris B, et al. Pancreatic involvement in von Hippel-Lindau disease. The Groupe Francophone d'Etude de la Maladie de von Hippel-Lindau. Gastroenterology 2000; 119:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22618/abstract/63\">",
"      Blansfield JA, Choyke L, Morita SY, et al. Clinical, genetic and radiographic analysis of 108 patients with von Hippel-Lindau disease (VHL) manifested by pancreatic neuroendocrine neoplasms (PNETs). Surgery 2007; 142:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22618/abstract/64\">",
"      Neumann HP, Dinkel E, Brambs H, et al. Pancreatic lesions in the von Hippel-Lindau syndrome. Gastroenterology 1991; 101:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22618/abstract/65\">",
"      Pyke CM, van Heerden JA, Colby TV, et al. The spectrum of serous cystadenoma of the pancreas. Clinical, pathologic, and surgical aspects. Ann Surg 1992; 215:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22618/abstract/66\">",
"      Binkovitz LA, Johnson CD, Stephens DH. Islet cell tumors in von Hippel-Lindau disease: increased prevalence and relationship to the multiple endocrine neoplasias. AJR Am J Roentgenol 1990; 155:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22618/abstract/67\">",
"      Libutti SK, Choyke PL, Alexander HR, et al. Clinical and genetic analysis of patients with pancreatic neuroendocrine tumors associated with von Hippel-Lindau disease. Surgery 2000; 128:1022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22618/abstract/68\">",
"      Shen T, Zhuang Z, Gersell DJ, Tavassoli FA. Allelic Deletion of VHL Gene Detected in Papillary Tumors of the Broad Ligament, Epididymis, and Retroperitoneum in von Hippel-Lindau Disease Patients. Int J Surg Pathol 2000; 8:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22618/abstract/69\">",
"      Choyke PL, Glenn GM, Wagner JP, et al. Epididymal cystadenomas in von Hippel-Lindau disease. Urology 1997; 49:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22618/abstract/70\">",
"      Gaffey MJ, Mills SE, Boyd JC. Aggressive papillary tumor of middle ear/temporal bone and adnexal papillary cystadenoma. Manifestations of von Hippel-Lindau disease. Am J Surg Pathol 1994; 18:1254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22618/abstract/71\">",
"      Gersell DJ, King TC. Papillary cystadenoma of the mesosalpinx in von Hippel-Lindau disease. Am J Surg Pathol 1988; 12:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22618/abstract/72\">",
"      Yao M, Yoshida M, Kishida T, et al. VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma. J Natl Cancer Inst 2002; 94:1569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22618/abstract/73\">",
"      Gnarra JR, Tory K, Weng Y, et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 1994; 7:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22618/abstract/74\">",
"      Dannenberg H, De Krijger RR, van der Harst E, et al. Von Hippel-Lindau gene alterations in sporadic benign and malignant pheochromocytomas. Int J Cancer 2003; 105:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22618/abstract/75\">",
"      Gijtenbeek JM, Jacobs B, Sprenger SH, et al. Analysis of von hippel-lindau mutations with comparative genomic hybridization in sporadic and hereditary hemangioblastomas: possible genetic heterogeneity. J Neurosurg 2002; 97:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22618/abstract/76\">",
"      Sprenger SH, Gijtenbeek JM, Wesseling P, et al. Characteristic chromosomal aberrations in sporadic cerebellar hemangioblastomas revealed by comparative genomic hybridization. J Neurooncol 2001; 52:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22618/abstract/77\">",
"      Stolle C, Glenn G, Zbar B, et al. Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene. Hum Mutat 1998; 12:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22618/abstract/78\">",
"      Sgambati MT, Stolle C, Choyke PL, et al. Mosaicism in von Hippel-Lindau disease: lessons from kindreds with germline mutations identified in offspring with mosaic parents. Am J Hum Genet 2000; 66:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22618/abstract/79\">",
"      Murgia A, Martella M, Vinanzi C, et al. Somatic mosaicism in von Hippel-Lindau Disease. Hum Mutat 2000; 15:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22618/abstract/80\">",
"      Obradors A, Fern&aacute;ndez E, Rius M, et al. Outcome of twin babies free of Von Hippel-Lindau disease after a double-factor preimplantation genetic diagnosis: monogenetic mutation analysis and comprehensive aneuploidy screening. Fertil Steril 2009; 91:933.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22618/abstract/81\">",
"      Hayden MG, Gephart R, Kalanithi P, Chou D. Von Hippel-Lindau disease in pregnancy: a brief review. J Clin Neurosci 2009; 16:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22618/abstract/82\">",
"      Frantzen C, Kruizinga RC, van Asselt SJ, et al. Pregnancy-related hemangioblastoma progression and complications in von Hippel-Lindau disease. Neurology 2012; 79:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/5/22618/abstract/83\">",
"      Ye DY, Bakhtian KD, Asthagiri AR, Lonser RR. Effect of pregnancy on hemangioblastoma development and progression in von Hippel-Lindau disease. J Neurosurg 2012; 117:818.",
"     </a>",
"    </li>",
"    <li>",
"     file://vhl.org/handbook/.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5193 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-217.117.136.88-94DAD92080-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_5_22618=[""].join("\n");
var outline_f22_5_22618=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TYPES OF VHL DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1759621\">",
"      Type 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1759629\">",
"      Type 2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1986453\">",
"      OCCURRENCE AND AGE OF ONSET OF VHL RELATED LESIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      HEMANGIOBLASTOMAS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      RETINAL CAPILLARY HEMANGIOBLASTOMAS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      RENAL CELL CARCINOMAS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Clinical presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      PHEOCHROMOCYTOMAS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9384130\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      ENDOLYMPHATIC SAC TUMORS OF THE MIDDLE EAR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      PANCREATIC TUMORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      PAPILLARY CYSTADENOMAS OF THE EPIDIDYMIS AND BROAD LIGAMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      VHL MUTATIONS IN SPORADIC TUMORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Genetic testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Somatic mosaicism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Genetic counseling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9384234\">",
"      PREGNANCY AND VHL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26218926\">",
"      ADDITIONAL RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SURVEILLANCE PROTOCOLS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26218941\">",
"      Ages 1 to 4",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H420144150\">",
"      - Annually",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9386088\">",
"      Ages 5 to 15",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H420144158\">",
"      - Annually",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H420144166\">",
"      - Every 2 to 3 years",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9386097\">",
"      Ages 16 and beyond",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H420144174\">",
"      - Annually",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H420144182\">",
"      - Every 2 years",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9386105\">",
"      - During pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/5193\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/5193|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/20/29004\" title=\"table 1\">",
"      Occurrence and age of onset in VHL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/27/42427\" title=\"table 2\">",
"      MGH screening VHL",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/20/15686?source=related_link\">",
"      Classification of pancreatic cysts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/14/23786?source=related_link\">",
"      Clinical presentation and diagnosis of pheochromocytoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/9/2200?source=related_link\">",
"      Diagnostic approach, differential diagnosis, and treatment of a small renal mass",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/52/18250?source=related_link\">",
"      Epidemiology, pathology, and pathogenesis of renal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/51/5942?source=related_link\">",
"      Evaluation of nonacute scrotal pathology in adult men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/24/39300?source=related_link\">",
"      Hearing amplification in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/43/695?source=related_link\">",
"      Hemangioblastoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/4/35910?source=related_link\">",
"      Hereditary kidney cancer syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/21/14678?source=related_link\">",
"      Molecular biology and pathogenesis of von Hippel-Lindau disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/14/38121?source=related_link\">",
"      Pheochromocytoma in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/54/21351?source=related_link\">",
"      Pheochromocytoma in genetic disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/56/23431?source=related_link\">",
"      Preimplantation genetic diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/44/26310?source=related_link\">",
"      Radiofrequency ablation and cryoablation for renal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/3/27704?source=related_link\">",
"      Simple and complex renal cysts in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/26/5546?source=related_link\">",
"      Surgical management of localized renal cell carcinoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_5_22619="Criteria for extubation or decannulation to continuous NPPV";
var content_f22_5_22619=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F64672&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F64672&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Indications and criteria for extubation or decannulation of patients unable to sustain autonomous breathing",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        The patient is mentally competent, cooperative, and not using heavy sedation or narcotics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Supplemental oxygen therapy is avoided or minimized",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SaO",
"        <sub>",
"         2",
"        </sub>",
"        is maintained above 95 percent by aggressive airway secretion elimination and assisted ventilation as necessary",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bulbar muscle function is sufficient so that aspiration of airway secretions does not cause O",
"        <sub>",
"         2",
"        </sub>",
"        desaturation below 95 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        There is no history of substance abuse or uncontrollable seizures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pulmonary compliance is adequate for noninvasive IPPV to provide normal alveolar ventilation at interface pressures under 40 cm H",
"        <sub>",
"         2",
"        </sub>",
"        O",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        There are no conditions which interfere with the use of IPPV interfaces, ie, facial fractures, inadequate bite or neck rotation for mouthpiece entry, presence of a nasogastric tube or a beard that hampers airtight interface seal, etc",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_5_22619=[""].join("\n");
var outline_f22_5_22619=null;
var title_f22_5_22620="Breast cancer risk Hodgkin lymphoma";
var content_f22_5_22620=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F78361&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F78361&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Cumulative absolute risk for developing breast cancer in young women treated for Hodgkin lymphoma after 30 years of follow-up",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Age at Dx",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Mediastinal RT (Gy)",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">",
"        Absolute risk of breast CA after 30 years of follow-up",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Alk agents used",
"       </td>",
"       <td class=\"subtitle2\">",
"        Alk agents not used",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        15",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0.8",
"       </td>",
"       <td>",
"        1.7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        20 - &lt;40",
"       </td>",
"       <td>",
"        4.1",
"       </td>",
"       <td>",
"        8.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &ge;40",
"       </td>",
"       <td>",
"        5.0",
"       </td>",
"       <td>",
"        10.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        20",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1.6",
"       </td>",
"       <td>",
"        3.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        20 -&lt;40",
"       </td>",
"       <td>",
"        7.9",
"       </td>",
"       <td>",
"        16.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &ge;40",
"       </td>",
"       <td>",
"        9.5",
"       </td>",
"       <td>",
"        19.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        25",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        2.6",
"       </td>",
"       <td>",
"        5.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        20 -&lt;40",
"       </td>",
"       <td>",
"        12.5",
"       </td>",
"       <td>",
"        24.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &ge;40",
"       </td>",
"       <td>",
"        15.0",
"       </td>",
"       <td>",
"        29.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        30",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        4.0",
"       </td>",
"       <td>",
"        8.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        20 -&lt;40",
"       </td>",
"       <td>",
"        18.1",
"       </td>",
"       <td>",
"        34.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &ge;40",
"       </td>",
"       <td>",
"        21.6",
"       </td>",
"       <td>",
"        39.6",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    This table shows the estimated absolute risk of developing breast cancer (percent) after 30 years of follow-up in young women treated for Hodgkin lymphoma as a function of age at diagnosis (dx), amount of mediastinal irradiation (Gy), and whether or not alkylating (alk) agents were employed in the treatment program.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Travis LB, Hill D, Dores GM, et al.&nbsp;Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. J Natl Cancer Inst 2005; 97:1428.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_5_22620=[""].join("\n");
var outline_f22_5_22620=null;
var title_f22_5_22621="Relative mortality variceal bleed";
var content_f22_5_22621=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F70212&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F70212&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Risk of death is highest early after variceal hemorrhage",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 349px; height: 220px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Relative risk of death compared to nonbleeding cirrhotics in patients with a variceal hemorrhage as a function of time from time zero. The risk increases dramatically in the first 48 hours and declines therafter to baseline values by week six.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Graham DY, Smith JL. Gastroenterology 1982; 82:968.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_5_22621=[""].join("\n");
var outline_f22_5_22621=null;
var title_f22_5_22622="OSA diagnosis algorithm";
var content_f22_5_22622=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F80288&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F80288&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 475px\">",
"   <div class=\"ttl\">",
"    Diagnosis of obstructive sleep apnea (OSA) algorithm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 455px; height: 520px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_5_22622=[""].join("\n");
var outline_f22_5_22622=null;
var title_f22_5_22623="Radiation thyroid ca dose";
var content_f22_5_22623=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F81877&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F81877&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Radiation-induced thyroid cancer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 433px; height: 468px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Dose-response patterns for thyroid cancer (A), benign neoplasms (B), and all thyroid nodules (C). &bull; =&nbsp;The observed relative risk. The horizontal position of circles gives the mean dose for each dose interval. For thyroid cancer, the dose-response line was adjusted to pass through 34.5 cGy, the mean dose for the above 50 cGy category. For benign neoplasms and all thyroid nodules, the categorization for the lower doses was expanded to less than 5, 5 to 9, 10 to 14, 15 to 19, 20 to 29, 30 to 39, and 40 to 49 cGy, and the dose-response lines were adjusted to pass through 2.7 cGy, the mean dose for the less than 5 cGy category. For benign neoplasms, the paucity of cases (n = 3) in the less than 5 cGy category and the lack of cases in the 5 to 9, 10 to 14, and 15 to 19 cGy categories resulted in a line with an unreasonably large slope (relative risk of 22 at 100 cGy). Therefore, the number of benign neoplasms in the 5 to 19 cGy range was adjusted based on an ERR/cGy of 0.08 (0). In panel B, the dashed line is the fit over the entire dose range [relative risk = (1 + 0.060 X d)/(l + 0.06 X 2.7)], and the solid line and equation are for the dose range below 200 cGy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Schneider AB, Ron E, Lubin J, et al. Dose-Response Relationships for Radiation-Induced Thyroid Cancer and Thyroid Nodules: Evidence for the Prolonged Effects of Radiation on the Thyroid. J Clin Endocrinol Metab 1993; 77:362. file://jcem.endojournals.org/. Copyright &copy; 1993 The Endocrine Society.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_5_22623=[""].join("\n");
var outline_f22_5_22623=null;
